U.S. patent application number 13/751588 was filed with the patent office on 2013-10-31 for immunoglobulins.
The applicant listed for this patent is Glaxo Group Limited. Invention is credited to Stephanie Jane CLEGG, Jonathan Henry Ellis, Volker Germaschewski, Paul Andrew Hamblin, George Kopsidas, Ruth McAdam, Rabiner Kumar Prinjha.
Application Number | 20130287781 13/751588 |
Document ID | / |
Family ID | 35736284 |
Filed Date | 2013-10-31 |
United States Patent
Application |
20130287781 |
Kind Code |
A1 |
CLEGG; Stephanie Jane ; et
al. |
October 31, 2013 |
IMMUNOGLOBULINS
Abstract
The present invention relates to antibodies to NOGO,
pharmaceutical formulations containing such antibodies and the use
of such antibodies in the treatment and/or prophylaxis of
neurological diseases/disorder.
Inventors: |
CLEGG; Stephanie Jane; (King
of Prussia, PA) ; Ellis; Jonathan Henry; (King of
Prussia, PA) ; Germaschewski; Volker; (King of
Prussia, PA) ; Hamblin; Paul Andrew; (King of
Prussia, PA) ; Kopsidas; George; (King of Prussia,
PA) ; McAdam; Ruth; (King of Prussia, PA) ;
Prinjha; Rabiner Kumar; (King of Prussia, PA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Glaxo Group Limited |
Greenford |
|
GB |
|
|
Family ID: |
35736284 |
Appl. No.: |
13/751588 |
Filed: |
January 28, 2013 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12097279 |
Jun 13, 2008 |
8362208 |
|
|
PCT/EP2006/069737 |
Dec 14, 2006 |
|
|
|
13751588 |
|
|
|
|
Current U.S.
Class: |
424/139.1 ;
530/387.9 |
Current CPC
Class: |
C07K 16/18 20130101;
C07K 2317/24 20130101; A61K 2039/505 20130101; A61P 9/10 20180101;
C07K 2317/56 20130101; A61P 25/28 20180101; A61P 9/00 20180101;
A61P 25/00 20180101; A61P 25/02 20180101; C07K 16/465 20130101;
C07K 16/22 20130101; C07K 2317/565 20130101 |
Class at
Publication: |
424/139.1 ;
530/387.9 |
International
Class: |
C07K 16/18 20060101
C07K016/18 |
Foreign Application Data
Date |
Code |
Application Number |
Dec 16, 2005 |
GB |
0525662.3 |
Claims
1. A heavy chain variable region comprising a third CDR consisting
essentially of the amino acid residues GQGY wherein the CDR
contains at least one substitution within the GQGY core sequence,
the substitutions being selected from the following substitutions:
where the G in the first position is replaced by R, I, W or M; the
Q in the second position is replaced by D, I, A, L, V or S; the G
in the third position is replaced by W, N, Y, S, L or F; and the Y
in the fourth position is replaced by W.
2. A heavy chain variable region as claimed in claim 1 wherein
there is a single substitution to the GQGY sequence to yield one of
the following CDR H3: RQGY (SEQ ID NO.75), IQGY (SEQ ID NO.76),
MQGY (SEQ ID NO.45), GDGY (SEQ ID NO.77), GIGY (SEQ ID NO.78), GSGY
(SEQ ID NO.79), GQNY (SEQ ID NO.80), GQYY (SEQ ID NO.81), GQSY (SEQ
ID NO.62), GQLY (SEQ ID NO.82), GQFY (SEQ ID NO.83), GQGW (SEQ ID
NO.84), WQGY (SEQ ID NO.86), GAGY (SEQ ID NO.87), GLGY (SEQ ID
NO.88), GVGY (SEQ ID NO.89), GQWY (SEQ ID NO.90).
3. A heavy chain variable region as claimed in claim 2 wherein the
CDR H3 is MQGY or GQSY.
4. A heavy chain variable region as claimed in claim 1, wherein the
heavy chain variable region comprises the sequence SYWMH as CDR H1
(SEQ ID NO. 1) and NINPSNGGTNYNEKFKS as CDR H2 (SEQ ID NO.2).
5. A heavy chain variable region as claimed in claim 1, wherein the
heavy chain variable region is a humanised sequence.
6. A heavy chain variable region as claimed in claim 5 wherein the
acceptor heavy chain variable region sequence has at least 40%
identity in the framework regions to the 2A10 donor antibody heavy
chain variable region sequence given in SEQ ID NO.7.
7. A heavy chain variable region as claimed in claim 6 wherein the
heavy chain variable region has an amino acid sequence of SEQ ID
NO. 66 (H98 variable region) or SEQ ID NO. 61 (H99 variable
region), further comprising a number of substitutions at one or
more of numerical positions 38, 40, 67, 68, 70, 72, 74, and 79;
wherein each substituted amino acid residue is replaced with the
amino acid residue at the equivalent position in SEQ ID NO 7.
8. A heavy chain variable region as claimed in claim 1, having the
amino acid sequence given in SEQ ID NO.47 (H26), SEQ ID NO.48
(H27), SEQ ID NO.49 (H28), SEQ ID NO. 63 (H100), SEQ ID NO. 54
(H101), SEQ ID NO. 65 (H102).
9. An isolated antibody, or fragment thereof, capable of binding to
human NOGO-A comprising a heavy chain variable region as claimed in
claim 1 and a light chain variable region.
10. An isolated antibody or fragment thereof as claimed in claim 7
comprising the following heavy and light chain variable region
pairs: H27L16 (SEQ ID NO.48+SEQ ID NO.14), H28L13 (SEQ ID NO.49+SEQ
ID NO.13), H28L16 (SEQ ID NO.49+SEQ ID NO.14).
11. An isolated antibody as claimed in claim 9 comprising the
following heavy and light chain sequences H27FL L16FL (SEQ ID NO.
54+SEQ ID NO.18), H28FL L13FL (SEQ ID NO. 55+SEQ ID NO.17), H28FL
L16FL (SEQ ID NO. 55+SEQ ID NO.18).
12. A pharmaceutical composition comprising an anti-NOGO antibody
or fragment thereof comprising the antibodies or fragments thereof
as claimed in claim 9, together with a pharmaceutically acceptable
diluent or carrier.
13. Use of an anti-NOGO antibody or fragment thereof as claimed in
claim 9, in the preparation of a medicament for treatment or
prophylaxis of stroke and other neurological diseases/disorders or
for the treatment of a patient suffering from a mechanical trauma
to the central or peripheral nervous system.
14. A method for the treatment or prophylaxis of stroke or other
neurological disease/disorder or for the treatment of a patient
suffering from a mechanical trauma to the central or peripheral
nervous system, in a human comprising the step of parenteral
administration of a therapeutically effective amount of an
anti-NOGO antibody or fragment thereof as claimed in claim 9.
15. An antibody or fragment thereof that is capable of binding to a
region of human NOGO protein consisting of the polypeptide sequence
of VLPDIVMEAPLN (SEQ ID NO. 60), characterised in that the
antibody, or fragment thereof is not an antibody comprising a
variable heavy domain having CDR H3 consisting of the amino acid
residues GQGY or analogues thereof having one amino acid
substitution therein.
16. (canceled)
17. An antibody, or fragment thereof, that is capable of binding to
human NOGO protein in an ELISA assay, wherein the binding of the
antibody, or fragment thereof, to human NOGO protein is reduced in
the presence of a peptide having the following sequence
VLPDIVMEAPLN (SEQ ID NO. 60), and is not reduced in the presence of
an irrelevant peptide, characterised in that the antibody or
fragment thereof is not an antibody comprising a heavy chain
variable domain having a CDR H3 consisting of the amino acid
residues GQGY or analogues thereof having one amino acid
substitution therein.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is continuation of application Ser. No.
12/097,279, filed on Jun. 13, 2008, which is the US National Stage
Application of International Application No. PCT/EP2006/069737,
filed Dec. 14, 2006, which claims priority from Great Britain
Application No. 0525662.3, filed Dec. 16, 2005, the contents of all
of which are herein incorporated by reference in their
entireties.
FIELD OF THE INVENTION
[0002] The present invention relates to immunoglobulins,
particularly antibodies that bind to NOGO and neutralise the
activity thereof, polynucleotides encoding such antibodies,
pharmaceutical formulations containing said antibodies and to the
use of such antibodies in the treatment and/or prophylaxis of
neurological diseases. Other aspects, objects and advantages of the
present invention will become apparent from the description
below.
BACKGROUND OF THE INVENTION
[0003] Stroke is a major cause of death and disability in the
Western World. There is no approved therapy for the treatment of
stroke other than tissue plasminogen (t-PA) which has to be
administered within 3 hours of onset following a computer
tomography (CT) scan to exclude haemorrhage. To date most
therapeutic agents directed towards the treatment of acute stroke
(i.e. neuroprotection), have predominantly involved targeting
glutamate receptors and their down stream signalling pathways known
to be involved in acute cell death. However to date these
strategies have proved unsuccessful in clinical trials and are
often associated with dose-limiting side effects (Hill &
Hachinski, The Lancet, 352: (suppl III) 10-14 (1998)). Therefore
there is a need for novel approaches directed towards the
amelioration of cell death following the cessation of blood flow.
Neuroprotection is the ability of a treatment to prevent or
ameliorate neuronal cell loss in response to an insult or disease
process. This may be achieved by targeting the neurons directly or
indirectly by preventing glial (including oligodendrocyte) cell
loss.
[0004] Following the onset of stroke, some degree of spontaneous
functional recovery is observed in many patients, suggesting that
the brain has the (albeit limited) ability to repair and/or remodel
following injury. Agents that have the potential to enhance this
recovery may therefore allow intervention to be made much later
(potentially days) following the onset of cerebral ischaemia.
Agents which are able to offer both acute neuroprotection and
enhance functional recovery may provide significant advantages over
current potential neuroprotective strategies.
[0005] Alzheimer's disease (AD) is characterised by the presence of
two diagnostic features of pathology. These are amyloid plaques and
neurofibrillary tangles composed of aggregated beta-amyloid peptide
(A.beta.40 and A.beta.42) and hyperphosphorylated tau respectively
(Dawbarn & Allen 2001 Neurobiology of Alzheimer's Disease
OUP).
[0006] A comprehensive study has shown a strong link in patients
between beta-amyloid accumulation and cognitive decline (Naslund et
al, JAMA, Mar. 22/29, 2000, Vol. 283, No; 12, page 1571-1577). This
is consistent with genetic and epidemiological studies that suggest
that some mutations in APP and presenilin genes can predispose to
early onset AD, which mutations also enhance the levels of
A.beta.40 and A.beta.42 peptide, including the ratio thereof.
[0007] Cleavage of the type I transmembrane amyloid precursor
protein (APP) by two distinct proteases designated beta- and
gamma-secretase is necessary for the formation of beta-amyloid
peptide. The molecular identity of beta-secretase as the
aspartyl-protease Asp2/BACE1 has been confirmed (Hussain et al Mol.
Cell. NeuroSci. 16, 609-619 (2000); Vassar et al, Science (1999),
Oct. 22; 286 (5440):735-741). The nature of gamma-secretase remains
the source of some debate and is likely to consist of a high
molecular weight complex consisting of at least the following
proteins: presenilins, Aph1, Pen2 and nicastrin (reviewed in Medina
& Dotti Cell Signalling 2003 15(9):829-41).
[0008] The processing of APP within the CNS is likely to occur
within a number of cell-types including neurons, oligodendrocytes,
astrocytes and microglia. While the overall rate of APP processing
in these cells will be influenced by the relative level of
expression of APP, BACE1/Asp2, presenilin-1 and -2, Aph1, Pen2 and
nicastrin.
[0009] Furthermore, additional factors regulating the subcellular
location of APP can also influence its processing as shown by the
finding that mutation of the YENP motif in the APP cytoplasmic
domain which blocks its endocytosis reduces beta-amyloid production
(Perez et al 1999 J Biol Chem 274 (27) 18851-6). Retention of the
APP-beta-CTF in the ER by the addition of the KKQN retention motif
is sufficient to reduce amyloid production in transfected cells
(Maltese et al 2001 J Biol Chem 276 (23) 20267-20279). Conversely,
elevation of endocytosis, by overexpression of Rab5 is sufficient
to elevate amyloid secretion from transfected cells (Grbovic et al
2003 J Biol Chem 278 (33) 31261-31268).
[0010] Consistent with these findings further studies have shown
that reduction of cellular cholesterol levels (a well known risk
factor for AD) reduced beta-amyloid formation. This change was
dependent on altered endocytosis as demonstrated by the use of the
dominant negative dynamin mutants (K44A) and overexpression of the
Rab5 GTPase activating protein RN-Tre (Ehehalt et al 2003 J Cell
Biol 160 (1) 113-123).
[0011] Cholesterol rich microdomains or rafts are also an important
cellular site of beta-amyloid production and APP, BACE1 and
components of the gamma-secretase complex have all been shown to
transiently reside within rafts. Antibody cross-linking of APP and
BACE1 towards cholesterol rich rafts was able to elevate
beta-amyloid production (Ehehalt et al 2003 J Cell Biol 160 (1)
113-123). Expression of GPI-anchored BACE1, which is exclusively
targeted to lipid rafts, is similarly able to elevate APP cleavage
and beta-amyloid production (Cordy et al 2003 PNAS 100(20)
11735-11740).
[0012] The mechanisms underlying functional recovery after a stroke
or other neurodamaging event or disease, are currently unknown. The
sprouting of injured or non-injured axons has been proposed as one
possible mechanism. However, although in vivo studies have shown
that treatment of spinal cord injury or stroke with neurotrophic
factors results in enhanced functional recovery and a degree of
axonal sprouting, these do not prove a direct link between the
degree of axonal sprouting and extent of functional recovery
(Jakeman, et al. 1998, Exp. Neurol. 154: 170-184, Kawamata et al.
1997, Proc Natl Acad. Sci. USA., 94:8179-8184, Ribotta, et al.
2000, J Neurosci. 20: 5144-5152). Furthermore, axonal sprouting
requires a viable neuron. In diseases such as stroke which is
associated with extensive cell death, enhancement of functional
recovery offered by a given agent post stroke may therefore be
through mechanisms other than axonal sprouting such as
differentiation of endogenous stem cells, activation of redundant
pathways, changes in receptor distribution or excitability of
neurons or glia (Fawcett & Asher, 1999, Brain Res. Bulletin,
49: 377-391, Horner & Gage, 2000, Nature 407 963-970).
[0013] The limited ability of the central nervous system (CNS) to
repair following injury is thought in part to be due to molecules
within the CNS environment that have an inhibitory effect on axonal
sprouting (neurite outgrowth). CNS myelin is thought to contain
inhibitory molecules (Schwab M E and Caroni P (1988) J. Neurosci.
8, 2381-2193). Two myelin proteins, myelin-associated glycoprotein
(MAG) and NOGO have been cloned and identified as putative
inhibitors of neurite outgrowth (Sato S. et al (1989) Biochem.
Biophys. Res. Comm. 163, 1473-1480; McKerracher L et al (1994)
Neuron 13, 805-811; Mukhopadhyay G et al (1994) Neuron 13, 757-767;
Torigoe K and Lundborg G (1997) Exp. Neurology 150, 254-262;
Schafer et al (1996) Neuron 16, 1107-1113; WO9522344; WO9701352;
Prinjha R et al (2000) Nature 403, 383-384; Chen M S et al (2000)
Nature 403, 434-439; GrandPre T et al (2000) Nature 403, 439-444;
US005250414A; WO200005364A1; WO0031235).
[0014] Three forms of human NOGO have been identified: NOGO-A
having 1192 amino acid residues (GenBank accession no. AJ251383);
NOGO-B, a splice variant which lacks residues 186 to 1004 in the
putative extracellular domain (GenBank accession no. AJ251384) and
a shorter splice variant, NOGO-C, which also lacks residues 186 to
1004 and also has smaller, alternative amino terminal domain
(GenBank accession no. AJ251385) (Prinjha et al (2000) supra).
[0015] Inhibition of the CNS inhibitory proteins such as NOGO may
provide a therapeutic means to ameliorate neuronal damage and
promote neuronal repair and growth thereby potentially assisting
recovery from neuronal injury such as that sustained in stroke.
Examples of such NOGO inhibitors may include small molecules,
peptides and antibodies.
[0016] It has been reported that a murine monoclonal antibody,
IN-1, that was raised against NI-220/250, a myelin protein which is
a potent inhibitor of neurite growth (and subsequently shown to be
fragment of NOGO-A), promotes axonal regeneration (Caroni, P and
Schwab, M E (1988) Neuron 1 85-96; Schnell, L and Schwab, M E
(1990) Nature 343 269-272; Bregman, B S et al (1995) Nature 378
498-501 and Thallmair, M et al (1998) Nature Neuroscience 1
124-131). It has also been reported that NOGO-A is the antigen for
IN-1 (Chen et al (2000) Nature 403 434-439). Administration of IN-1
Fab fragment or humanised IN-1 to rats that have undergone spinal
cord transection, enhanced recovery (Fiedler, M et al (2002)
Protein Eng 15 931-941; Brosamle, C et al (2000) J. Neuroscience 20
8061-8068).
[0017] Monoclonal antibodies which bind to NOGO are described in WO
04/052932 and WO2005028508. WO 04/052932 discloses a murine
antibody 11C7 which binds to certain forms of human NOGO with high
affinity.
[0018] Patent application WO05/061544 also discloses high affinity
monoclonal antibodies, including a murine monoclonal antibody 2A10,
and generally discloses humanised variants thereof, for example
H1L11 (the sequences for the H1 and L11 are provided in SEQ ID NOs.
33 and 34 respectively (VH or VL sequences only)). The antibodies
disclosed bind to human NOGO-A with high affinity. The murine 2A10
antibody (and CDR-grafted humanised variants thereof) are
characterised by the following complementarity determining region
(CDR) sequences (as determined using the Kabat methodology (Kabat
et al. (1991) "Sequences of proteins of immunological interest";
Fifth Edition; US Department of Health and Human Services; NIH
publication No 91-3242)) within their light and heavy chain
variable regions:
TABLE-US-00001 TABLE 1 Antibody 2A10 light chain CDRs CDR Sequence
L1 RSSKSLLYKDGKTYLN (SEQ ID NO: 4) L2 LMSTRAS (SEQ ID NO: 5) L3
QQLVEYPLT (SEQ ID NO: 6)
TABLE-US-00002 TABLE 2 Antibody 2A10 heavy chain CDRs CDR Sequence
H1 SYWMH (SEQ ID NO: 1) H2 NINPSNGGTNYNEKFKS (SEQ ID NO: 2) H3 GQGY
(SEQ ID NO: 3)
[0019] WO05/061544 further discloses "analogues" of the antibodies
that comprise the CDRs of Tables 1 and 2 above, such "analogues"
the have same antigen binding specificity and/or neutralizing
ability as the donor antibody from which they were derived.
[0020] Despite the art providing high affinity anti-NOGO
antibodies, it remains a highly desirable goal to isolate and
develop alternative, or improved, therapeutically useful monoclonal
antibodies that bind and inhibit the activity of human NOGO.
[0021] The process of neurodegeneration underlies many neurological
diseases/disorders including, but not limited to, acute diseases
such as stroke (ischemic or haemorrhagic), traumatic brain injury
and spinal cord injury as well as chronic diseases including
Alzheimer's disease, fronto-temporal dementias (tauopathies),
peripheral neuropathy, Parkinson's disease, Creutzfeldt-Jakob
disease (CJD), Schizophrenia, amyotrophic lateral sclerosis (ALS),
multiple sclerosis, Huntington's disease, multiple sclerosis and
inclusion body myositis. Consequently the anti-NOGO monoclonal
antibodies, and the like, of the present invention may be useful in
the treatment of these diseases/disorders. Antibodies for the
treatment of the above mentioned disease/disorders are provided by
the present invention and described in detail below.
BRIEF SUMMARY OF THE INVENTION
[0022] The invention provides specific heavy chain variable
regions, and antibodies or fragments thereof comprising the said
specific heavy chain variable regions and a light chain variable
region that allows, when paired with the heavy chain variable
regions, the Fv dimer to bind human NOGO-A with high affinity, and
thereby neutralise the activity of human NOGO-A.
[0023] The heavy chain variable regions of the present invention
may be formatted, together with light chain variable regions to
allow binding to human NOGO-A, in the conventional immunoglobulin
manner (for example, human IgG, IgA, IgM etc.) or in any other
fragment thereof or "antibody-like" format that binds to human
NOGO-A (for example, single chain Fv, diabodies, Tandabs.TM. etc
(for a summary of alternative "antibody" formats see Holliger and
Hudson, Nature Biotechnology, 2005, Vol 23, No. 9, 1126-1136)).
[0024] A heavy chain variable region comprising a third CDR
consisting essentially of the amino acid residues GQGY wherein the
CDR contains at least one substitution within the GQGY core
sequence, the substitutions being selected from the following
substitutions: where the G in the first position is replaced by R,
I, W or M; the Q in the second position is replaced by D, I, A, L,
V or S; the G in the third position is replaced by W, N, Y, S, L or
F; and the Y in the fourth position is replaced by W.
[0025] In another embodiment, the third heavy chain CDR (CDR H3)
only contains one substitutions to yield the following CDR H3: RQGY
(SEQ ID NO.75), IQGY (SEQ ID NO.76), MQGY (SEQ ID NO.45), GDGY (SEQ
ID NO.77), GIGY (SEQ ID NO.78), GSGY (SEQ ID NO.79), GQNY (SEQ ID
NO.80), GQYY (SEQ ID NO.81), GQSY (SEQ ID NO.62), GQLY (SEQ ID
NO.82), GQFY (SEQ ID NO.83), GQGW (SEQ ID NO.84), WQGY(SEQ ID
NO.86), GAGY (SEQ ID NO.87), GLGY (SEQ ID NO.88), GVGY (SEQ ID
NO.89), GQWY (SEQ ID NO.90).
[0026] In another embodiment, the heavy chain variable regions
above further contain the other CDRs listed in Table 2, i.e. CDR H1
(SEQ ID NO. 1) and CDR H2 (SEQ ID NO.2).
[0027] The antibodies of the present invention, or fragments
thereof, retain the human NOGO binding activity of antibodies that
comprise the CDR H3: GQGY, in terms of their activity as measured
in ELISA and Biacore experiments, and in some cases the activity in
these experiments is increased.
Human or Humanised Heavy Chain Variable Regions Containing G95M
(Substitution Numbering by Kabat)
[0028] In one embodiment of the present invention, the heavy chain
variable regions of the present invention comprise the CDRs defined
in Table 3 (as defined by Kabat):
TABLE-US-00003 TABLE 3 CDR Sequence H1 SYWMH (SEQ ID NO: 1) H2
NINPSNGGTNYNEKFKS (SEQ ID NO: 2) H3 MQGY (SEQ ID NO: 45)
[0029] In one embodiment of the present invention there is provided
a human or humanised heavy chain variable region comprising each of
the CDRs listed in Table 3. In another embodiment of the present
invention there is provided a humanised heavy chain variable region
comprising the CDRs listed in Table 3 within the larger sequence of
a human heavy chain variable region. In yet another embodiment the
humanised heavy chain variable region comprises the CDRs listed in
Table 3 within an acceptor antibody framework having greater than
40% identity in the framework regions, or greater than 50%, or
greater than 60%, or greater than 65% identity to the murine 2A10
donor antibody heavy chain variable region (SEQ ID NO.7).
[0030] When the CDRs of Table 3 are all used, in one embodiment the
heavy chain variable region sequence is sequence H98 provided as
SEQ ID NO. 66 (H98 VH is the equivalent of H1 VH (SEQ ID NO.33)
differing only in that the CDR H3 is MQGY in H98 instead of GQGY as
found in H1).
[0031] In one aspect of the present invention the antibodies
comprise a heavy chain variable region having the amino acid
sequence of SEQ ID NO. 66 (H98 variable region) further comprising
a number of substitutions at one or more of positions 38, 40, 48,
67, 68, 70, 72, 74, and 79; wherein each substituted amino acid
residue is replaced with the amino acid residue at the equivalent
position in SEQ ID NO 7 (the heavy chain variable region of the
donor antibody 2A10) and the number of substitutions is between 1
and 9. In other embodiments the number of substitutions is 1, or 2,
or 3, or 4, or 5, or 6, or 7, or 8 or 9.
[0032] In this context the substitutions that are described are
equivalent in concept to "back-mutations" where the human framework
amino acid residues in specific positions within the H98 sequence
are back-mutated to the amino acid residues in the equivalent
position within the 2A10 donor antibody sequence.
[0033] Unless specifically stated otherwise to the contrary herein,
when a numerical position of an amino acid residue found within a
specific sequence is mentioned in this document, for example
"position 12", it is intended that the skilled reader assigns the
first amino acid in the sequence the position "1" and counts from
position one and identifies the amino acid which is in the desired
position, in this example the twelfth amino acid residue in the
sequence. The skilled reader will notice that this numbering system
does not correspond with the Kabat numbering system which is often
used to define amino acid positions within antibody sequences.
[0034] For optimal binding affinity, it was found for the
humanisation of the mouse antibody 2A10 (the VH for which is SEQ ID
NO. 7) that the pair of amino acid residues in positions 48 and 68,
should be I and A respectively (as they exist in 2A10) or M and V
respectively (as they exist in H98). It is expected that the above
finding is also of relevance to the humanisation of the G95M
variant of 2A10.
[0035] The following table includes details of three different
heavy chain variable (VH) regions which may form part of the
antibodies of the present invention. Each of the disclosed VH is
based on the H98 VH (SEQ ID NO. 66) further comprising the
substitutions mentioned in the table (Table 4) where the H98
residue at the relevant position is substituted with the 2A10
residue at that position (in the table, "-" means that there is no
substitution in that position, and so the residue remains as in the
sequence of H98):
TABLE-US-00004 TABLE 4 Numerical Residue No. 38 40 48 67 68 70 72
74 79 Kabat No. 38 40 48 66 67 69 71 73 78 2A10 New VH K R I K A L
V K A (SEQ ID H98 NO. X) R A M R V M R T V H26 (47) -- -- I -- A --
-- -- A H27 (48) K R I K A L V K A H28 (49) -- -- I K A -- -- --
A
[0036] In one embodiment of the present invention, therefore, the
heavy chain variable regions (VH) of the present invention are H26
VH (SEQ ID NO. 47), H27 VH (SEQ ID NO. 48) and H28 VH (SEQ ID NO.
49)
TABLE-US-00005 SEQ ID 47: VH humanised construct H26
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWI
GNINPSNGGTNYNEKFKSRATMTRDTSTSTAYMELSSLRSEDTAVYYC ELMQGYWGQGTLVTVSS
SEQ ID 48: VH humanised construct H27
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVKQRPGQGLEWI
GNINPSNGGTNYNEKFKSKATLTVDKSTSTAYMELSSLRSEDTAVYYC ELMQGYWGQGTLVTVSS
SEQ ID 49: VH humanised construct H28
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWI
GNINPSNGGTNYNEKFKSKATMTRDTSTSTAYMELSSLRSEDTAVYYC
ELMQGYWGQGTLVTVSS
Human or Humanised Heavy Chain Variable Regions Including G101S
(Substitution Numbering by Kabat)
[0037] In another embodiment of the present invention there is
provided a human or humanised heavy chain variable region which
comprises CDRs defined in Table 5:
TABLE-US-00006 TABLE 5 CDR According to Kabat H1 SYWMH (SEQ ID NO:
1) H2 NINPSNGGTNYNEKFKS (SEQ ID NO: 2) H3 GQSY (SEQ ID NO: 62)
[0038] In one embodiment the CDRs of Table 5 are incorporated
within a human heavy chain variable region sequence. In another
embodiment the humanised heavy chain variable region comprises the
CDRs listed in Table 5 within an acceptor antibody framework having
greater than 40% identity in the framework regions, or greater than
50%, or greater than 60%, or greater than 65% identity to the
murine 2A10 donor antibody heavy chain variable region (SEQ ID
NO.7).
[0039] In another embodiment the CDRs of Table 5 are inserted into
a human heavy chain variable region to give the following sequence
(H99):
TABLE-US-00007 (SEQ ID 61: 2A10 VH humanised construct H99)
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWM
GNINPSNGGTNYNEKFKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYC
ELGQSYWGQGTLVTVSS.
[0040] In other embodiments, further back mutations are added to
the H99 VH sequence in any one of positions (denoted by numerical
residue position) 38, 40. 48, 67, 68, 70, 72, 74 or 79; wherein
each substituted amino acid residue is replaced with the amino acid
residue at the equivalent position in SEQ ID NO 7 (the heavy chain
variable region of the donor antibody 2A10) and the number of
substitutions is between 1 and 9. In other embodiments the number
of substitutions is 1, or 2, or 3, or 4, or 5, or 6, or 7, or 8 or
9. H99 VH is the equivalent of H1 VH (SEQ ID NO.33) differing only
in that the CDR H3 is GQSY in H99 instead of GQGY as found in
H1.
[0041] For optimal binding affinity, it was found for the
humanisation of the mouse antibody 2A10 (the VH for which is SEQ ID
NO. 7) that the pair of amino acid residues in positions 48 and 68,
should be I and A respectively (as they exist in 2A10) or M and V
respectively (as they exist in H98). It is expected that the above
finding is also of relevance to the humanisation of the G95M
variant of 2A10.
[0042] In one embodiment the back mutations are located in the
positions indicated in Table 6 below where the H99 residue at the
relevant position is substituted with the 2A10 residue at that
position (in the table, "-" means that there is no substitution in
that position, and so the residue remains as in the sequence of
H1):
Table 6,
TABLE-US-00008 [0043] TABLE 6 Numerical Residue No. 38 40 48 67 68
70 72 74 79 Kabat No. 38 40 48 66 67 69 71 73 78 2A10 New VH K R I
K A L V K A (SEQ ID H99 NO. X) R A M R V M R T V H100 (63) -- -- I
-- A -- -- -- A H101 (64) K R I K A L V K A H102 (65) -- -- I K A
-- -- -- A
Antibodies or Fragments that Comprise the Human or Humanised Heavy
Chain Variable Regions and Light Chain Variable Regions
[0044] The VH constructs of the present invention may be paired
with a light chain to form a human NOGO-A binding unit (Fv) in any
format, including a conventional IgG antibody format having full
length (FL) variable and constant domain heavy chain sequences.
Examples of full length (FL) IgG1 heavy chain sequences comprising
the VH constructs of the present invention and inactivating
mutations in positions 235 and 237 (EU Index numbering) to render
the antibody non-lytic are SEQ ID NOs 53, 54 and 55.
TABLE-US-00009 SEQ ID 53: Heavy chain humanised construct H26
MGWSCIILFLVATATGVHSQVQLVQSGAEVKKPGASVKVSCKASGYTFTS
YWMHWVRQAPGQGLEWIGNINPSNGGTNYNEKFKSRATMTRDTSTSTAYM
ELSSLRSEDTAVYYCELMQGYWGQGTLVTVSSASTKGPSVFPLAPSSKST
SGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSW
TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAG
APSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN
AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ
PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY TQKSLSLSPGK. SEQ
ID 54: Heavy chain humanised construct H27
MGWSCIILFLVATATGVHSQVQLVQSGAEVKKPGASVKVSCKASGYTFTS
YWMHWVKQRPGQGLEWIGNINPSNGGTNYNEKFKSKATLTVDKSTSTAYM
ELSSLRSEDTAVYYCELMQGYWGQGTLVTVSSASTKGPSVFPLAPSSKST
SGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELA
GAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH
NAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ
PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY TQKSLSLSPGK SEQ
ID 55: Heavy chain humanised construct H28
MGWSCIILFLVATATGVHSQVQLVQSGAEVKKPGASVKVSCKASGYTFTS
YWMHWVRQAPGQGLEWIGNINPSNGGTNYNEKFKSKATMTRDTSTSTAYM
ELSSLRSEDTAVYYCELMQGYWGQGTLVTVSSASTKGPSVFPLAPSSKST
SGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSW
TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAG
APSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN
AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ
PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY TQKSLSLSPGK
[0045] The light chain variable region sequence that forms an Fv
with the heavy chain variable region sequences of the present
invention may be any sequence that allows the Fv to bind to Human
NOGO-A.
[0046] In one embodiment of the present invention the light chain
variable region is the 2A10 light chain (see WO 05/061544), the
light chain variable region of which is provided herein as SEQ ID
NO. 8 or humanised variants thereof. Humanised variants of the 2A10
light chain preferably contain all of the light chain variable
region CDRs that are described in Table 1 grafted onto a human
light chain variable region acceptor framework. In one embodiment
the humanised light chain variable regions are L11 (SEQ ID NO.34),
L13 (SEQ ID NO.13) or L16 (SEQ ID NO.14). Alternative light chain
variable regions that are based on L13 and L16, which comprise
specific substitutions in kabat positions 37 and/or 45, are
provided in Table 7.
TABLE-US-00010 TABLE 7 SEQ Description ID NO. Sequence L100 (L13 +
Q37R) 67 DIVMTQSPLSLPVTLGQPASISCRSSKSLLYKDGKTYLNWFRQ
RPGQSPQLLIYLMSTRASGVPDRFSGGGSGTDFTLKISRVEA
EDVGVYYCQQLVEYPLTFGQGTKLEIK L101 (L13 + Q45R) 68
DIVMTQSPLSLPVTLGQPASISCRSSKSLLYKDGKTYLNWFQQ
RPGQSPRLLIYLMSTRASGVPDRFSGGGSGTDFTLKISRVEAE
DVGVYYCQQLVEYPLTFGQGTKLEIK L102 69
DIVMTQSPLSLPVTLGQPASISCRSSKSLLYKDGKTYLNWFRQ (L13 + Q37R/Q45R)
RPGQSPRLLIYLMSTRASGVPDRFSGGGSGTDFTLKISRVEAE
DVGVYYCQQLVEYPLTFGQGTKLEIK L103 (L16 + Q37R) 70
DIVMTQSPLSNPVTLGQPVSISCRSSKSLLYKDGKTYLNWFRQ
RPGQSPQLLIYLMSTRASGVPDRFSGGGSGTDFTLKISRVEA
EDVGVYYCQQLVEYPLTFGQGTKLEIK L104 (L16 + Q45R) 71
DIVMTQSPLSNPVTLGQPVSISCRSSKSLLYKDGKTYLNWFLQ
RPGQSPRLLIYLMSTRASGVPDRFSGGGSGTDFTLKISRVEAE
DVGVYYCQQLVEYPLTFGQGTKLEIK L105 72
DIVMTQSPLSNPVTLGQPVSISCRSSKSLLYKDGKTYLNWFRQ (L16 + Q37R/Q45R)
RPGQSPRLLIYLMSTRASGVPDRFSGGGSGTDFTLKISRVEAE
DVGVYYCQQLVEYPLTFGQGTKLEIK
[0047] In another embodiment the full length (FL) light chain
sequences are L11FL (SEQ ID NO.36), L13FL (SEQ ID NO.17) or L16FL
(SEQ ID NO.18).
[0048] In another embodiment the antibodies, fragments or
functional equivalents thereof comprise a VH sequence selected from
H26, H27, H28, H100, H101 and H102; in combination with any one of
the following VL sequences L11, L13, L16, L100, L101, L102, L103,
L104, and L105. It is intended that all possible combinations of
the listed heavy chain variable regions and light chain variable
regions be specifically disclosed (e.g. H28L104 et. al.).
[0049] In particular embodiments the antibodies, fragments or
functional equivalents thereof comprise the following variable
region pairs:
[0050] H27L16 (SEQ ID NO.48+SEQ ID NO.14)
[0051] H28L13 (SEQ ID NO.49+SEQ ID NO.13)
[0052] H28L16 (SEQ ID NO.49+SEQ ID NO.14)
[0053] In another embodiment the antibodies of the present
invention comprise the following full length sequences:
[0054] H27FL L16FL (SEQ ID NO. 54+SEQ ID NO.18)
[0055] H28FL L13FL (SEQ ID NO. 55+SEQ ID NO.17)
[0056] H28FL L16FL (SEQ ID NO. 55+SEQ ID NO.18)
[0057] In one embodiment the antibody of the present invention
comprises H27L16 (SEQ ID NO.48+SEQ ID NO.14), or is the full length
antibody H28FL L16FL (SEQ ID NO. 55+SEQ ID NO.18).
[0058] In another embodiment, the antibody or fragment thereof
binds to the same human NOGO epitope as H28L16, or competes with
the binding of H28L16 to human NOGO, characterised in both
instances in that the competing antibody, or fragment thereof, is
not the murine antibody 2A10 or a human or humanised variant
thereof comprising a CDR H3 having the sequence GQGY (SEQ ID NO.3)
or a sequence containing one amino acid substitution in the CDR
H3.
[0059] In particular embodiments the antibodies, fragments or
functional equivalents thereof comprise the following variable
region pairs:
[0060] H100L16 (SEQ ID NO.63+SEQ ID NO.14)
[0061] H101L13 (SEQ ID NO.64+SEQ ID NO.13)
[0062] H102L16 (SEQ ID NO.65+SEQ ID NO.14)
Epitope Mapping and Further Antibodies that Bind to the Same
Epitope
[0063] In another embodiment there is provided an antibody, or
fragment thereof, that is capable of binding to human NOGO protein,
or fragment thereof such as a GST-NOGO-A56 protein (SEQ ID NO.32),
in an ELISA assay, wherein the binding of the antibody, or fragment
thereof, to the human NOGO protein, or fragment thereof, in the
ELISA assay is reduced in the presence of a peptide having the
following sequence VLPDIVMEAPLN (SEQ ID NO. 60), and is not reduced
in the presence of an irrelevant peptide, for instance a peptide
from human NOGO that does not overlap with SEQ ID NO.60 (such as
SEQ ID NO. 85, YESIKHEPENPPPYEE), characterised in that the
antibody or fragment thereof is not an antibody comprising a heavy
chain variable domain having a CDR H3 consisting of the amino acid
residues GQGY or analogues thereof having one amino acid
substitution in the CDR H3. Alternatively the competing peptide is
TPSPVLPDIVMEAPLN (SEQ ID NO. 73) or VLPDIVMEAPLNSAVP (SEQ ID NO.
74). In addition, the antibody that binds to the same epitope as
the antibodies, or fragments thereof, may be an antibody that does
not comprise all of the CDRs listed in Tables 1 and 2, or any
antibody that comprises a set of CDRs that has 80% or greater
homology to the CDRs listed in Tables 1 and 2 combined, or Tables 1
or 2 alone.
[0064] In another embodiment of the present invention there is
provided an antibody or fragment thereof, that is capable of
binding in an ELISA assay to a region of human NOGO protein
consisting of the polypeptide sequence of VLPDIVMEAPLN (SEQ ID NO.
60), characterised in that the antibody, or fragment thereof is not
an antibody comprising a variable heavy domain having CDR H3
consisting of the amino acid residues GQGY or analogues thereof
having one amino acid substitution in the CDR H3. Alternatively the
antibody or fragment thereof is capable of binding to
TPSPVLPDIVMEAPLN (SEQ ID NO. 73) or VLPDIVMEAPLNSAVP (SEQ ID NO.
74). In addition, the antibody that binds to the same epitope as
the antibodies, or fragments thereof, may be an antibody that does
not comprise all of the CDRs listed in Tables 1 and 2, or any
antibody that comprises a set of CDRs that has 80% or greater
homology to the CDRs listed in Tables 1 and 2 combined, or Tables 1
or 2 alone.
[0065] In another embodiment of the present invention there is
provided a method of obtaining an antibody, or binding fragment
thereof, that binds to human NOGO epitope VLPDIVMEAPLN (SEQ ID NO.
60), comprising immunising a mammal with said peptide and isolating
cells capable of producing an antibody which binds to said peptide.
In another embodiment of the present invention there is provided a
method of obtaining an isolated antibody, or binding fragment
thereof, that binds to human NOGO epitope VLPDIVMEAPLN (SEQ ID NO.
60) comprising screening a library which comprises a plurality of
antibodies or binding fragments thereof, each being isolatable from
the library together with a nucleotide sequence that encodes the
antibody or binding fragment thereof, by the binding of the
antibody, or binding fragment thereof to the NOGO epitope
VLPDIVMEAPLN (SEQ ID NO. 60).
Pharmaceutical Compositions
[0066] A further aspect of the invention provides a pharmaceutical
composition comprising an anti-NOGO antibody of the present
invention or functional fragment or equivalent thereof together
with a pharmaceutically acceptable diluent or carrier.
[0067] In a further aspect, the present invention provides a method
of treatment or prophylaxis of stroke (particularly ischemic
stroke) and other neurological diseases, in particular Alzheimer's
disease, and treatment of a patient suffering from a mechanical
trauma to the CNS (such as spinal chord injury), in a human which
comprises administering to said human in need thereof an effective
amount of an anti-NOGO antibody of the invention or functional
fragments thereof.
[0068] In another aspect, the invention provides the use of an
anti-NOGO antibody of the invention or a functional fragment
thereof in the preparation of a medicament for treatment or
prophylaxis of stroke (particularly ischemic stroke) and other
neurological diseases, in particular Alzheimer's disease and
treatment of a patient suffering from a mechanical trauma to the
CNS (such as spinal chord injury).
[0069] In a further aspect, the present invention provides a method
of inhibiting neurodegeneration and/or promoting functional
recovery in a human patient afflicted with, or at risk of
developing, a stroke (particularly ischemic stroke) or other
neurological disease, in particular Alzheimer's disease, and
treatment of a patient suffering from a mechanical trauma to the
CNS (such as spinal chord injury), which comprises administering to
said human in need thereof an effective amount of an anti-NOGO
antibody of the invention or a functional fragment thereof.
[0070] In a yet further aspect, the invention provides the use of
an anti-NOGO antibody of the invention or a functional fragment
thereof in the preparation of a medicament for inhibiting
neurodegeneration and/or promoting functional recovery in a human
patient afflicted with, or at risk of developing, a stroke and
other neurological disease, in particular Alzheimer's disease and
treatment of a patient suffering from a mechanical trauma to the
CNS (such as spinal chord injury).
[0071] Other aspects and advantages of the present invention are
described further in the detailed description and the preferred
embodiments thereof.
BRIEF DESCRIPTION OF THE DRAWINGS
[0072] FIG. 1: GST-human NOGO-A56 coated at 1.0 mcg/ml. ELISA on
purified antibodies.
[0073] FIG. 2: GST-human NOGO-A56 coated at 0.05 mcg/ml. ELISA on
purified antibodies.
[0074] FIG. 3: GST-human NOGO-A56 coated at 1.0 mcg/ml. ELISA on
purified antibodies.
[0075] FIG. 4: GST-human NOGO-A56 coated at 0.05 mcg/ml. ELISA on
purified antibodies.
[0076] FIG. 5: Epitope mapping using 2A10.
[0077] FIG. 6: epitope mapping using H28L16
[0078] FIG. 7: Comparison of the binding activity of Hc(G95M)Lc and
HcLc as determined using a human NOGO-A binding ELISA when NOGO was
coated onto Nunc immunosorp plates at 0.05 .mu.g/ml.
[0079] FIG. 8: Comparison of the binding activity of Hc(G95M)Lc and
HcLc as determined using a human NOGO-A binding ELISA when NOGO was
coated onto Nunc immunosorp plates at 1 .mu.g/ml.
[0080] FIG. 9: Comparison of the binding activity of variants of
H6FL in comparison to H6FL L13FL.
[0081] FIG. 10: Comparison of the binding activity of variants of
H6FL in comparison to H6FL L13FL.
[0082] FIG. 11: Direct binding ELISA of the pre-candidate pool
antibodies to recombinant human Nogo-A (GST-Nogo-A 5+6).
Recombinant GST-Nogo-A 5+6 was coated to the plates at A) 1.0
mcg/ml and B) 0.05 mcg/ml. Binding of the antibodies was detected
using an anti-human IgG-HRP conjugate (Sigma, #A7340X). The
negative control was an anti .beta.-amyloid antibody (H2L1). EC50
values were derived using Robosage. Each of the graphs below show a
representative figure from three independent assays.
[0083] FIG. 12: Reverse format binding ELISA of the pre-candidate
pool antibodies to recombinant human Nogo-A (GST-Nogo-A 5+6). The
anti-Nogo-A antibodies were captured with anti-human IgG (Sigma,
#19764). The binding of recombinant GST-Nogo-A 5+6 was detected
using an anti-GST-HRP conjugate (Sigma, #A7340). The negative
control was an irrelevant antibody. EC50 values were derived using
Robosage. The graph below shows a representative figure from three
independent assays.
[0084] FIG. 13: Competition ELISA of the pre-candidate pool
antibodies with the parental antibody 2A10. Recombinant human
Nogo-A (GST-Nogo-A 5+6) was coated to the plates. 2A10 and the
humanised antibodies pre-mixed and binding of 2A10 determined using
an anti-mouse IgG-HRP conjugate (Dakocytomation, #P0260). The
positive control was HcLc. IC50 values were derived using Robosage.
The graph below shows a representative figure from three
independent assays.
[0085] FIG. 14: Binding of the anti-Nogo-A humanised antibodies to
cell-surface expressed human Nogo-A. CHO-K1 cells were engineered
to express human Nogo-A. The cells were stained in duplicate with
100 mcg/ml of the anti-Nogo-A humanised antibodies followed by a
1:100 dilution of the PE-labelled anti-human IgG secondary (Sigma,
#P8047). An irrelevant antibody was included as a negative control.
The data shown are a representative example of one of the
duplicates.
[0086] FIG. 15: Binding of the anti-Nogo-A humanised antibodies to
intracellular human Nogo-A. IMR32 cells were permeabilised, fixed
and stained with 3-90 mcg/ml of the anti-Nogo-A humanised
antibodies followed by 30 mcg/ml of the PE-labelled anti-human IgG
secondary (Sigma P-9047). An irrelevant antibody was included as a
negative control (-ve Ab). The data shown below is representative
of three independent experiments.
[0087] FIG. 16: Comparison of anti-Nogo-A humanised antibodies in
the neurite outgrowth assay. H28L16, H27L16 and H20L16 were
compared to the parental antibodies (2A10, HcLc), the antibody 11C7
and various control antibodies (Control IgG and Campath). Increased
neurite-outgrowth was only seen with anti-Nogo-A antibodies. The
effects were dose-dependent and statistically significant.
[0088] FIG. 17: Direct binding ELISA of H28L16 to recombinant
full-length human Nogo-A splice (GST-Nogo-A-Biocat 113015).
Recombinant Nogo-A splice was coated to the plates at 1.0 mcg/ml.
Binding of the antibodies was detected using an anti-human IgG-HRP
conjugate (Sigma, #A7340X). The negative control was an anti
.beta.-amyloid antibody. EC50 values were derived using Robosage.
The graph below shows a representative figure from two independent
assays.
[0089] FIG. 18: H28L16 shows reduced C1q binding. ELISA plates were
coated with a fixed concentration of the purified humanised and
control antibodies (1 mcg/ml). Human C1q (Sigma, C0660) was
incubated with the antibodies and bound C1q quantified using an
anti-human c1q-HRP conjugate (The Binding Site, PP020X). The
control antibodies are Campath IgG1, Campath IgG4 and Campath IgG1
Fc-.
[0090] FIG. 19: Direct binding ELISA of H28L16, HcLc and 11C7 to
GST-NOGO-A56 from A) rat B) cynomolgus, C) marmoset and D) squirrel
monkey. HcLc was included as a reference. An irrelevant antibody
was included as a negative control. The graphs below shows a
representative figure from three independent assays.
[0091] FIG. 20: Competition ELISA to compare the binding epitopes
of H28L16 and 11C7. Recombinant human Nogo-A (GST-Nogo-A 5+6) was
coated to the plates. 2A10 and either 11C7 or H28L16 were pre-mixed
and binding of 2A10 determined using an anti-mouse IgG-HRP
conjugate (Dakocytomation, #P0260). IC50 values were derived using
Robosage. The graph below shows a representative figure from three
independent assays.
[0092] FIG. 21: Competition ELISA to compare the binding of
NOGO-5+6 (GST-Nogo-A 5+6) and peptide fragments to H28L16. The
graph below shows a representative figure from two independent
assays.
[0093] FIG. 22: ELISA data for the G101S/Q37R variant in comparison
with H6L13 and H27L16
DETAILED DESCRIPTION OF THE INVENTION
[0094] The heavy chain variable regions of the invention may be
formatted into the structure of a natural antibody or functional
fragment or equivalent thereof. The antibody may therefore comprise
the VH regions of the invention formatted into a full length
antibody, a (Fab').sub.2 fragment, a Fab fragment, or equivalent
thereof (such as scFV, bi- tr- or tetra-bodies, Tandabs, etc.),
when paired with an appropriate light chain. The antibody may be an
IgG1, IgG2, IgG3, or IgG4; or IgM; IgA, IgE or IgD or a modified
variant thereof. The constant domain of the antibody heavy chain
may be selected accordingly. The light chain constant domain may be
a kappa or lambda constant domain. Furthermore, the antibody may
comprise modifications of all classes e.g. IgG dimers, Fc mutants
that no longer bind Fc receptors or mediate C1q binding. The
antibody may also be a chimeric antibody of the type described in
WO86/01533 which comprises an antigen binding region and a
non-immunoglobulin region.
[0095] The constant region is selected according to the
functionality required. Normally an IgG1 will demonstrate lytic
ability through binding to complement and/or will mediate ADCC
(antibody dependent cell cytotoxicity). An IgG4 will be preferred
if a non-cytotoxic blocking antibody is required. However, IgG4
antibodies can demonstrate instability in production and therefore
it may be more preferable to modify the generally more stable IgG1.
Suggested modifications are described in EP0307434 preferred
modifications include at positions 235 and 237. The invention
therefore provides a lytic or a non-lytic form of an antibody
according to the invention.
[0096] In preferred forms therefore the antibody of the invention
is a full length (i.e. H2L2 tetramer) non-lytic IgG1 antibody
having the heavy chain variable regions described herein.
[0097] In a further aspect, the invention provides polynucleotides
encoding the heavy chain variable regions as described herein.
[0098] "NOGO" refers to any NOGO polypeptide, including variant
forms. This includes, but is not limited to, NOGO-A having 1192
amino acid residues (GenBank accession no. AJ251383); NOGO-B, a
splice variant which lacks residues 186 to 1004 in the putative
extracellular domain (GenBank accession no. AJ251384) and a shorter
splice variant, NOGO-C, which also lacks residues 186 to 1004 and
also has smaller, alternative amino terminal domain (GenBank
accession no. AJ251385) (Prinjha et al (2000) supra). All
references to "NOGO" herein is understood to include any and all
variant forms of NOGO such as NOGO-A and the splice variants
described, unless a specific form is indicated.
[0099] "Neutralising" and grammatical variations thereof refers to
inhibition, either total or partial, of NOGO function including its
binding to neurones and inhibition of neurite growth.
[0100] The terms Fv, Fc, Fd, Fab, or F(ab).sub.2 are used with
their standard meanings (see, e.g., Harlow et al., Antibodies A
Laboratory Manual, Cold Spring Harbor Laboratory, (1988)).
[0101] A "chimeric antibody" refers to a type of engineered
antibody which contains a naturally-occurring variable region
(light chain and heavy chains) derived from a donor antibody in
association with light and heavy chain constant regions derived
from an acceptor antibody.
[0102] A "humanized antibody" refers to a type of engineered
antibody having its CDRs derived from a non-human donor
immunoglobulin, the remaining immunoglobulin-derived parts of the
molecule being derived from one (or more) human immunoglobulin(s).
In addition, framework support residues may be altered to preserve
binding affinity (see, e.g., Queen et al., Proc. Natl. Acad Sci
USA, 86:10029-10032 (1989), Hodgson et al., Bio/Technology, 9:421
(1991)). A suitable human acceptor antibody may be one selected
from a conventional database, e.g., the KABAT.RTM. database, Los
Alamos database, and Swiss Protein database, by homology to the
nucleotide and amino acid sequences of the donor antibody (in this
case the murine donor antibody 2A10). A human antibody
characterized by a homology to the framework regions of the donor
antibody (on an amino acid basis) may be suitable to provide a
heavy chain constant region and/or a heavy chain variable framework
region for insertion of the donor CDRs (see Table 1 for the 2A10
CDRs for insertion into the acceptor framework). A suitable
acceptor antibody capable of donating light chain constant or
variable framework regions may be selected in a similar manner. It
should be noted that the acceptor antibody heavy and light chains
are not required to originate from the same acceptor antibody. The
prior art describes several ways of producing such humanised
antibodies--see for example EP-A-0239400 and EP-A-054951.
[0103] The term "donor antibody" refers to a non-human antibody
which contributes the amino acid sequences of its variable regions,
CDRs, or other functional fragments or analogs thereof to the
humanised antibody, and thereby provide the humanised antibody with
the antigenic specificity and neutralizing activity characteristic
of the donor antibody.
[0104] The term "acceptor antibody" refers to an antibody
heterologous to the donor antibody, which provides the amino acid
sequences of its heavy and/or light chain framework regions and/or
its heavy and/or light chain constant regions to the humanised
antibody. The acceptor antibody may be derived from any mammal
provided that it is non-immunogenic in humans. Preferably the
acceptor antibody is a human antibody.
[0105] Alternatively, humanisation maybe achieved by a process of
"veneering". A statistical analysis of unique human and murine
immunoglobulin heavy and light chain variable regions revealed that
the precise patterns of exposed residues are different in human and
murine antibodies, and most individual surface positions have a
strong preference for a small number of different residues (see
Padlan E. A. et al; (1991) Mol. Immunol. 28, 489-498 and Pedersen
J. T. et al (1994) J. Mol. Biol. 235; 959-973). Therefore it is
possible to reduce the immunogenicity of a non-human Fv by
replacing exposed residues in its framework regions that differ
from those usually found in human antibodies. Because protein
antigenicity can be correlated with surface accessibility,
replacement of the surface residues may be sufficient to render the
mouse variable region "invisible" to the human immune system (see
also Mark G. E. et al (1994) in Handbook of Experimental
Pharmacology vol. 113: The pharmacology of monoclonal Antibodies,
Springer-Verlag, pp 105-134). This procedure of humanisation is
referred to as "veneering" because only the surface of the antibody
is altered, the supporting residues remain undisturbed. A further
alternative approach is set out in WO04/006955.
[0106] "CDRs" are defined as the complementarity determining region
amino acid sequences of an antibody which are the hypervariable
regions of immunoglobulin heavy and light chains. See, e.g., Kabat
et al., Sequences of Proteins of Immunological Interest, 4th Ed.,
U.S. Department of Health and Human Services, National Institutes
of Health (1987). There are three heavy chain and three light chain
CDRs (or CDR regions) in the variable portion of an immunoglobulin.
Thus, "CDRs" as used herein refers to all three heavy chain CDRs,
or all three light chain CDRs (or both all heavy and all light
chain CDRs, if appropriate). The structure and protein folding of
the antibody may mean that other residues are considered part of
the antigen binding region and would be understood to be so by a
skilled person. See for example Chothia et al., (1989)
Conformations of immunoglobulin hypervariable regions; Nature 342,
p 877-883.
[0107] A bispecific antibody is an antibody having binding
specificities for at least two different epitopes. Methods of
making such antibodies are known in the art. Traditionally, the
recombinant production of bispecific antibodies is based on the
coexpression of two immunoglobulin H chain-L chain pairs, where the
two H chains have different binding specificities see Millstein et
al, Nature 305 537-539 (1983), WO93/08829 and Traunecker et al
EMBO, 10, 1991, 3655-3659. Because of the random assortment of H
and L chains, a potential mixture of ten different antibody
structures are produced of which only one has the desired binding
specificity. An alternative approach involves fusing the variable
domains with the desired binding specificities to heavy chain
constant region comprising at least part of the hinge region, CH2
and CH3 regions. It is preferred to have the CH1 region containing
the site necessary for light chain binding present in at least one
of the fusions. DNA encoding these fusions, and if desired the L
chain are inserted into separate expression vectors and are then
cotransfected into a suitable host organism. It is possible though
to insert the coding sequences for two or all three chains into one
expression vector. In one preferred approach, the bispecific
antibody is composed of a H chain with a first binding specificity
in one arm and a H-L chain pair, providing a second binding
specificity in the other arm, see WO94/04690. See also Suresh et al
Methods in Enzymology 121, 210, 1986.
[0108] In one embodiment of the invention there is provided a
bispecific therapeutic antibody wherein at least one binding
specificity of said antibody binds to human NOGO at the epitope
described in SEQ ID NO. 60. In another embodiment of the present
invention the bispecific antibody comprises the heavy chain
variable region CDR H3 sequence MQGY (SEQ ID NO. 45). In another
embodiment the bispecific antibody comprises the following pairs of
heavy and light chain variable regions: H27L16 (SEQ ID NO.48+SEQ ID
NO.14), H28L13 (SEQ ID NO.49+SEQ ID NO.13) or H28L16 (SEQ ID
NO.49+SEQ ID NO.14).
[0109] The antibodies of the present invention may be produced by
transfection of a host cell with an expression vector comprising
the coding sequence for the antibodies of the invention. An
expression vector or recombinant plasmid is produced by placing
these coding sequences for the antibody in operative association
with conventional regulatory control sequences capable of
controlling the replication and expression in, and/or secretion
from, a host cell. Regulatory sequences include promoter sequences,
e.g., CMV promoter, and signal sequences, which can be derived from
other known antibodies. Similarly, a second expression vector can
be produced having a DNA sequence which encodes a complementary
antibody light or heavy chain. Preferably this second expression
vector is identical to the first except insofar as the coding
sequences and selectable markers are concerned, so to ensure as far
as possible that each polypeptide chain is functionally expressed.
Alternatively, the heavy and light chain coding sequences for the
altered antibody may reside on a single vector.
[0110] A selected host cell is co-transfected by conventional
techniques with both the first and second vectors (or simply
transfected by a single vector) to create the transfected host cell
of the invention comprising both the recombinant or synthetic light
and heavy chains. The transfected cell is then cultured by
conventional techniques to produce the engineered antibody of the
invention. The antibody which includes the association of both the
recombinant heavy chain and/or light chain is screened from culture
by appropriate assay, such as ELISA or RIA. Similar conventional
techniques may be employed to construct other altered antibodies
and molecules.
[0111] One useful expression system is a glutamate synthetase
system (such as sold by Lonza Biologics), particularly where the
host cell is CHO or NS0 (see below). Polynucleotide encoding the
antibody is readily isolated and sequenced using conventional
procedures (e.g. oligonucleotide probes). Vectors that may be used
include plasmid, virus, phage, transposons, minichromsomes of which
plasmids are a typical embodiment. Generally such vectors further
include a signal sequence, origin of replication, one or more
marker genes, an enhancer element, a promoter and transcription
termination sequences operably linked to the light and/or heavy
chain polynucleotide so as to facilitate expression. Polynucleotide
encoding the light and heavy chains may be inserted into separate
vectors and introduced (e.g. by electroporation) into the same host
cell or, if desired both the heavy chain and light chain can be
inserted into the same vector for transfection into the host cell.
Thus according to one embodiment of the present invention there is
provided a process of constructing a vector encoding the light
and/or heavy chains of a therapeutic antibody or antigen binding
fragment thereof of the invention, which method comprises inserting
into a vector, a polynucleotide encoding either a light chain
and/or heavy chain of a therapeutic antibody of the invention.
[0112] In another embodiment there is provided a polynucleotide
encoding a humanised heavy chain variable region having the
sequence set forth as SEQ. I.D. NO: 47, 48 or 49.
In another embodiment there is provided a polynucleotide encoding a
humanised heavy chain having the sequence set forth as SEQ. I.D.
NO: 53, 54 or 55.
[0113] It will be immediately apparent to those skilled in the art
that due to the redundancy of the genetic code, alternative
polynucleotides to those disclosed herein are also available that
will encode the polypeptides of the invention.
[0114] Suitable vectors for the cloning and subcloning steps
employed in the methods and construction of the compositions of
this invention may be selected by one of skill in the art. For
example, the conventional pUC series of cloning vectors may be
used. One vector, pUC19, is commercially available from supply
houses, such as Amersham (Buckinghamshire, United Kingdom) or
Pharmacia (Uppsala, Sweden). Additionally, any vector which is
capable of replicating readily, has an abundance of cloning sites
and selectable genes (e.g., antibiotic resistance), and is easily
manipulated may be used for cloning. Thus, the selection of the
cloning vector is not a limiting factor in this invention.
Other preferable vector sequences include a poly A signal sequence,
such as from bovine growth hormone (BGH) and the betaglobin
promoter sequence (betaglopro). The expression vectors useful
herein may be synthesized by techniques well known to those skilled
in this art. Typical selection genes encode proteins that (a)
confer resistance to antibiotics or other toxins e.g. ampicillin,
neomycin, methotrexate or tetracycline or (b) complement
auxiotrophic deficiencies or supply nutrients not available in the
complex media. The selection scheme may involve arresting growth of
the host cell. Cells, which have been successfully transformed with
the genes encoding the therapeutic antibody of the present
invention, survive due to e.g. drug resistance conferred by the
selection marker. Another example is the so-called DHFR selection
marker wherein transformants are cultured in the presence of
methotrexate. CHO cells are a particularly useful cell line for the
DHFR selection. Methods of selecting transformed host cells and
amplifying the cell copy number of the transgene include using the
DHFR system see Kaufman R. J. et al J. Mol. Biol. (1982) 159,
601-621, for review, see Werner R G, Noe W, Kopp K, Schluter M,"
Appropriate mammalian expression systems for biopharmaceuticals",
Arzneimittel-Forschung. 48(8):870-80, 1998 August A further example
is the glutamate synthetase expression system (Lonza Biologics). A
suitable selection gene for use in yeast is the trp1 gene; see
Stinchcomb et al Nature 282, 38, 1979.
[0115] The components of such vectors, e.g. replicons, selection
genes, enhancers, promoters, signal sequences and the like, may be
obtained from commercial or natural sources or synthesized by known
procedures for use in directing the expression and/or secretion of
the product of the recombinant DNA in a selected host. Other
appropriate expression vectors of which numerous types are known in
the art for mammalian, bacterial, insect, yeast, and fungal
expression may also be selected for this purpose.
[0116] The present invention also encompasses a cell line
transfected with a recombinant plasmid containing the coding
sequences of the antibodies or equivalents of the present
invention. Host cells useful for the cloning and other
manipulations of these cloning vectors are also conventional.
However, most desirably, cells from various strains of E. coli are
used for replication of the cloning vectors and other steps in the
construction of altered antibodies of this invention.
[0117] Suitable host cells or cell lines for the expression of the
antibody of the invention are preferably mammalian cells such as
NS0, Sp2/0, CHO (e.g. DG44), COS, a fibroblast cell (e.g., 3T3),
and myeloma cells, and more preferably a CHO or a myeloma cell.
Human cells may be used, thus enabling the molecule to be modified
with human glycosylation patterns. Alternatively, other eukaryotic
cell lines may be employed. The selection of suitable mammalian
host cells and methods for transformation, culture, amplification,
screening and product production and purification are known in the
art. See, e.g., Sambrook et al., cited above.
[0118] Bacterial cells may prove useful as host cells suitable for
the expression of the antibodies or fragments thereof (such as
recombinant Fabs or ScFvs) of the present invention (see, e.g.,
Pluckthun, A., Immunol. Rev., 130:151-188 (1992)). However, due to
the tendency of proteins expressed in bacterial cells to be in an
unfolded or improperly folded form or in a non-glycosylated form,
any recombinant fragment produced in a bacterial cell would have to
be screened for retention of antigen binding ability. If the
molecule expressed by the bacterial cell was produced in a properly
folded form, that bacterial cell would be a desirable host. For
example, various strains of E. coli used for expression are
well-known as host cells in the field of biotechnology. Various
strains of B. subtilis, Streptomyces, other bacilli and the like
may also be employed in this method.
[0119] Where desired, strains of yeast cells known to those skilled
in the art are also available as host cells, as well as insect
cells, e.g. Drosophila and Lepidoptera and viral expression
systems. See, e.g. Miller et al., Genetic Engineering, 8:277-298,
Plenum Press (1986) and references cited therein.
[0120] The general methods by which the vectors may be constructed,
the transfection methods required to produce the host cells of the
invention, and culture methods necessary to produce the antibody of
the invention from such host cell are all conventional techniques.
Typically, the culture method of the present invention is a
serum-free culture method, usually by culturing cells serum-free in
suspension. Likewise, once produced, the antibodies of the
invention may be purified from the cell culture contents according
to standard procedures of the art, including ammonium sulfate
precipitation, affinity columns, column chromatography, gel
electrophoresis and the like. Such techniques are within the skill
of the art and do not limit this invention. For example,
preparation of antibodies are described in WO 99/58679 and WO
96/16990.
[0121] Yet another method of expression of the antibodies may
utilize expression in a transgenic animal, such as described in
U.S. Pat. No. 4,873,316. This relates to an expression system using
the animal's casein promoter which when transgenically incorporated
into a mammal permits the female to produce the desired recombinant
protein in its milk.
[0122] In a further aspect of the invention there is provided a
method of producing an antibody of the invention which method
comprises the step of culturing a host cell transformed or
transfected with a vector encoding the light and/or heavy chain of
the antibody of the invention and recovering the antibody thereby
produced.
[0123] Suitable host cells for cloning or expressing vectors
encoding antibodies of the invention are prokaroytic, yeast or
higher eukaryotic cells. Suitable prokaryotic cells include
eubacteria e.g. enterobacteriaceae such as Escherichia e.g. E. Coli
(for example ATCC 31,446; 31,537; 27,325), Enterobacter, Erwinia,
Klebsiella Proteus, Salmonella e.g. Salmonella typhimurium,
Serratia e.g. Serratia marcescans and Shigella as well as Bacilli
such as B. subtilis and B. licheniformis (see DD 266 710),
Pseudomonas such as P. aeruginosa and Streptomyces. Of the yeast
host cells, Saccharomyces cerevisiae, schizosaccharomyces pombe,
Kluyveromyces (e.g. ATCC 16,045; 12,424; 24178; 56,500), yarrowia
(EP402, 226), Pichia Pastoris (EP183, 070, see also Peng et al J.
Biotechnol. 108 (2004) 185-192), Candida, Trichoderma reesia
(EP244, 234), Penicillin, Tolypocladium and Aspergillus hosts such
as A. nidulans and A. niger are also contemplated.
[0124] Although Prokaryotic and yeast host cells are specifically
contemplated by the invention, typically however, host cells of the
present invention are vertebrate cells. Suitable vertebrate host
cells include mammalian cells such as COS-1 (ATCC No.CRL 1650)
COS-7 (ATCC CRL 1651), human embryonic kidney line 293, baby
hamster kidney cells (BHK) (ATCC CRL.1632), BHK570 (ATCC NO: CRL
10314), 293 (ATCC NO.CRL 1573), Chinese hamster ovary cells CHO
(e.g. CHO-K1, ATCC NO: CCL 61, DHFR-CHO cell line such as DG44 (see
Urlaub et al, (1986) Somatic Cell Mol. Genet. 12, 555-556)),
particularly those CHO cell lines adapted for suspension culture,
mouse sertoli cells, monkey kidney cells, African green monkey
kidney cells (ATCC CRL-1587), HELA cells, canine kidney cells (ATCC
CCL 34), human lung cells (ATCC CCL 75), Hep G2 and myeloma or
lymphoma cells e.g. NS0 (see U.S. Pat. No. 5,807,715), Sp2/0,
Y0.
[0125] Thus in one embodiment of the invention there is provided a
stably transformed host cell comprising a vector encoding a heavy
chain and/or light chain of the therapeutic antibody or antigen
binding fragment thereof as described herein. Typically such host
cells comprise a first vector encoding the light chain and a second
vector encoding said heavy chain.
[0126] Host cells transformed with vectors encoding the therapeutic
antibodies of the invention or antigen binding fragments thereof
may be cultured by any method known to those skilled in the art.
Host cells may be cultured in spinner flasks, roller bottles or
hollow fibre systems but it is preferred for large scale production
that stirred tank reactors are used particularly for suspension
cultures. Typically the stirred tankers are adapted for aeration
using e.g. spargers, baffles or low shear impellers. For bubble
columns and airlift reactors direct aeration with air or oxygen
bubbles maybe used. Where the host cells are cultured in a serum
free culture media it is preferred that the media is supplemented
with a cell protective agent such as pluronic F-68 to help prevent
cell damage as a result of the aeration process. Depending on the
host cell characteristics, either microcarriers maybe used as
growth substrates for anchorage dependent cell lines or the cells
maybe adapted to suspension culture (which is typical). The
culturing of host cells, particularly vertebrate host cells may
utilise a variety of operational modes such as fed-batch, repeated
batch processing (see Drapeau et al (1994) cytotechnology 15:
103-109), extended batch process or perfusion culture. Although
recombinantly transformed mammalian host cells may be cultured in
serum-containing media such media comprising fetal calf serum
(FCS), it is preferred that such host cells are cultured in
synthetic serum-free media such as disclosed in Keen et al (1995)
Cytotechnology 17:153-163, or commercially available media such as
ProCHO-CDM or UltraCHO.TM. (Cambrex N.J., USA), supplemented where
necessary with an energy source such as glucose and synthetic
growth factors such as recombinant insulin. The serum-free
culturing of host cells may require that those cells are adapted to
grow in serum free conditions. One adaptation approach is to
culture such host cells in serum containing media and repeatedly
exchange 80% of the culture medium for the serum-free media so that
the host cells learn to adapt in serum free conditions (see e.g.
Scharfenberg K et al (1995) in Animal Cell technology: Developments
towards the 21st century (Beuvery E. C. et al eds), pp 619-623,
Kluwer Academic publishers).
[0127] Antibodies of the invention secreted into the media may be
recovered and purified from the media using a variety of techniques
to provide a degree of purification suitable for the intended use.
For example the use of therapeutic antibodies of the invention for
the treatment of human patients typically mandates at least 95%
purity, more typically 98% or 99% purity compared to the culture
media comprising the therapeutic antibodies. In the first instance,
cell debris from the culture media is typically removed using
centrifugation followed by a clarification step of the supernatant
using e.g. microfiltration, ultrafiltration and/or depth
filtration. A variety of other techniques such as dialysis and gel
electrophoresis and chromatographic techniques such as
hydroxyapatite (HA), affinity chromatography (optionally involving
an affinity tagging system such as polyhistidine) and/or
hydrophobic interaction chromatography (HIC, see U.S. Pat. No.
5,429,746) are available. In one embodiment, the antibodies of the
invention, following various clarification steps, are captured
using Protein A or G affinity chromatography followed by further
chromatography steps such as ion exchange and/or HA chromatography,
anion or cation exchange, size exclusion chromatography and
ammonium sulphate precipitation. Typically, various virus removal
steps are also employed (e.g. nanofiltration using e.g. a DV-20
filter). Following these various steps, a purified (typically
monoclonal) preparation comprising at least 75 mg/ml or greater
e.g. 100 mg/ml or greater of the antibody of the invention or
antigen binding fragment thereof is provided and therefore forms an
embodiment of the invention. Suitably such preparations are
substantially free of aggregated forms of antibodies of the
invention.
[0128] In accordance with the present invention there is provided a
method of producing an anti-NOGO antibody of the present invention
which specifically binds to and neutralises the activity of human
NOGO-A which method comprises the steps of; [0129] (a) providing a
first vector encoding a heavy chain of the antibody; [0130] (b)
providing a second vector encoding the light chain of the antibody;
[0131] (c) transforming a mammalian host cell (e.g. CHO) with said
first and second vectors; [0132] (d) culturing the host cell of
step (c) under conditions conducive to the secretion of the
antibody from said host cell into said culture media; [0133] (e)
recovering the secreted antibody of step (d).
[0134] Once expressed by the desired method, the antibody is then
examined for in vitro activity by use of an appropriate assay.
Presently conventional ELISA assay formats are employed to assess
qualitative and quantitative binding of the antibody to NOGO.
Additionally, other in vitro assays may also be used to verify
neutralizing efficacy prior to subsequent human clinical studies
performed to evaluate the persistence of the antibody in the body
despite the usual clearance mechanisms.
[0135] Other modifications to the antibodies of the present
invention include glycosylation variants of the antibodies of the
invention. Glycosylation of antibodies at conserved positions in
their constant regions is known to have a profound effect on
antibody function, particularly effector functioning such as those
described above, see for example, Boyd et al (1996), Mol. Immunol.
32, 1311-1318. Glycosylation variants of the therapeutic antibodies
or antigen binding fragments thereof of the present invention
wherein one or more carbonhydrate moiety is added, substituted,
deleted or modified are contemplated. Introduction of an
asparagine-X-serine or asparagine-X-threonine motif creates a
potential site for enzymatic attachment of carbonhydrate moieties
and may therefore be used to manipulate the glycosylation of an
antibody. In Raju et al (2001) Biochemistry 40, 8868-8876 the
terminal sialyation of a TNFR-IgG immunoadhesin was increased
through a process of regalactosylation and/or resialylation using
beta-1,4-galactosyltransferace and/or alpha, 2,3 sialyltransferase.
Increasing the terminal sialylation is believed to increase the
half-life of the immunoglobulin. Antibodies, in common with most
glycoproteins, are typically produced in nature as a mixture of
glycoforms. This mixture is particularly apparent when antibodies
are produced in eukaryotic, particularly mammalian cells. A variety
of methods have been developed to manufacture defined glycoforms,
see Zhang et al Science (2004), 303, 371, Sears et al, Science,
(2001) 291, 2344, Wacker et al (2002) Science, 298 1790, Davis et
al (2002) Chem. Rev. 102, 579, Hang et al (2001) Acc. Chem. Res 34,
727. Thus the invention concerns a plurality of therapeutic
(typically monoclonal) antibodies (which maybe of the IgG isotype,
e.g. IgG1) as described herein comprising a defined number (e.g. 7
or less, for example 5 or less such as two or a single)
glycoform(s) of said antibodies or antigen binding fragments
thereof.
[0136] The therapeutic agents of this invention may be administered
as a prophylactic or following the stroke event/on-set of clinical
symptoms, or as otherwise needed. The dose and duration of
treatment relates to the relative duration of the molecules of the
present invention in the human circulation, and can be adjusted by
one of skill in the art depending upon the condition being treated
and the general health of the patient. It is envisaged that
repeated dosing (e.g. once a week or once every two weeks) over an
extended time period (e.g. four to six months) maybe required to
achieve maximal therapeutic efficacy.
[0137] The mode of administration of the therapeutic agent of the
invention may be any suitable route which delivers the agent to the
host. The antibodies, and pharmaceutical compositions of the
invention are particularly useful for parenteral administration,
i.e., subcutaneously (s.c.), intrathecally, intraperitoneally
(i.p.), intramuscularly (i.m.), intravenously (i.v.), or
intranasally (i.n.).
[0138] Therapeutic agents of the invention may be prepared as
pharmaceutical compositions containing an effective amount of the
antibody of the invention as an active ingredient in a
pharmaceutically acceptable carrier. In the prophylactic agent of
the invention, an aqueous suspension or solution containing the
engineered antibody, preferably buffered at physiological pH, in a
form ready for injection is preferred. The compositions for
parenteral administration will commonly comprise a solution of the
antibody of the invention or a cocktail thereof dissolved in a
pharmaceutically acceptable carrier, preferably an aqueous carrier.
A variety of aqueous carriers may be employed, e.g., 0.9% saline,
0.3% glycine, and the like. These solutions are sterile and
generally free of particulate matter. These solutions may be
sterilized by conventional, well known sterilization techniques
(e.g., filtration). The compositions may contain pharmaceutically
acceptable auxiliary substances as required to approximate
physiological conditions such as pH adjusting and buffering agents,
etc. The concentration of the antibody of the invention in such
pharmaceutical formulation can vary widely, i.e., from less than
about 0.5%, usually at or at least about 1% to as much as 15 or 20%
by weight and will be selected primarily based on fluid volumes,
viscosities, etc., according to the particular mode of
administration selected.
[0139] Thus, a pharmaceutical composition of the invention for
intramuscular injection could be prepared to contain 1 mL sterile
buffered water, and between about 1 ng to about 100 mg, e.g. about
50 ng to about 30 mg or more preferably, about 5 mg to about 25 mg,
of an antibody of the invention. Similarly, a pharmaceutical
composition of the invention for intravenous infusion could be made
up to contain about 250 ml of sterile Ringer's solution, and about
1 to about 30 and preferably 5 mg to about 25 mg of an engineered
antibody of the invention per ml of Ringer's solution. Actual
methods for preparing parenterally administrable compositions are
well known or will be apparent to those skilled in the art and are
described in more detail in, for example, Remington's
Pharmaceutical Science, 15th ed., Mack Publishing Company, Easton,
Pa. For the preparation of intravenously administrable antibody
formulations of the invention see Lasmar U and Parkins D "The
formulation of Biopharmaceutical products", Pharma. Sci. Tech.
today, page 129-137, Vol. 3 (3.sup.rd April 2000), Wang, W
"Instability, stabilisation and formulation of liquid protein
pharmaceuticals", Int. J. Pharm 185 (1999) 129-188, Stability of
Protein Pharmaceuticals Part A and B ed Ahern T. J., Manning M. C.,
New York, N.Y.: Plenum Press (1992), Akers, M. J. "Excipient-Drug
interactions in Parenteral Formulations", J. Pharm Sci 91 (2002)
2283-2300, Imamura, K et al "Effects of types of sugar on
stabilization of Protein in the dried state", J Pharm Sci 92 (2003)
266-274, Izutsu, Kkojima, S. "Excipient crystallinity and its
protein-structure-stabilizing effect during freeze-drying", J
Pharm. Pharmacol, 54 (2002) 1033-1039, Johnson, R,
"Mannitol-sucrose mixtures-versatile formulations for protein
lyophilization", J. Pharm. Sci, 91 (2002) 914-922.
[0140] Ha, E Wang W, Wang Y. j. "Peroxide formation in polysorbate
80 and protein stability", J. Pharm Sci, 91, 2252-2264, (2002) the
entire contents of which are incorporated herein by reference and
to which the reader is specifically referred.
[0141] It is preferred that the therapeutic agent of the invention,
when in a pharmaceutical preparation, be present in unit dose
forms. The appropriate therapeutically effective dose will be
determined readily by those of skill in the art. To effectively
treat stroke and other neurological diseases in a human, one dose
within the range of 700 to 3500 mg per 70 kg body weight of an
antibody of this invention is envisaged to be administered
parenterally, preferably s.c., i.v. or i.m. (intramuscularly). Such
dose may, if necessary, be repeated at appropriate time intervals
selected as appropriate by a physician.
[0142] The antibodies described herein can be lyophilized for
storage and reconstituted in a suitable carrier prior to use. This
technique has been shown to be effective with conventional
immunoglobulins and art-known lyophilization and reconstitution
techniques can be employed.
[0143] In another aspect, the invention provides a pharmaceutical
composition comprising anti-NOGO antibody of the present invention
or a functional fragment thereof and a pharmaceutically acceptable
carrier for treatment or prophylaxis of stroke and other
neurological diseases.
[0144] In a yet further aspect, the invention provides a
pharmaceutical composition comprising the anti-NOGO antibody of the
present invention or a functional fragment thereof and a
pharmaceutically acceptable carrier for inhibiting
neurodegeneration and/or promoting functional recovery in a human
patient suffering, or at risk of developing, a stroke or other
neurological disease.
[0145] The invention further provides a method of treatment or
prophylaxis of stroke (particularly ischemic stroke) and other
neurological diseases/disorders, in particular Alzheimer's disease,
in a human which comprises administering to said human in need
thereof an effective amount of an anti-NOGO antibody of the present
invention or a functional fragment thereof. Antibodies of the
invention may be used in methods of treatment to slow or halt the
progression and/or onset of Alzheimer's disease in addition to (or
as an alternative to) treating established disease in a human
patient.
[0146] Further the invention provides the use of an anti-NOGO
antibody of the present invention, or a functional fragment
thereof, in the preparation of a medicament for treatment or
prophylaxis of stroke and other neurological diseases/disorders, in
particular Alzheimer's disease.
[0147] The invention also provides a method of inhibiting
neurodegeneration and/or promoting functional recovery in a human
patient suffering, or at risk of developing, a stroke or other
neurological disease/disorder, in particular Alzheimer's disease,
which comprises administering to said human in need thereof an
effective amount of an anti-NOGO antibody of the present invention
or a functional fragment thereof.
[0148] In addition the invention provides the use of an anti-NOGO
antibody of the present invention or a functional fragment thereof
in the preparation of a medicament for inhibiting neurodegeneration
and/or promoting functional recovery in a human patient afflicted
with, or at risk of developing, a stroke and other neurological
disease/disorder, in particular Alzheimer's disease.
[0149] The invention further provides a method of treating or
prophylaxis of stroke or other neurological disease/disorder, in
particular Alzheimer's disease, in a human comprising the step of
parenteral administration of a therapeutically effective amount of
an anti-NOGO antibody of the present invention. Preferably the said
anti-NOGO antibody is administered intravenously.
[0150] Neurological diseases or disorders as used hereinabove
includes, but is not limited to traumatic brain injury, spinal cord
injury, fronto-temporal dementias (tauopathies), peripheral
neuropathy, Parkinson's disease, Huntington's disease, and in
particular Alzheimer's disease, multiple sclerosis or amyotrophic
lateral sclerosis (ALS).
[0151] The invention also provides a method of promoting axonal
sprouting comprising the step of contacting a human axon with an
anti-NOGO antibody of the present invention. This method may be
performed in-vitro or in-vivo, preferably the method is performed
in-vivo.
[0152] In a further aspect therefore there is provided a method of
treating stroke (particularly ischemic stroke), brain injury,
spinal cord injury, fronto-temporal dementias (tauopathies),
peripheral neuropathy, Parkinson's disease, Huntington's disease,
multiple sclerosis and in particular Alzheimer's disease in a human
patient which method comprises the intravenous administration of a
therapeutically effective amount of an anti-NOGO antibody of the
invention.
[0153] In a further aspect of the present invention there is
provided a method of promoting axon sprouting of neurons within the
central nervous system of a human subject (e.g. patient) which
method comprises administering (e.g. intravenously administering) a
therapeutically effective amount of an anti-NOGO antibody of the
present invention.
[0154] In a further aspect of the present invention there is
provided the use of an anti-NOGO antibody of the present invention
(e.g. an anti-NOGO antibody comprising the CDRs set forth herein)
in the manufacture of an intravenously administrable medicament for
the treatment of stroke (particularly ischemic stroke), brain
injury, spinal cord injury, fronto-temporal dementias
(tauopathies), peripheral neuropathy, Parkinson's disease,
Huntington's disease, and in particular Alzheimer's disease,
multiple sclerosis or amyotrophic lateral sclerosis (ALS) in a
human patient.
[0155] In a further aspect of the invention there is provided a
method of regenerating axon processes in neurons of the central
nervous system in a human patient afflicted with (or susceptible
to) stroke (particularly ischemic stroke), brain injury, spinal
cord injury, fronto-temporal dementias (tauopathies), peripheral
neuropathy, Parkinson's disease, Huntington's disease, multiple
sclerosis and in particular Alzheimer's disease which method
comprises the step of administering (e.g. intravenously) a
therapeutically effective amount of an anti-NOGO antibody of the
present invention.
[0156] In a further aspect of the invention there is provided the
use of an anti-NOGO antibody of the present invention in the
manufacture of an intravenously administrable pharmaceutical
composition for regenerating axon processes in neurons of the
central nervous system in a human patient afflicted with (or
susceptible to) stroke (particularly ischemic stroke), brain
injury, spinal cord injury, fronto-temporal dementias
(tauopathies), peripheral neuropathy, Parkinson's disease,
Huntington's disease, multiple sclerosis and in particular
Alzheimer's disease.
[0157] In a further aspect of the invention there is provided a
method of modulating the production of an amyloidogenic peptide
comprising contacting a cell which is expressing the precursor from
which the amyloidogenic peptide is derived and a NOGO polypeptide
(e.g. human NOGO-A) with an anti-NOGO antibody of the present
invention. In typical embodiments, the precursor is APP. In further
typical embodiments the amyloidogenic peptide is A.beta., most
preferably A.beta.40, A.beta.42 or a combination of both.
[0158] As used herein, the term "functional recovery" refers to a
motor and/or sensory and/or behavioural improvement in a subject
following e.g. an ischemic event or injury or on-set of clinical
symptoms. Functional recovery in humans may be evaluated by
instruments designed to measure elemental neurological functions
such as motor strength, sensation and coordination, cognitive
functions such as memory, language and the ability to follow
directions, and functional capacities such as basic activities of
daily living or instrumental activities. Recovery of elemental
neurological function can be measured with instruments such as the
NIH Stroke Scale (NIHSS), recovery of cognitive function can be
measured with neuropsychological tests such as Boston Naming Test,
Trail-making Tests, and California Verbal Learning Test, and
activities of daily living may be measured with instruments such as
the ADCS/ADL (Alzheimer's Disease Clinical Studies/Activities of
Daily Living) scale or the Bristol Activities of Daily Living
Scale, all tests and scales known in the art.
[0159] The following examples illustrate but do not limit the
invention.
Example 1
Construction and Expression of Humanised Anti-NOGO Antibodies
[0160] Humanised V.sub.H and V.sub.L constructs were prepared de
novo by build up of overlapping oligonucleotides including
restriction sites for cloning into Rld and Rln mammalian expression
vectors (or any other suitable expression vector for expression of
proteins in mammalian cells) as well as a human signal sequence.
Hind III and Spe I restriction sites were introduced to frame the
V.sub.H domain containing the CAMPATH-1H signal sequence for
cloning into Rld containing the human .gamma.1 mutated constant
region to prevent ADCC and CDC activity (L235A and G237A--EU Index
numbering system). Hind III and BsiWI restriction sites were
introduced to frame the V.sub.L domain containing the CAMPATH-1H
signal sequence for cloning into Rln containing the human kappa
constant region.
TABLE-US-00011 CAMPATH-1H signal sequence: (SEQ. ID. NO: 31)
MGWSCIILFLVATATGVHS
[0161] Plasmids encoding human IgG heavy chain amino acid
sequences, wherein the CDR were that described in table 2, were
produced. Plasmids encoding human IgG heavy chain amino acid
sequences, wherein the CDRs were that described in table 3, were
produced from those existing earlier plasmids by introducing
single point mutations, G95M (Kabat numbering), using the
Quickchange kit (Stratagene).
[0162] The following table discloses which full length heavy chain
protein sequences were made in the plasmid vectors and which of the
sequences were paired, in the sense that the only difference in the
amino acid sequences of the paired full length (FL) heavy chain
sequences was a substitution at G95M (kabat numbering) within the
CDR H3 of the variable region:
TABLE-US-00012 TABLE 8 G95M substitution CDRs as defined in Table 2
(to form CDR H3 of Table 3) H1 FL (SEQ ID NO. 35) Not done H6 FL
(SEQ ID NO. 15) H26 FL (SEQ ID NO. 53) H16 FL (SEQ ID NO. 16) H27
FL (SEQ ID NO. 54) H20 FL (SEQ ID NO. 42) H28 FL (SEQ ID NO.
55)
[0163] Plasmids encoding the heavy chains were then co-transfected
into CHO cells (for details see example 2) with the one of the
following full length light chain sequences: L11 FL (SEQ ID NO.
36), L13 FL (SEQ ID NO. 17), or L16 FL (SEQ ID NO. 18).
[0164] In parallel a chimera termed HcLc (which is the chimera of
2A10 (SEQ ID NO. 9 and 10--the full length chains comprising the
2A10 murine VH (SEQ ID NO. 7) and VL (SEQ ID NO.8) and human IgG
constant regions)) was produced.
Example 2
Antibody Expression in CHO Cells
[0165] Rld and Rln plasmids (or other vectors suitable for use in
mammalian cells) encoding the heavy and light chains respectively
were transiently co-transfected into CHO cells and expressed at
small scale or large scale to produce antibody. Alternatively the
same plasmids were co-transfected into DHFR-CHO cells by
electroporation and a stable polyclonal population of cells
expressing the appropriate antibody were selected using a
nucleoside-free media (Rld contains the DHFR gene, Rln contains a
neomycin selection marker). In some assays, antibodies were
assessed directly from the tissue culture supernatant. In other
assays, recombinant antibody was recovered and purified by affinity
chromatography on Protein A sepharose.
Example 3
Humanised Anti-NOGO Antibody Binds to NOGO
[0166] GST-human NOGO-A56 (see example 5) at 0.05-1 .mu.g/ml in PBS
was coated onto Nunc Immunosorp plates (100 .mu.l per well) at
4.degree. C. overnight. Wells were rinsed once with TBS+0.05% Tween
(TBST) then incubated with 2% BSA in TBST to block non-specific
binding sites at room temperature for 1 hour. Antibodies were
diluted in TBST+2% BSA to 10 .mu.g/ml and 1/2 dilutions made from
this. Antibodies were added to wells in duplicate and incubated at
room temperature for 1 hour. Wells were washed three times with
TBST then incubated with anti-human kappa peroxidase conjugate
(1:2000) for 1 hour. The wells were washed three times with TBST
and then incubated with 100 .mu.l OPD peroxidase substrate (Sigma)
per well for 10 minutes. The colour reaction was stopped by the
addition of 25 .mu.l concentrated H.sub.2SO.sub.4. Optical density
at 490 nm was measured using a plate reader. Background values read
from wells with no antibody were subtracted.
[0167] FIGS. 1-4 illustrate the dose-dependent binding of humanised
antibodies in comparison with the chimera (termed HcLc which is the
chimera of 2A10 (comprising the 2A10 murine VH (SEQ ID NO. 7) and
VL (SEQ ID NO.8) and human IgG constant regions)) to GST-human
NOGO-A56 (see Example 5 for details) in an ELISA assay. The Y-axis
shows the measured optical density (OD) at 490 nm, a quantitative
measure of antibody captured in the wells. The X-axis shows the
concentration of antibody used (mcg/ml) per well at each data
point.
[0168] The antibody material used in FIGS. 1-4 is purified antibody
generated by either the polyclonal expression system or large scale
transient transfections. In these cases, IgG levels were quantified
by ELISA and optical density.
[0169] The results from the experiments shown in FIGS. 1-4 shows
that the inclusion of the G95M mutation improves the performance of
the antibody. The only exception is H27L16 shown in FIGS. 3 and 4
which performed very poorly. We believe that this data resulted
from an unidentified technical problem with the H27L16 assay, since
H27L16 has otherwise consistently performed well in other assays
(in ELISA shown in FIGS. 1 and 2, and in BIAcore assays (Tables 9
and 10)). H27L16 has also been shown to work very well in later
experiments (see FIGS. 11 and 12).
Example 4
Antibody Quantification Protocol
[0170] Nunc Immunosorp plates were coated with a goat anti-human
IgG chain capture antibody (Sigma #13382) at 2 .mu.g/ml in
Bicarbonate buffer (Sigma #C3041) and incubated overnight at
4.degree. C. The plates were washed twice with TBS containing 0.05%
Tween20 (TBST) and blocked with 200 .mu.l TBST containing 2% (or
from 1-3%) BSA (block buffer) for 1 hr at room temperature. The
plates were washed twice with TBST. Tissue culture supernatants
containing antibody were titrated across the plate in 2-fold
dilution steps into block buffer and incubated at room temperature
for 1 hr. The plates were washed three times with TBST. HRP
conjugated antibody H23 (goat anti-human kappa chain, Sigma #A7164)
was diluted 1:2000 in TBST and 100 .mu.l added to each well. The
plates were incubated at room temperature for 1 hr. The plates were
washed three times with TBST and developed with 100 .mu.l of
Fast-OPD substrate (Sigma #P9187). Colour was allowed to develop
for 5-10 mins after which time the ELISA was stopped with 25 .mu.l
3M H.sub.2SO.sub.4. The absorbance at 490 nM was read plate and
antibody concentration determined by reference to a standard
curve.
Example 5
Production of NOGO-A Fragment (NOGO-A56, SEQ. ID. NO:32)
[0171] A cDNA sequence encoding a polypeptide comprising amino
acids 586-785 and a GST tag (SEQ. I.D. NO:32) of human NOGO-A was
created by cloning a cDNA encoding amino acids 586-785 of human
NOGO-A into the BamHI-XhoI sites of pGEX-6P1 to generate a
GST-tagged fusion protein designated GST-human-NOGO-A56. Plasmid
was expressed in BL21 cells in 2XTY medium with 100 .mu.g/ml
ampicillin following induction with IPTG to 0.5 mM at 37 C for 3
hours. Cell pellets were lysed by sonication and the fusion protein
purified using Glutathione-sepharose (Amersham Pharmacia) following
manufacturers instructions. Purified protein was eluted using
reduced glutathione and extensively dialysed against PBS,
quantitated using BSA standards and a BioRad coomassie based
protein assay and then stored in aliquots at -80 C.
Example 6
BiaCore Analysis of Humanised Anti NOGO Monoclonal Antibodies
[0172] The binding kinetics of the anti-NOGO monoclonal antibody
(mAb) to recombinantly expressed GST-human NOGO-A was analysed
using the Biacore3000 biosensor or BIAcore T100. The hNOGO-A chip
was prepared as follows:
Method
[0173] GST-human NOGO-A56 was immobilised to a CM5 chip by primary
amine coupling using the Biacore Wizard program designed for
targeted immobilisation levels. The CM5 sensor surface was
activated by passing a solution of 50 mM N-hydroxy-succinimide
(NHS) and 200 mM N-ethyl-N'-dimethylaminopropyl carbonide (EDC).
Then GST-human NOGO-A56 in sodium acetate buffer, pH5.0 or pH 4.5,
was passed over the chip and immobilised. After immobilisation was
complete any still activated esters were blocked by an injection of
1M ethanolamine hydrochloride, pH8.5.
[0174] The anti-NOGO mAbs were diluted down in HBS-EP (10 mM HEPES,
pH 7.4, 150 mM NaCl, 3 mM EDTA, and 0.005% P-20 surfactant) for the
BIAcore 3000 or HBS-EP+ (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM
EDTA, and 0.05% P-20 surfactant) in the case of the T100 and
binding studies were carried out at range of defined antibody
concentrations. All runs were referenced against a blanked sensor
surface (one that had been activated and blocked as described
earlier but had no addition of ligand). Analysis of binding was
carried out using the BIAevaluation kinetic analysis software
version 4.1 for the BIAcore 3000 and T100 kinetic analysis software
version 1.0. Biacore analysis of other antibodies of the invention
essentially followed the same protocol as described herein. Unless
otherwise stated, the BIAcore experiments were performed at
25.degree. C.
[0175] In the following Results section each data table represents
the results obtained from an individual experiment.
TABLE-US-00013 TABLE 9 Results Antibody ka (1/Ms) kd (1/s) KD (pM)
HcLc 3.19E6 2.49E-3 779 H27L13 6.2E6 1.8E-3 291 H26L13 3.23E6
3.11E-3 963 H28L13 7.26E6 3.3E-3 454 H27L16 6.24E6 1.21E-3 194
H28L16 7.25E6 2.14E-3 296
TABLE-US-00014 TABLE 10 Results Antibody ka (1/Ms) kd (1/s) KD (nM)
HcLc (25.degree. C.) 2.66E6 3.13E-3 1.18 HcLc (37.degree. C.)
5.08E6 7.74E-3 1.46 H16L16 (25.degree. C.) 3.43E6 3.72E-3 1.08
H16L16 (37.degree. C.) 5.31E6 6.16E-3 1.16 H20L16 (25.degree. C.)
4.69E6 5.42E-3 1.16 H20L16 (37.degree. C.) 7.17E6 1.08E-3 1.51
H27L16 (25.degree. C.) 3.94E6 1.50E-3 0.380 H27L16 (37.degree. C.)
7.18E6 3.06E-3 0.426 H27L13 (25.degree. C.) 3.50E6 2.13E-3 0.606
H27L13 (37.degree. C.) 6.58E6 4.22E-3 0.641 H28L16 (25.degree. C.)
4.33E6 2.64E-3 0.610 H28L16 (37.degree. C.) 7.73E6 5.24E-3 0.678
H28L13 (25.degree. C.) 4.16E6 3.89E-3 0.936 H28L13 (37.degree. C.)
7.43E6 7.59E-3 1.02
TABLE-US-00015 TABLE 11 Results Antibodies ka (1/Ms) Kd (1/s) KD
(nM) HcLc 3.17E6 2.33E-3 0.74 H26L13 3.45E6 2.88E-3 0.87 H27L13
6.58E6 1.83E-3 0.28 H28L13 6.97E6 3.17E-3 0.45 H28L16 6.89E6
1.95E-3 0.28
Example 7
BiaCore Analysis of Humanised Anti NOGO Monoclonal Antibodies Using
Off-Rate Ranking
[0176] The GST-human NOGO-A56 chip was prepared as for kinetic
analysis. Cell supernatants where taken directly from transient
transfections of CHO-K1 cells. These were passed directly over the
sensor surface and the interaction measured. A mock transfected
cell supernatant was used for double referencing to remove any
artefacts due to the tissue culture media. All runs were referenced
against a blanked sensor surface (one that had been activated and
blocked as described earlier but had no addition of ligand).
Analysis of binding was carried out using the BIAevaluation kinetic
analysis software version 4.1.
Example 8
Peptide Mapping
[0177] 47 overlapping peptides spanning the NOGO-A56 portion of
GST-human NOGO-A56 domain (SEQ ID NO. 32) were obtained (from
Mimotope.TM.). The peptides are 16 amino acids in length with a
twelve amino acid overlap with the adjacent peptide (each peptide
further comprising a biotin-SGSG sequence at the N-terminus) with
the exception of the first peptide which has a GSG-biocytin tag at
the C-terminus. The peptides were used to epitope map the binding
site of 2A10 and H28L16.
Method for Epitope Mapping:
[0178] Streptavidin at 5 .mu.g/ml in sterile water was coated onto
Nunc immunosorp plates (100 .mu.l per well) at 37.degree. C.
overnight. The plates were rinsed 3 times with PBS containing 0.05%
Tween (PBST) then blocked with 3% BSA in PBST at 4.degree. C.
overnight. The plates were washed 3 times with PBST. Peptides were
then added to the wells at a concentration of approximately 10
.mu.g/ml (diluted in 3% BSA in PBST) and incubated at room
temperature for 1 hour. The plates were washed 3 times with PBST
then incubated for 1 hour with anti-NOGO antibodies diluted to 5
.mu.g/ml in 3% BSA in PBST. The plates were washed 3 times with
PBST then incubated with anti-human or anti-mouse kappa peroxidase
conjugate (1:1000, diluted in 3% BSA in PBST) for 1 hour. The
plates were washed 3 times with PBST and then incubated with 100
.mu.l OPD peroxidase substrate (Sigma) per well for 10 minutes. The
colour reaction was stopped by the addition of 50 .mu.l 3 molar
H.sub.2SO.sub.4. Absorbance at 490 nm was measured using a plate
reader.
[0179] The results are shown in FIG. 5 (epitope mapping using
H28L16), FIG. 6 (epitope mapping using 2A10). FIGS. 5 and 6 show
the results of the epitope mapping of 2A10 and H28L16,
respectively. The data shown indicates that 2A10 and H28L16 bind to
peptides 6 and 7 of which the NOGO specific portion is given in SEQ
ID NO.73 and SEQ ID NO.74 respectively, both of which contain the
sequence VLPDIVMEAPLN (SEQ ID NO.60). These results indicate that
VLPDIVMEAPLN (SEQ ID NO.60) contains the binding epitope of 2A10
and H28L16.
Example 9
Comparison of HcLc and HcLc Containing the G95M Mutation of the CDR
H3
[0180] A modified variant of HcLc was constructed from existing
expression plasmids by introducing a single point mutation, G95M
(Kabat numbering), using the Quikchange kit (Stratagene). The
protein sequence of the variable heavy domain Hc (G95M) protein is
given in SEQ ID 59.
[0181] Hc(G95M)Lc was expressed in CHO cells as described
previously. The antibody was quantified as described in Example 4.
FIG. 7 and FIG. 8 show a comparison of the binding activity of
Hc(G95M)Lc and HcLc as determined using a human NOGO-A binding
ELISA when NOGO was coated onto Nunc immunosorp plates at 0.05
(FIG. 7) and 1 .mu.g/ml (FIG. 8). Table below shows a comparison of
the binding affinities of Hc(G95M)Lc and HcLc.
TABLE-US-00016 TABLE 12 Off-rate measured by Biacore ranking based
on one experiment Sequence ID of heavy Antibody chain variable
region Off-rate kd (1/s) H6L13 11 1.38E-2 H6(G95M)L13 47 4.31E-3
HcLc 7 2.66E-3 Hc(G95M)Lc 59 6.14E-4
[0182] The data demonstrates that the G95M substitution within CDR
H3 not only increases the binding activity of the humanised
antibodies (H6L13), but also the murine donor antibody 2A10
(HcLc).
Example 10
Construction and Testing of NOGO Antibodies Containing
Substitutions in CDR H3
[0183] A panel of 90 heavy chain variable regions was created by
single point mutations in the residues contained in the CDR H3, or
the preceding Leucine. Specifically, vectors encoding a heavy chain
(based on H6FL, SEQ ID NO. 15) were made encoding heavy chain
variable regions where each amino acid residue in CDR H3 and the
preceding Leucine was substituted (using the Quikchange kit
(Stratagene)) with all other naturally occurring amino acids,
excluding cysteine, and expressed in conjunction with a light chain
(L13FL, SEQ ID NO. 17) to give 90 different antibodies. These
antibodies were assayed for binding to NOGO in ELISA and Biacore
experiments.
[0184] FIGS. 9 and 10 show a comparison of the binding activity of
the variants of H6FL in comparison to H6FL L13FL. Tables 14 and 15
show a comparison of the off-rate kinetics as measured by
Biacore--only the results for those antibodies that had a
measurable off rate in the Biacore assay and had comparable binding
activity to H6L13 in ELISA are shown.
TABLE-US-00017 TABLE 14 Parent Antibody VH CDR3 kd (1/s) H6L13 MQGY
(SEQ ID NO: 45) 4.85E-03 HcLc GQGY (SEQ ID NO: 1) 5.58E-03 H6L13
GQNY (SEQ ID NO: 80) 9.66E-03 H6L13 GQLY (SEQ ID NO: 82) 1.32E-02
H6L13 IQGY (SEQ ID NO: 76) 1.72E-02 H6L13 RQGY (SEQ ID NO: 75)
1.75E-02 H6L13 GQSY (SEQ ID NO: 62) 1.86E-02 H6L13 GQGY (SEQ ID NO:
1) 1.98E-02 H6L13 GSGY (SEQ ID NO: 79) 2.07E-02 H6L13 GDGY (SEQ ID
NO: 77) 2.12E-02 H6L13 GQGW (SEQ ID NO: 84) 2.16E-02 H6L13 GIGY
(SEQ ID NO: 78) 2.57E-02 H6L13 GQYY (SEQ ID NO: 81) 3.28E-02 H6L13
GQFY (SEQ ID NO: 83) 3.35E-02 H6L13 WQGY (SEQ ID NO: 86) 1.98E-02
H6L13 GAGY (SEQ ID NO: 87) 3.15E-02 H6L13 GLGY (SEQ ID NO: 88)
1.90E-02 H6L13 GVGY (SEQ ID NO: 89) 1.78E-02 H6L13 GQWY (SEQ ID NO:
90) 1.77E-02
Conclusions
[0185] The results indicate that the antibodies which retain the
binding properties of the murine 2A10, and the GQGY containing
antibody H6L13, are those containing following CDR H3: RQGY (SEQ ID
NO:75), IQGY (SEQ ID NO:76), MQGY (SEQ ID NO:45), GDGY (SEQ ID
NO:77), GIGY (SEQ ID NO:78), GSGY (SEQ ID NO:79), GQNY (SEQ ID
NO:80), GQYY (SEQ ID NO:81), GQSY (SEQ ID NO:62), GQLY (SEQ ID
NO:82), GQFY (SEQ ID NO:83), GQGW (SEQ ID NO:84), WQGY (SEQ ID
NO:86), GAGY (SEQ ID NO:87), GLGY (SEQ ID NO:88), GVGY (SEQ ID
NO:89), GQWY (SEQ ID NO:90).
Example 11
Comparison of GQGY Containing Mab (H20L16) with G95M Variant Mabs
(H27L16 and H28L13 and H28L16)
[0186] The antibodies listed in Table 15 were manufactured as
described above.
TABLE-US-00018 TABLE 15 humanised 2A10 anti-Nogo-A antibodies
giving the total number of back- mutations for the whole antibody
(2x heavy chain + 2x light chain). Antibody Total number of
back-mutations per whole antibody/tetramer H20L16 22 H28L16 22
H28L13 16 H27L16 32
In Vitro Binding Characteristics
[0187] In an attempt to rank the antibodies, their binding
properties were investigated in a range of assays including ELISA,
reverse format ELISA, competition ELISA, Biacore and by flow
cytometry.
11.1 Binding to Recombinant Human NOGO-A in ELISA
[0188] The ability of the antibodies to bind recombinant human
Nogo-A (GST-human Nogo-A 56) was investigated by various related
ELISA assays (performed in a related, but slightly different,
protocol as that described in Example 3). In the first assay, the
recombinant Nogo-A is directly coated to the plate at various
different antigen concentrations. The results of the direct binding
ELISA when the antigen is loaded at 1 mcg/ml or 0.05 mcg/ml are
shown in FIG. 11A and FIG. 11B respectively. The data confirms that
all the antibodies show comparable binding activity to recombinant
human Nogo-A when compared with the chimeric form of the parental
antibody (HcLc). At higher antigen coating concentrations, all
antibodies yield a similar EC50 value. In contrast, at a lower
antigen coating concentration the assay was able to discriminate
between the antibodies. Although saturation curves were not
obtained, a trend analysis on the lines revealed the following rank
order: H27L16>H28L16, H28L13, H20L16.
[0189] In a parallel experiment, the format of the assay was
reversed. In this format, the antibody is captured on to the plate
and the binding of the recombinant human Nogo-A (GST-human
Nogo-A-56) detected using the GST tag. The results of the reverse
format ELISA are shown in FIG. 12. The data confirms that all the
antibodies show comparable binding activity to recombinant human
Nogo-A when compared with the chimeric form of the parental
antibody (HcLc). This format of the binding ELISA did not
distinguish between the antibodies.
11.2 Competition ELISA
[0190] The ability of the antibodies to compete directly with the
parental antibody for the same epitope on human Nogo-A was assessed
using a competition ELISA. The recombinant human Nogo-A (GST-human
Nogo-A 56) was coated onto the plates. The parental antibody 2A10
and the humanised antibodies were pre-mixed prior to adding to the
plates. The binding of 2A10 was quantified using an anti-mouse
IgG-HRP conjugate (Dakocytomation, #P0260). The results shown in
FIG. 13 confirm that all four antibodies can compete with 2A10.
This suggests that the humanised antibodies and parental antibody
recognise an overlapping epitope on human Nogo-A. Furthermore, the
activity of the humanised antibodies is comparable or better than
the chimera HcLc. The results indicate that H27L16, H28L16 and
H28L13 are more potent than H20L16.
11.3 Biacore Affinity Measurements
[0191] Biacore was used to determine affinities and rank antibodies
using two different methodologies. In the first approach, the
recombinant Nogo-A was coupled to the surface of the chip and
anti-Nogo-A antibodies passed over this surface. In the second
approach, Protein A was used to capture the antibody onto the
surface of the chip over which the recombinant GST-human Nogo-A56
was passed. The results shown in Table 16 were obtained by coupling
the antigen to the surface and confirm that all four antibodies
show comparable/better affinity than the parental antibody (HcLc).
Based on the average of six independent runs, the antibodies rank
in the following order in terms of overall affinity:
H27L16>H28L16>H28L13>H20L16, consistent with the rank
order of the direct binding ELISA (FIG. 11B). In the case of H27L16
and H28L16, the humanised antibodies demonstrate 2-3.times. higher
affinity that the parental antibody (HcLc).
TABLE-US-00019 TABLE 16 Binding kinetics of the anti-Nogo-A
humanised antibodies to recombinant human Nogo-A (GST-human Nogo-A
56) as determined using the Biacore T100. The antigen was bound to
the CM5 chip by primary amine coupling. The antibodies were flowed
over a various concentrations (0.125-8 nM). The values show the
mean and standard deviation (in brackets) of six independent runs
carried out in duplicate. Each completed data set was analysed
independently prior to the calculation of mean and standard
deviation. Antibody Ka kd KD (nM) H20L16** 5.37E6 (7.65E5) 9.70E-3
(2.65E-3) 1.80 (0.31) H27L16 3.96E6 (9.93E5) 2.30E-3 (1.11E-3) 0.56
(0.15) H28L13 8.13E6 (1.35E6) 9.10E-3 (2.65E-3) 1.11 (0.18) H28L16
6.97E6 (6.62E5) 4.43E-3 (1.18E-3) 0.64 (0.15) HcLc 3.80E6 (7.11E5)
7.09E-3 (2.22E-3) 1.86 (0.32) **Only 11 sets of data analysed for
H20L16 as one set could not be analysed.
[0192] In a similar manner to the ELISA, the kinetics of antibody
binding to recombinant human Nogo-A (GST-human Nogo-A 56) was also
assessed in a reverse format (see Example 11.1). In this assay, the
humanised antibodies were captured onto the CM5 chip by Protein A.
The averaged results for six independent runs are shown in Table
17. Consistent with the reverse format ELISA, all the humanised
Nogo-A antibodies show similar binding kinetics to the chimera
(HcLc) in the reverse format Biacore.
TABLE-US-00020 TABLE 17 Reverse format binding kinetics of the
anti-Nogo-A humanised antibodies to recombinant human Nogo-A (GST
Nogo-A 5 + 6) as determined using the Biacore T100. Protein A was
immobilised to approximately 4000RUs by primary amine and used to
capture 200-300RUs of the sample antibodies. Recombinant human
Nogo-A was passed over at various concentrations (0.125-8 nM). The
values show the mean and standard deviation (in brackets) of three
independent runs in duplicate. Each data set was independently
analysed prior to the calculation of the mean and standard
deviation. Antibody Ka kd KD (nM) H20L16 1.01E6 (1.35E5) 3.13E-4
(2.79E-5) 0.31 (0.036) H27L16 9.93E5 (2.02E4) 3.04E-4 (1.83E-5)
0.31 (0.019) H28L13 1.12E6 (1.21E5) 3.84E-4 (3.24E-5) 0.34 (0.015)
H28L16 1.18E6 (8.32E4) 4.01E-4 (2.48E-5) 0.34 (0.032) HcLc 1.38E6
(3.70E5) 5.69E-4 (1.54E-4) 0.41 (0.062)
11.4 Binding to Native Human NOGO
[0193] To demonstrate that the humanised antibodies bind to native
human Nogo-A with a profile comparable to the parental antibody,
two flow cytometry based assays were developed. In the first assay,
a CHO-K1-based cell line expressing human Nogo-A extracellular
domain on the cell surface was generated. Binding of the humanised
anti-Nogo-A antibodies was assessed by flow cytometry using a
PE-labelled anti-human IgG (Sigma, #P8047). FIG. 14 below shows a
typical profile for the anti-Nogo-A antibodies on the CHO-Nogo-A
cell line. Whilst the assay is not sensitive enough to distinguish
between the antibodies, the results confirm that all four
antibodies can recognise cell surface expressed human Nogo-A at
levels comparable to that of the chimera. None of the antibodies
recognise the parental cell line (CHO-K1--data not shown).
[0194] In the second assay, the ability of the humanised antibodies
to bind native Nogo-A was assessed using a human neuroblastoma cell
line--IMR32. This cell line is characterised by high
intracellular/low cell surface levels of Nogo-A protein. In an
attempt to increase the binding signal, the assay was set-up to
detect intracellular Nogo-A (ER-resident). IMR32 cells were
permeabilised and fixed prior to staining with the anti-Nogo-A
humanised antibodies. Binding of the antibodies to Nogo-A was
detected using an anti-human IgG-PE labelled secondary (Sigma,
#P8047). The results, shown in FIG. 15 below, confirm that all the
antibodies bind to intracellular Nogo-A at levels comparable or
higher than the parental antibody HcLc. These data, in conjunction
with the results from the CHO-Nogo-A cell line, confirm that the
humanised antibodies can recognise a more native form of the Nogo-A
protein at levels comparable or better than the chimera, HcLc. The
assays are not sufficiently sensitive to rank the antibody
panel.
11.5 Neurite-Outgrowth Assays
[0195] Humanised anti-Nogo-A antibodies were tested for their
ability to neutralise neurite-outgrowth (NO) inhibitory activity of
Nogo-A in an assay that is based on quantifying NO as described
previously. Antibodies tested in the assay were selected on the
basis of their binding kinetics for Nogo-A. High affinity humanised
antibodies namely, H28L16, H27L16, H20L16 and for reference their
parental antibodies 2A10 (mouse monoclonal) and HcLc (human mouse
chimera) were tested for Nogo-A neutralisation. For comparison,
antibody 11C7 (see Example 13) was also tested in the assay.
[0196] In order to test the neutralising activity of selected
humanised antibodies, wells coated with human recombinant GST-human
Nogo-A56 and treated with varying concentrations of antibodies at
37.degree. C. for 1 h prior to the addition of cerebellum granular
neurons (CGNs). Control wells were treated with HBSS. Average
neurite length per neurite was measured for each well. FIG. 16
shows the results for the humanised antibodies tested in the assay.
A panel of control antibodies (control IgG, purified mouse IgG;
Campath and another irrelevant humanised antibodies) used to
confirm the specificity of the activity. As a further control, the
same humanised antibodies were titrated onto GST coated plates. The
results confirm that H28L16, H27L16 and H20L16 reverse
Nogo-A-mediated inhibition of neurite outgrowth to a similar degree
observed for the parental antibodies (2A10 and HcLc). The effects
appear to be robust and stable and were seen with H28L16 in eight
out of eleven independent neurite-outgrowth experiments. In
contrast, the humanised antibodies do not increase
neurite-outgrowth on GST coated plates and the panel of control
antibodies do not show any dose dependent reversal of inhibition,
confirming that the effect of the humanised antibodies is specific
for Nogo-A-mediated inhibition. The data presented for the neurtite
outgrowth is selected from number of repeat experiments. Whilst a
number of the repeats which are not shown appeared to be variable
in nature, it is believed that the data shown reflects a true
activity of the antibodies of the present invention in reducing the
inhibitory effect of NOGO in the neurite outgrowth assay.
Example 12
Further Characterisation of H28L 16
12.1 Binding to Full-Length Recombinant Nogo-A
[0197] The ability of the antibodies to bind full-length
extracellular domain recombinant human Nogo-A (GST-human
Nogo-A-ECD) was investigated by a direct binding ELISA assay. In
this case the ECD was a splice variant falling within the region of
approximately position 186-1004 of human NOGO A (the portion
beginning DETFAL (SEQ ID NO.95) and ending with ELSKTS (SEQ ID
NO.96)).
[0198] The recombinant GST-human Nogo-A-ECD was directly coated to
the plate at 1 .mu.g/ml. The data shown in FIG. 17 confirms that
H28L16 can recognise GST-human Nogo-A-ECD as levels comparable or
better than the parental (HcLc) or H20L16.
12.2 Inhibition of Fc Functionality
[0199] To improve the safety profile of the candidate, residues
L235 and G237 within the CH2 domain of the heavy chain constant
region (EU Index system) were mutated to alanine residues thus
reducing the likelihood of triggering antibody-mediated
immunological effector functions. Reduced human C1q binding was
used as a surrogate for inhibition of Fc functionality. FIG. 18
below shows that H28L16 has significantly reduced C1q binding
activity, compared to Campath-IgG1 (wild-type) and comparable to a
Campath IgG1 construct bearing the same mutations (Fc-mutated
antibody (Fc-)) and Campath IgG4. These data suggest that the
CH2-domain mutations present in H28L16 will significantly reduce
the likelihood of triggering Fc mediated effector functions.
12.3 Orthologue Binding
[0200] To confirm that H28L16 shows binding activity to various
orthologues of Nogo-A, comparable to that of the parental antibody
(HcLc), a series of binding assays were performed. FIG. 19 A-D
below shows the results of a direct binding ELISA to recombinant
NOGO (GST-human Nogo-A 56) from rat (SEQ ID NO.94), cynomolgus (SEQ
ID NO. 92), marmoset (SEQ ID NO. 93) and squirrel monkey
respectively (SEQ ID NO. 91). In all cases, H28L16 shows activity
comparable or better than the chimeric antibody (HcLc). The
calculated EC50 values are very similar to those calculated for
binding to human recombinant Nogo-A.
[0201] The kinetics of binding of H28L16 to the various orthologues
of Nogo-A in comparison to HcLc and 11C7 was determined using the
Biacore. Table 18 and Table 19 below show the kinetics of binding
in two different formats of the assay. Where the recombinant Nogo-A
was coupled directly to the CM5 chip (Table 18), the binding
kinetics for rat, cynomolgus monkey, squirrel monkey and marmoset
are very similar to that for human (range=0.33-0.67 nM). When the
format of the assay was reversed and the antibodies are captured
onto the chip using Protein A (Table 19), the binding affinity of
H28L16 to rat Nogo-A is approximately 4-fold lower than for human
Nogo-A. A similar trend is observed for cynomolgus Nogo-A
(8.5.times. lower affinity than human) and the other primate
orthologues (12-17.times. lower affinity than human). The chimeric
antibody HcLc shows a similar profile of binding to the orthologues
of Nogo-A in both orientations of the assay. Since it is unclear
which assay format best represents the in vivo situation, the
primary conclusions that can be drawn from this study are 1) H28L16
has retained the orthologue cross-reactivity profile associated
with the chimeric antibody HcLc and 2) the affinity of HcLc for rat
and cynomolgus Nogo-A is within 4-fold and 8.5-fold of the affinity
for human Nogo-A and under certain conditions may be very
similar.
TABLE-US-00021 TABLE 18 Binding kinetics of H28L16, 11C7 and HcLc
to the recombinant orthologues of human Nogo-A as determined using
the Biacore T100. Approximately 140-180RUs of the various Nogo-A
orthologues were captured to the CM5 chip by primary amine
coupling. The antibodies were flowed over a various concentrations
(0.125-8 nM). The values show the mean and standard deviation (in
brackets) of 1-2 independent runs carried out in duplicate with
each data set independently analysed prior to calculation of the
mean and standard deviation. H28L16 11C7 HcLc Orthologue Ka Kd KD
(nM) Ka Kd KD (nM) Ka Kd KD (nM) Cynomolgus 4.65E6 3.07E-3 0.67
1.47E6 3.40E-4 0.23 2.94E6 4.78E-3 1.68 (2 runs)* (7.47E5)
(2.37E-4) (0.06) (1.67E5) (4.45E-5) (0.01) (7.13E5) (6.34E-4)
(0.35) Rat 4.64E6 1.54E-3 0.33 8.36E5 1.20E-4 0.11 2.53E6 2.83E-3
1.12 (2 runs) (2.34E5) (3.06E-5) (0.01) (5.58E5) (2.14E-5) (0.03)
(5.32E4) (2.30E-5) (0.03) Marmoset 4.2E6 3.02E-3 0.626 1.16E6
2.80E-4 0.24 3.13E6 4.44E-3 1.419 (1 run) (2.47E4) (5.09E-5)
(0.000) (5.37E4) (6.15E-6) (0.006) (2.76E4) (1.41E-4) (0.03)
Squirrel 4.46E6 2.73E-3 0.61 1.10E6 2.86E-4 0.26 3.04E6 4.68E-3
1.54 Monkey (6.08E4) (4.95E-6) (0.000) (3.25E4) (1.87E-5) (0.010)
(1.64E5) (2.11E-4) (0.15) (1 run) Human 6.97E6 4.43E-3 0.64 1.58E6
2.64E-4 0.19 3.80E6 7.09E-3 1.86 (6.62E5) (1.18E-3) (0.15) (6.42E5)
(5.57E-5) (7.96E-2) (7.11E5) (2.22E-3) (0.32) *One set of curves
was discarded due to uninterpretable curves for antibody 11C7.
TABLE-US-00022 TABLE 19 Reverse format binding kinetics of H28L16,
11C7 and HcLc to the recombinant orthologues of human Nogo-A as
determined on the Biacore T100. Protein A was immobilised on the
surface at about 4000RUs and anti-Nogo-A antibodies were captured
at approximately 300-400RUs. The recombinant proteins
(GST-NOGO-A56) were flowed over a various concentrations (0.125-64
nM) dependent on the construct. All the runs were done in
duplicates. The values show the mean and standard deviation (in
brackets) of 1-3 independent runs with each run done in duplicate
and each data set analysed independently prior to calculation of
the mean and standard deviation. H28L16 11C7 HcLc KD KD KD
Orthologue Ka Kd (nM) Ka Kd (nM) Ka Kd (nM) Cynomolgus 3.26E5
1.11E-3 3.41 4.02E5 2.97E-4 0.76 3.03E5 1.41E-3 4.66 (3 runs)
(4.06E3) (2.23E-5) (0.05) (6.85E4) (1.11E-5) (0.12) (4.58E3)
(2.84E-5) (0.08) Rat 3.80E5 6.69E-4 1.76 2.83E5 1.77E-4 0.64 5.47E5
1.10E-3 2.01 (3 runs) (5.68E3) (1.24E-5) (0.03) (4.66E4) (1.34E-5)
(0.09) (1.20E4) (2.86E-5) (0.07) Marmoset 2.22E5 1.09E-3 4.89
1.91E5 2.54E-4 1.33 3.02E5 1.36E-3 4.51 (1 run) (3.61E3) (7.35E-5)
(0.25) (2.90E3) (3.46E-6) (0.00) (9.90E2) (7.92E-5) (0.28) Squirrel
1.57E5 1.08E-3 6.86 1.03E5 2.78E-4 2.69 1.74E5 1.29E-3 7.45 Monkey
(1 (2.69E3) (5.02E-5) (0.20) (2.12E3) (3.61E-6) (0.02) (2.19E3)
(7.64E-5) (0.34) run) Human 1.20E6 4.75E-4 0.40 2.64E5 1.49E-4 0.57
1.32E6 7.00E-4 0.54 (1 run) (8.49E4) (9.97E-6) (0.02) (3.32E3)
(1.61E-5) (0.07) (2.71E5) (3.18E-5) (0.09)
12.4 Physical Properties
[0202] The physicochemical properties of H28L16 and H20L16 were
assessed by SEC-HPLC and SDS-PAGE. SEC-HPLC was carried out at 1.0
ml/minute using 100 mM sodium phosphate, 400 mM sodium chloride pH
6.8 and a TSK G3000 SW.times.l30 cm.times.7.8 mm stainless steel
column with detection at 214 nm and 280 nm. SDS-PAGE was carried
out on a 4-20% Novex Tris-HCL gel loading 10 .mu.g product and
staining with Sypro Ruby. C-IEF was carried out on a Beckman MDQ
using pH 3.5-10 ampholines. The following results were
obtained:
TABLE-US-00023 TABLE 20 Size exclusion chromatography (SEC) HPLC
analysis of the anti-Nogo-A antibodies. The values shown are
percentages of the antibody assigned to each of the three different
species. Antibody Aggregate % Monomer % Fragment % H28L16 0.50
99.50 0.00 H20L16 14.21 85.75 0.05
TABLE-US-00024 TABLE 21 SDS-PAGE analysis of the anti-Nogo-A
antibodies. The values shown are percentages of the antibody found
in the major bands. Antibody Non-reduced Reduced H28L16 82.4% HC:
67.2% LC: 27.7% H + L: 94.9% H20L16 84.6% HC: 69.3% LC: 26.4% H +
L: 95.7%
[0203] The SEC-HPLC data suggests that H20L16 is more susceptible
to aggregation than H28L16 (H28L16). If the data reported here were
to be repeated at large scale, this could impact the ability of the
manufacturing process to produce material of acceptable quality for
clinical use (>95% monomer). The SDS-PAGE data shows both
candidates are acceptable with both showing a typical profile.
Example 13
Comparison of H28L16 with 11C7
[0204] A murine anti-Nogo-A antibody designated 11C7 is described
in WO2004052932, which was raised to a peptide epitope. A chimeric
11C7 was made based on the sequence information provided in
WO2004052932. To compare the binding epitopes of 2A10 and 11C7, a
competition ELISA was established to investigate if 11C7 and 2A10
recognise an overlapping epitope on Nogo-A. As shown in FIG. 20
below, HcLc (the chimeric form of 2A10) was able to compete with
2A10 for binding to human recombinant Nogo-A whereas 11C7 showed no
competition with 2A10, even at concentrations of up to 100
mcg/ml.
Example 14
Competition ELISA to Demonstrate the Ability of Peptides to Compete
Directly with Human NOGO-5+6 for Binding to NOGO H28L 16
Method for Competition ELISA
[0205] The ability of peptides to compete directly with NOGO-A
(GST-human Nogo-A56) for binding to NOGO H28L16 was assessed using
a competition ELISA. Rabbit anti-human IgG (Sigma, #1-9764) at 5
g/ml in bicarbonate buffer was coated onto Nunc immunosorp plates
(100 ul per well) at 4.degree. C. overnight. The plates were rinsed
3 times with TBS containing 0.05% Tween (TBST) then blocked with 1%
BSA in TBST at room temperature for 1 hour. H28L16 was then
captured onto the plate (1 ug/ml, diluted in 1% BSA in TBST, 50 ul
per well) at room temperature for 1 hour. The plates were washed 3
times with TBST. Peptides (from 0 to 100 g/ml) and GST-human
NOGO-A56 at a concentration of 1 ug/ml (diluted in 1% BSA in TBST)
were pre-mixed prior to addition into the wells and incubated at
room temperature for 1 hour. The plates were washed 3 times with
TBST then incubated for 1 hour with rabbit anti-GST peroxidase
conjugate (Sigma, #A7340, 1:2000, diluted in 1% BSA in TBST) for 1
hour. The plates were washed 3 times with TBST and then incubated
with 50 l OPD peroxidase substrate (Sigma) per well for 10 minutes.
The colour reaction was stopped by the addition of 25 l
concentrated H.sub.2SO.sub.4. Absorbance at 490 nm was measured
using a plate reader.
[0206] The results shown in FIG. 21 confirm that peptides 6 and 7,
which were positive in the epitope mapping ELISA (Example 8) can
compete with GST-human NOGO-A56 binding to H28L16. This suggests
that the peptides which were positive in the epitope mapping study
contain an epitope for H28L16 binding. Peptides 16 and 17 (which
contain NOGO peptides, but not overlapping with peptides 6 or 7),
which do not contain the proposed epitope, do not compete with
NOGO-5+6.
Example 15
ELISA Analysis of a Humanised Anti NOGO Monoclonal Antibody Based
on the NOGO antibody variant G101S/Q37R
[0207] G101S (also known as H100 (SEQ ID NO.63)), a modified
variant of the heavy chain variable region of H6 (SEQ ID NO.11) was
generated by introducing a single substitution, G101S (Kabat
numbering) into CDR H3 as described above. Similarly, Q37R, a
modified variant of the light chain variable region of L13 (SEQ ID
NO. 13) were generated by introducing a single substitution (Kabat
numbering Q37R) into the framework region (to form L100). The
protein sequence of the variable light domain Q37R is given in SEQ
ID NO. 67.
[0208] Genes encoding full length versions of the heavy and light
chains containing the G101S/Q37R substitutions were expressed in
CHO cells as described previously and assayed in a direct binding
ELISA as described previously.
[0209] The results of the direct binding ELISA when the antigen is
loaded at 0.05 ug/ml are shown in FIG. 22. The data confirms that
antibody H100L100 shows comparable binding activity to recombinant
GST-human NOGO-A56 when compared with H27L16 and that H100L100 has
an improved binding profile when compared to H6L13. Corresponding
EC50 values are shown in the table below:
TABLE-US-00025 TABLE 22 EC50 measurements for the G101S/Q37R
variant in comparison with H6L13 and H27L16 Antibody EC50 value
H6L13 0.086 H27L16 0.052 H100/L100 0.048
Example 16
BiaCore Analysis of Humanised Anti NOGO Monoclonal Antibodies Based
on the CDR H3 Variant G101S
[0210] H100, A modified variant of the heavy chain variable region
of H6 (SEQ ID NO.11) was generated by introducing a single
substitution, G101S (Kabat numbering) into CDR H3. The protein
sequence of the variable heavy domain H100 protein is given in SEQ
ID NO.63. Similarly, L100 and L101, modified variants of the light
chain variable region of L13 (SEQ ID NO. 13) were generated by
introducing a single substitution (Kabat numbering Q37R and Q45R
respectively) into the framework region. The protein sequences of
the variable light domains L100 and L101 proteins are given in SEQ
ID NO.67 and SEQ ID NO.68 respectively.
[0211] Full length versions of H100L100 and H100L101 were expressed
in CHO cells as described previously. Table 23 shows a comparison
of the binding affinities of H6L13 with H100L100 and H100L101 and
indicates that H100L100 and H100L101 have an improved binding
affinity when compared with H6L13. In this example, the method was
performed essentially as described in Example 6 where the CM5 chip
was activated by passing the NHS and EDC solutions over the chip at
5 .mu.l/ml for 7 minutes and the NOGO was suspended in 10 nM sodium
acetate buffer (pH 4.5) before passing over the chip.
TABLE-US-00026 TABLE 23 Biacore measurements for the G101S variants
of the H6 variable heavy chain in combination with variants of the
L13 variable light chain in comparison with H6L13. Antibody On rate
ka (1/Ms) Off-rate kd (1/s) Affinity (KD, nM) H6L13 1.04E+06
7.22E-03 6.97 H100L100 1.28E+07 5.07E-03 0.396 H100L101 1.30E+07
4.29E-03 0.329
TABLE-US-00027 TABLE 24 NOGO antibody sequences Summary Sequence
identifier (SEQ. I.D. NO) amino acid Polynucleotide Description
sequence sequence 2A10, CDR-H1 1 -- 2A10, CDR-H2 2 -- 2A10, CDR-H3
3 -- 2A10, CDR-L1 4 -- 2A10, CDR-L2 5 -- 2A10, CDR-L3 6 -- 2A10, VH
(murine) 7 19 2A10, VL (murine) 8 20 Chimeric heavy chain Hc 9 21
Chimeric light chain Lc 10 22 2A10 VH humanised construct H6 11 23
2A10 VH humanised construct H16 12 24 2A10 VL humanised construct
L13 13 25 2A10 VL humanised construct L16 14 26 2A10 heavy chain
humanised construct H6 15 27 2A10 heavy chain humanised construct
16 28 H16 2A10 light chain humanised construct L13 17 29 2A10 light
chain humanised construct L16 18 30 Campath leader sequence 31 --
Amino acids 586-785 of human NOGO A 32 -- (NOGO-A56) fused to GST
2A10 VH humanised construct H1 33 37 2A10 VL humanised construct
L11 34 38 2A10 heavy chain humanised construct H1 35 39 2A10 light
chain humanised construct L11 36 40 2A10 VH humanised construct H20
41 43 2A10 heavy chain humanised construct 42 44 H20 2A10, CDR-H3
(G95M) 45 Sequence of Marmoset NOGO-A fragment 46 VH humanised
construct H26 47 50 VH humanised construct H27 48 51 VH humanised
construct H28 49 52 Heavy chain humanised construct H26 53 56 Heavy
chain humanised construct H27 54 57 Heavy chain humanised construct
H28 55 58 Chimeric heavy chain Hc (G95M) 59 Epitope 60 2A10 VH
humanised construct H99 61 CDR (G101S) 62 VH humanised construct
H100 63 VH humanised construct H101 64 VH humanised construct H102
65 VH humanised construct H98 66 L100 (L13 + Q37R) 67 L101 (L13 +
Q45R) 68 L102 (L13 + Q37R/Q45R) 69 L103 (L16 + Q37R) 70 L104 (L16 +
Q45R) 71 L105 (L16 + Q37R/Q45R) 72 Peptide 73 peptide 74 CDR H3
analogue 75 CDR H3 analogue 76 CDR H3 analogue 77 CDR H3 analogue
78 CDR H3 analogue 79 CDR H3 analogue 80 CDR H3 analogue 81 CDR H3
analogue 82 CDR H3 analogue 83 CDR H3 analogue 84 NOGO peptide 85
CDR H3 analogue 86 CDR H3 analogue 87 CDR H3 analogue 88 CDR H3
analogue 89 CDR H3 analogue 90 Squirrel monkey NOGO (A56) plus GST
91 tag Cynomolgus monkey NOGO (A56) plus 92 GST tag Marmoset NOGO
(A56) plus GST tag 93 Rat NOGO (A56) plus GST tag 94 Human NOGO
peptide 95 Human NOGO peptide 96
TABLE-US-00028 Sequences SEQ ID NO. 1 2A10 CDR-H1 SYWMH SEQ ID NO.
2: 2A10 CDR-H2 NINPSNGGTNYNEKFKS SEQ ID NO. 3: 2A10 CDR-H3 GQGY SEQ
ID NO. 4: 2A10 CDR-L1 RSSKSLLYKDGKTYLN SEQ ID NO. 5: 2A10 CDR-L2
LMSTRAS SEQ ID NO. 6: 2A10 CDR-L3 QQLVEYPLT SEQ ID NO. 7: 2A10, VH
(murine)
QVQLQQPGTELVKPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGNINPSNGGTNYNEKFKSKATLTVDK-
SSS TAYMQLSSLTSEDSAVYYCELGQGYWGQGTTLTVSS SEQ ID NO. 8: 2A10, VL
(murine)
DIVITQDELSNPVTSGESVSISCRSSKSLLYKDGKTYLNWFLQRPGQSPQLLIYLMSTRASGVSDRFSGSGSGT-
DFT LEISRVKAEDVGVYYCQQLVEYPLTFGAGTKLELK SEQ ID NO. 9: Chimeric
heavy chain Hc
MGWSCIILFLVAAATGVHSQVQLQQPGTELVKPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGNINPSN-
GGT
NYNEKFKSKATLTVDKSSSTAYMQLSSLTSEDSAVYYCELGQGYWGQGTLVTVSSASTKGPSVFPLAPSSKSTS-
GGT
AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDK-
KVE
PKSCDKTHTCPPCPAPELAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK-
PRE
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTC-
LVK
GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS-
PGK SEQ ID NO. 10: Chimeric light chain Lc
MRCSLQFLGVLMFWISGVSGDIVITQDELSNPVTSGESVSISCRSSKSLLYKDGKTYLNWFLQRPGQSPQLLIY-
LMS
TRASGVSDRFSGSGSGTDFTLEISRVKAEDVGVYYCQQLVEYPLTFGAGTKLELKRTVAAPSVFIFPPSDEQLK-
SGT
ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSS-
PVT KSFNRGEC SEQ ID 11: 2A10 VH humanised construct H6
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWIGNINPSNGGTNYNEKFKSRATMTRDT-
STS TAYMELSSLRSEDTAVYYCELGQGYWGQGTLVTVSS SEQ ID NO. 12 2A10 VH
humanised construct H16
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVKQRPGQGLEWIGNINPSNGGTNYNEKFKSKATLTVDK-
STS TAYMELSSLRSEDTAVYYCELGQGYWGQGTLVTVSS SEQ ID NO. 13: 2A10 VL
humanised construct L13
DIVMTQSPLSLPVTLGQPASISCRSSKSLLYKDGKTYLNWFQQRPGQSPQLLIYLMSTRASGVPDRFSGGGSGT-
DFT LKISRVEAEDVGVYYCQQLVEYPLTFGQGTKLEIK SEQ ID NO. 14: 2A10 VL
humanised construct L16
DIVMTQSPLSNPVTLGQPVSISCRSSKSLLYKDGKTYLNWFLQRPGQSPQLLIYLMSTRASGVPDRFSGGGSGT-
DFT LKISRVEAEDVGVYYCQQLVEYPLTFGQGTKLEIK SEQ ID NO. 15: 2A10 heavy
chain humanised construct H6
MGWSCIILFLVATATGVHSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWIGNINPSN-
GGT
NYNEKFKSRATMTRDTSTSTAYMELSSLRSEDTAVYYCELGQGYWGQGTLVTVSSASTKGPSVFPLAPSSKSTS-
GGT
AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDK-
KVE
PKSCDKTHTCPPCPAPELAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK-
PRE
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTC-
LVK
GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS-
PGK SEQ ID NO. 16: 2A10 heavy chain humanised construct H16
MGWSCIILFLVATATGVHSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVKQRPGQGLEWIGNINPSN-
GGT
NYNEKFKSKATLTVDKSTSTAYMELSSLRSEDTAVYYCELGQGYWGQGTLVTVSSASTKGPSVFPLAPSSKSTS-
GGT
AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDK-
KVE
PKSCDKTHTCPPCPAPELAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK-
PRE
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTC-
LVK
GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS-
PGK SEQ ID NO. 17: 2A10 light chain humanised construct L13
MGWSCIILFLVATATGVHSDIVMTQSPLSLPVTLGQPASISCRSSKSLLYKDGKTYLNWFQQRPGQSPQLLIYL-
MST
RASGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCQQLVEYPLTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKS-
GTA
SVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSP-
VTK SFNRGEC SEQ ID NO. 18: 2A10 light chain humanised construct L16
MGWSCIILFLVATATGVHSDIVMTQSPLSNPVTLGQPVSISCRSSKSLLYKDGKTYLNWFLQRPGQSPQLLIYL-
MST
RASGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCQQLVEYPLTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKS-
GTA
SVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSP-
VTK SFNRGEC SEQ ID NO. 19: PN encoding 2A10, VH (murine) SEQ ID: 7
CAGGTCCAACTGCAGCAGCCTGGGACTGAACTGGTGAAGCCTGGGGCTTCAGTGAAGCTGTCCTGCAAGGCTTC-
TGG
CTACACCTTCACCAGCTACTGGATGCACTGGGTGAAGCAGAGGCCTGGACAAGGCCTTGAGTGGATTGGAAATA-
TTA
ATCCTAGCAATGGTGGTACTAACTACAATGAGAAGTTCAAGAGCAAGGCCACACTGACTGTAGACAAATCCTCC-
AGC
ACAGCCTACATGCAGCTCAGCAGCCTGACATCTGAGGACTCTGCGGTCTATTATTGTGAACTGGGACAGGGCTA-
CTG GGGCCAAGGCACCACTCTCACAGTCTCCTCA SEQ ID NO. 20: PN encoding
2A10, VL (murine) SEQ ID: 8
GATATTGTGATAACCCAGGATGAACTCTCCAATCCTGTCACTTCTGGAGAATCAGTTTCCATCTCCTGCAGGTC-
TAG
TAAGAGTCTCCTATATAAGGATGGGAAGACATACTTGAATTGGTTTCTGCAGAGACCAGGACAATCTCCTCAGC-
TCC
TGATCTATTTGATGTCCACCCGTGCATCAGGAGTCTCAGACCGGTTTAGTGGCAGTGGGTCAGGAACAGATTTC-
ACC
CTGGAAATCAGTAGAGTGAAGGCTGAGGATGTGGGTGTGTATTACTGTCAACAACTTGTAGAGTATCCGCTCAC-
GTT CGGTGCTGGGACCAAGCTGGAGCTGAAA SEQ ID NO. 21: PN encoding
Chimeric heavy chain Hc SEQ ID: 9
ATGGGATGGAGCTGTATCATCCTCTTTTTGGTAGCAGCAGCTACAGGTGTCCACTCCCAGGTCCAACTGCAGCA-
GCC
TGGGACTGAACTGGTGAAGCCTGGGGCTTCAGTGAAGCTGTCCTGCAAGGCTTCTGGCTACACCTTCACCAGCT-
ACT
GGATGCACTGGGTGAAGCAGAGGCCTGGACAAGGCCTTGAGTGGATTGGAAATATTAATCCTAGCAATGGTGGT-
ACT
AACTACAATGAGAAGTTCAAGAGCAAGGCCACACTGACTGTAGACAAATCCTCCAGCACAGCCTACATGCAGCT-
CAG
CAGCCTGACATCTGAGGACTCTGCGGTCTATTATTGTGAACTGGGACAGGGCTACTGGGGCCAAGGCACACTAG-
TCA
CAGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGC-
ACA
GCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGAC-
CAG
CGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCT-
CCA
GCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTT-
GAG
CCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCGCGGGGGCACCGTCAGTCTT-
CCT
CTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGA-
GCC
ACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGG-
GAG
GAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGA-
GTA
CAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCC-
GAG
AACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTC-
AAA
GGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCC-
TCC
CGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGA-
ACG
TCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGT-
AAA TGA SEQ ID NO. 22: PN encoding Chimeric light chain Lc SEQ ID:
10
ATGAGGTGCTCTCTTCAGTTTCTGGGGGTGCTTATGTTCTGGATCTCTGGAGTCAGTGGGGATATTGTGATAAC-
CCA
GGATGAACTCTCCAATCCTGTCACTTCTGGAGAATCAGTTTCCATCTCCTGCAGGTCTAGTAAGAGTCTCCTAT-
ATA
AGGATGGGAAGACATACTTGAATTGGTTTCTGCAGAGACCAGGACAATCTCCTCAGCTCCTGATCTATTTGATG-
TCC
ACCCGTGCATCAGGAGTCTCAGACCGGTTTAGTGGCAGTGGGTCAGGAACAGATTTCACCCTGGAAATCAGTAG-
AGT
GAAGGCTGAGGATGTGGGTGTGTATTACTGTCAACAACTTGTAGAGTATCCGCTCACGTTCGGTGCTGGGACCA-
AGC
TGGAGCTGAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGA-
ACT
GCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGACAACGCCCT-
CCA
ATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGA-
CGC
TGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTC-
ACA AAGAGCTTCAACAGGGGAGAGTGTTAG SEQ ID NO. 23: PN encoding 2A10 VH
humanised construct H6 SEQ ID: 11
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCATC-
TGG
ATACACCTTCACCAGCTACTGGATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATCGGAAATA-
TTA
ATCCTAGCAATGGTGGTACTAACTACAATGAGAAGTTCAAGAGCAGAGCCACCATGACCAGGGACACGTCCACG-
AGC
ACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGAACTGGGACAGGGCTA-
CTG GGGCCAGGGAACACTAGTCACAGTCTCCTCA SEQ ID NO. 24: PN encoding 2A10
VH humanised construct H16 SEQ ID: 12
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCATC-
TGG
ATACACCTTCACCAGCTACTGGATGCACTGGGTGAAACAGCGACCTGGACAAGGGCTTGAGTGGATCGGAAATA-
TTA
ATCCTAGCAATGGTGGTACTAACTACAATGAGAAGTTCAAGAGCAAAGCCACCCTCACCGTCGACAAATCCACG-
AGC
ACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGAACTGGGACAGGGCTA-
CTG GGGCCAGGGAACACTAGTCACAGTCTCCTCA SEQ ID NO. 25: PN encoding 2A10
VL humanised construct L13 SEQ ID: 13
GATATTGTGATGACCCAGTCTCCACTCTCCCTGCCCGTCACCCTTGGACAGCCGGCCTCCATCTCCTGCAGGTC-
TAG
TAAGAGTCTCCTATATAAGGATGGGAAGACATACTTGAATTGGTTTCAGCAGAGGCCAGGCCAATCTCCACAGC-
TCC
TAATTTATTTGATGTCCACCCGTGCATCTGGGGTCCCAGACAGATTCAGCGGCGGTGGGTCAGGCACTGATTTC-
ACA
CTGAAAATCAGCAGGGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCCAACAACTTGTAGAGTATCCGCTCAC-
GTT TGGCCAGGGGACCAAGCTGGAGATCAAA SEQ ID NO. 26: PN encoding 2A10 VL
humanised construct L16 SEQ ID: 14
GATATTGTGATGACCCAGTCTCCACTCTCCAACCCCGTCACCCTTGGACAGCCGGTCTCCATCTCCTGCAGGTC-
TAG
TAAGAGTCTCCTATATAAGGATGGGAAGACATACTTGAATTGGTTTCTCCAGAGGCCAGGCCAATCTCCACAGC-
TCC
TAATTTATTTGATGTCCACCCGTGCATCTGGGGTCCCAGACAGATTCAGCGGCGGTGGGTCAGGCACTGATTTC-
ACA
CTGAAAATCAGCAGGGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCCAACAACTTGTAGAGTATCCGCTCAC-
GTT TGGCCAGGGGACCAAGCTGGAGATCAAA SEQ ID NO. 27: PN encoding 2A10
heavy chain humanised construct H6 SEQ ID: 15
ATGGGATGGAGCTGTATCATCCTCTTCTTGGTAGCAACAGCTACAGGTGTCCACTCCCAGGTGCAGCTGGTGCA-
GTC
TGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCATCTGGATACACCTTCACCAGCT-
ACT
GGATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATCGGAAATATTAATCCTAGCAATGGTGGT-
ACT
AACTACAATGAGAAGTTCAAGAGCAGAGCCACCATGACCAGGGACACGTCCACGAGCACAGCCTACATGGAGCT-
GAG
CAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGAACTGGGACAGGGCTACTGGGGCCAGGGAACACTAG-
TCA
CAGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGC-
ACA
GCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGAC-
CAG
CGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCT-
CCA
GCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTT-
GAG
CCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCGCGGGGGCACCGTCAGTCTT-
CCT
CTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGA-
GCC
ACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGG-
GAG
GAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGA-
GTA
CAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCC-
GAG
AACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTC-
AAA
GGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCC-
TCC
CGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGA-
ACG
TCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGT-
AAA TGA SEQ ID NO. 28: PN encoding 2A10 heavy chain humanised
construct H16 SEQ ID: 16
ATGGGATGGAGCTGTATCATCCTCTTCTTGGTAGCAACAGCTACAGGTGTCCACTCCCAGGTGCAGCTGGTGCA-
GTC
TGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCATCTGGATACACCTTCACCAGCT-
ACT
GGATGCACTGGGTGAAACAGCGACCTGGACAAGGGCTTGAGTGGATCGGAAATATTAATCCTAGCAATGGTGGT-
ACT
AACTACAATGAGAAGTTCAAGAGCAAAGCCACCCTCACCGTCGACAAATCCACGAGCACAGCCTACATGGAGCT-
GAG
CAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGAACTGGGACAGGGCTACTGGGGCCAGGGAACACTAG-
TCA
CAGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGC-
ACA
GCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGAC-
CAG
CGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCT-
CCA
GCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTT-
GAG
CCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCGCGGGGGCACCGTCAGTCTT-
CCT
CTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGA-
GCC
ACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGG-
GAG
GAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGA-
GTA
CAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCC-
GAG
AACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTC-
AAA
GGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCC-
TCC
CGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGA-
ACG
TCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGT-
AAA TGA SEQ ID NO. 29: PN encoding 2A10 light chain humanised
construct L13 SEQ ID: 17
ATGGGATGGAGCTGTATCATCCTCTTCTTGGTAGCAACAGCTACAGGTGTCCACTCCGATATTGTGATGACCCA-
GTC
TCCACTCTCCCTGCCCGTCACCCTTGGACAGCCGGCCTCCATCTCCTGCAGGTCTAGTAAGAGTCTCCTATATA-
AGG
ATGGGAAGACATACTTGAATTGGTTTCAGCAGAGGCCAGGCCAATCTCCACAGCTCCTAATTTATTTGATGTCC-
ACC
CGTGCATCTGGGGTCCCAGACAGATTCAGCGGCGGTGGGTCAGGCACTGATTTCACACTGAAAATCAGCAGGGT-
GGA
GGCTGAGGATGTTGGGGTTTATTACTGCCAACAACTTGTAGAGTATCCGCTCACGTTTGGCCAGGGGACCAAGC-
TGG
AGATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACT-
GCC
TCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGACAACGCCCTCCA-
ATC
GGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGC-
TGA
GCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACA-
AAG AGCTTCAACAGGGGAGAGTGTTAG
SEQ ID NO. 30: PN encoding 2A10 light chain humanised construct L16
SEQ ID: 18
ATGGGATGGAGCTGTATCATCCTCTTCTTGGTAGCAACAGCTACAGGTGTCCACTCCGATATTGTGATGACCCA-
GTC
TCCACTCTCCAACCCCGTCACCCTTGGACAGCCGGTCTCCATCTCCTGCAGGTCTAGTAAGAGTCTCCTATATA-
AGG
ATGGGAAGACATACTTGAATTGGTTTCTCCAGAGGCCAGGCCAATCTCCACAGCTCCTAATTTATTTGATGTCC-
ACC
CGTGCATCTGGGGTCCCAGACAGATTCAGCGGCGGTGGGTCAGGCACTGATTTCACACTGAAAATCAGCAGGGT-
GGA
GGCTGAGGATGTTGGGGTTTATTACTGCCAACAACTTGTAGAGTATCCGCTCACGTTTGGCCAGGGGACCAAGC-
TGG
AGATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACT-
GCC
TCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGACAACGCCCTCCA-
ATC
GGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGC-
TGA
GCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACA-
AAG AGCTTCAACAGGGGAGAGTGTTAG SEQ ID NO. 31: Campath leader sequence
MGWSCIILFLVATATGVHS SEQ ID NO. 32: Amino acids 586-785 of human
NOGO A (NOGO-A56) fused to GST
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSMAIIRY-
IAD
KHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHP-
DFM
LYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLEVLFQGP-
LGS
MQESLYPAAQLCPSFEESEATPSPVLPDIVMEAPLNSAVPSAGASVIQPSSSPLEASSVNYESIKHEPENPPPY-
EEA
MSVSLKKVSGIKEEIKEPENINAALQETEAPYISIACDLIKETKLSAEPAPDFSDYSEMAKVEQPVPDHSELVE-
DSS PDSEPVDLFSDDSIPDVPQKQDETVMLVKESLTETSFESMIEYENKELERPHRD SEQ ID
NO. 33: 2A10 VH humanised construct H1
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWMGNINPSNGGTNYNEKFKSRVTMTRDT-
STS TVYMELSSLRSEDTAVYYCELGQGYWGQGTLVTVSS SEQ ID NO. 34: 2A10 VL
humanised construct L11
DIVITQSPLSLPVTLGQPASISCRSSKSLLYKDGKTYLNWFQQRPGQSPQLLIYLMSTRASGVPDRFSGGGSGT-
DFT LKISRVEAEDVGVYYCQQLVEYPLTFGQGTKLEIK SEQ ID NO. 35: 2A10 heavy
chain humanised construct H1
MGWSCIILFLVATATGVHSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWMGNINPSN-
GGT
NYNEKFKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCELGQGYWGQGTLVTVSSASTKGPSVFPLAPSSKSTS-
GGT
AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDK-
KVE
PKSCDKTHTCPPCPAPELAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK-
PRE
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTC-
LVK
GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS-
PGK SEQ ID NO. 36: A10 light chain humanised construct L11
MGWSCIILFLVATATGVHSDIVITQSPLSLPVTLGQPASISCRSSKSLLYKDGKTYLNWFQQRPGQSPQLLIYL-
MST
RASGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCQQLVEYPLTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKS-
GTA
SVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSP-
VTK SFNRGEC SEQ ID NO. 37: PN encoding 2A10 VH humanised construct
H1 SEQ ID: 33
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCATC-
TGG
ATACACCTTCACCAGCTACTGGATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAAATA-
TTA
ATCCTAGCAATGGTGGTACTAACTACAATGAGAAGTTCAAGAGCAGAGTCACCATGACCAGGGACACGTCCACG-
AGC
ACAGTCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGAACTGGGACAGGGCTA-
CTG GGGCCAGGGAACACTAGTCACAGTCTCCTCA SEQ ID NO. 38: PN encoding 2A10
VL humanised construct L11 SEQ ID: 34
GATATTGTGATAACCCAGTCTCCACTCTCCCTGCCCGTCACCCTTGGACAGCCGGCCTCCATCTCCTGCAGGTC-
TAG
TAAGAGTCTCCTATATAAGGATGGGAAGACATACTTGAATTGGTTTCAGCAGAGGCCAGGCCAATCTCCACAGC-
TCC
TAATTTATTTGATGTCCACCCGTGCATCTGGGGTCCCAGACAGATTCAGCGGCGGTGGGTCAGGCACTGATTTC-
ACA
CTGAAAATCAGCAGGGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCCAACAACTTGTAGAGTATCCGCTCAC-
GTT TGGCCAGGGGACCAAGCTGGAGATCAAA SEQ ID NO. 39: PN encoding 2A10
humanised heavy chain H1 SEQ ID: 35
ATGGGATGGAGCTGTATCATCCTCTTCTTGGTAGCAACAGCTACAGGTGTCCACTCCCAGGTGCAGCTGGTGCA-
GTC
TGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCATCTGGATACACCTTCACCAGCT-
ACT
GGATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAAATATTAATCCTAGCAATGGTGGT-
ACT
AACTACAATGAGAAGTTCAAGAGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGGAGCT-
GAG
CAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGAACTGGGACAGGGCTACTGGGGCCAGGGAACACTAG-
TCA
CAGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGC-
ACA
GCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGAC-
CAG
CGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCT-
CCA
GCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTT-
GAG
CCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCGCGGGGGCACCGTCAGTCTT-
CCT
CTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGA-
GCC
ACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGG-
GAG
GAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGA-
GTA
CAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCC-
GAG
AACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTC-
AAA
GGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCC-
TCC
CGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGA-
ACG
TCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGT-
AAA TGA SEQ ID NO. 40: PN encoding 2A10 humanised light chain
construct L11 SEQ ID: 36
ATGGGATGGAGCTGTATCATCCTCTTCTTGGTAGCAACAGCTACAGGTGTCCACTCCGATATTGTGATAACCCA-
GTC
TCCACTCTCCCTGCCCGTCACCCTTGGACAGCCGGCCTCCATCTCCTGCAGGTCTAGTAAGAGTCTCCTATATA-
AGG
ATGGGAAGACATACTTGAATTGGTTTCAGCAGAGGCCAGGCCAATCTCCACAGCTCCTAATTTATTTGATGTCC-
ACC
CGTGCATCTGGGGTCCCAGACAGATTCAGCGGCGGTGGGTCAGGCACTGATTTCACACTGAAAATCAGCAGGGT-
GGA
GGCTGAGGATGTTGGGGTTTATTACTGCCAACAACTTGTAGAGTATCCGCTCACGTTTGGCCAGGGGACCAAGC-
TGG
AGATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACT-
GCC
TCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGACAACGCCCTCCA-
ATC
GGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGC-
TGA
GCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACA-
AAG AGCTTCAACAGGGGAGAGTGTTAG SEQ ID NO. 41: 2A10 VH humanised
construct H20
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWIGNINPSNGGTNYNEKFKSKATMTRDT-
STS TAYMELSSLRSEDTAVYYCELGQGYWGQGTLVTVSS SEQ ID NO. 42: 2A10 heavy
chain humanised construct H20
MGWSCIILFLVATATGVHSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWIGNINPSN-
GGT
NYNEKFKSKATMTRDTSTSTAYMELSSLRSEDTAVYYCELGQGYWGQGTLVTVSSASTKGPSVFPLAPSSKSTS-
GGT
AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDK-
KVE
PKSCDKTHTCPPCPAPELAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK-
PRE
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTC-
LVK
GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS-
PGK SEQ ID NO. 43:
PN encoding 2A10 VH humanised construct H20 SEQ ID: 41
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCATC-
TGG
ATACACCTTCACCAGCTACTGGATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATCGGAAATA-
TTA
ATCCTAGCAATGGTGGTACTAACTACAATGAGAAGTTCAAGAGCAAGGCCACCATGACCAGGGACACGTCCACG-
AGC
ACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGAACTGGGACAGGGCTA-
CTG GGGCCAGGGAACACTAGTCACAGTCTCCTCA SEQ ID NO. 44: PN encoding 2A10
heavy chain humanised construct H20 SEQ ID: 42
ATGGGATGGAGCTGTATCATCCTCTTCTTGGTAGCAACAGCTACAGGTGTCCACTCCCAGGTGCAGCTGGTGCA-
GTC
TGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCATCTGGATACACCTTCACCAGCT-
ACT
GGATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATCGGAAATATTAATCCTAGCAATGGTGGT-
ACT
AACTACAATGAGAAGTTCAAGAGCAAGGCCACCATGACCAGGGACACGTCCACGAGCACAGCCTACATGGAGCT-
GAG
CAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGAACTGGGACAGGGCTACTGGGGCCAGGGAACACTAG-
TCA
CAGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGC-
ACA
GCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGAC-
CAG
CGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCT-
CCA
GCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTT-
GAG
CCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCGCGGGGGCACCGTCAGTCTT-
CCT
CTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGA-
GCC
ACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGG-
GAG
GAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGA-
GTA
CAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCC-
GAG
AACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTC-
AAA
GGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCC-
TCC
CGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGA-
ACG
TCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGT-
AAA TGA SEQ ID NO. 45: 2A10 CDR-H3 (G95M) MQGY SEQ ID NO. 46: Amino
acid sequence of Marmoset NOGO-A fragment
VQDSLCPVAQLCPSFEESEATPSPVLPDIVMEAPLNSAVPSAGASAVQPSSSPLEASSVNFESVKHEPENPPPY-
EEA
MNVSRKKVSGIKEEIKEPESINAAVQETEAPYISIACDLIKETKLSAEPTPDFSSYSEMAKVEQPLPDHSELVE-
DSS PDSEPVDLFSDDSIPDVPQKQDEAVILVKETLTETSFESMIEHENK SEQ ID NO. 47:
VH humanised construct H26
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWIGNINPSNGGTNYNEKFKSRATMTRDT-
STS TAYMELSSLRSEDTAVYYCELMQGYWGQGTLVTVSS SEQ ID NO. 48: VH
humanised construct H27
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVKQRPGQGLEWIGNINPSNGGTNYNEKFKSKATLTVDK-
STS TAYMELSSLRSEDTAVYYCELMQGYWGQGTLVTVSS SEQ ID NO. 49: VH
humanised construct H28
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWIGNINPSNGGTNYNEKFKSKATMTRDT-
STS TAYMELSSLRSEDTAVYYCELMQGYWGQGTLVTVSS SEQ ID NO. 50: PN encoding
VH humanised construct H26 SEQ ID: 47
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCATC-
TGG
ATACACCTTCACCAGCTACTGGATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATCGGAAATA-
TTA
ATCCTAGCAATGGTGGTACTAACTACAATGAGAAGTTCAAGAGCAGAGCCACCATGACCAGGGACACGTCCACG-
AGC
ACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGAACTGATGCAGGGCTA-
CTG GGGCCAGGGAACACTAGTCACAGTCTCCTCA SEQ ID NO. 51: PN encoding VH
humanised construct H27 SEQ ID: 48
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCATC-
TGG
ATACACCTTCACCAGCTACTGGATGCACTGGGTGAAACAGCGACCTGGACAAGGGCTTGAGTGGATCGGAAATA-
TTA
ATCCTAGCAATGGTGGTACTAACTACAATGAGAAGTTCAAGAGCAAAGCCACCCTCACCGTCGACAAATCCACG-
AGC
ACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGAACTGATGCAGGGCTA-
CTG GGGCCAGGGAACACTAGTCACAGTCTCCTCA SEQ ID NO. 52: PN encoding VH
humanised construct H28 SEQ ID: 49
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCATC-
TGG
ATACACCTTCACCAGCTACTGGATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATCGGAAATA-
TTA
ATCCTAGCAATGGTGGTACTAACTACAATGAGAAGTTCAAGAGCAAGGCCACCATGACCAGGGACACGTCCACG-
AGC
ACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGAACTGATGCAGGGCTA-
CTG GGGCCAGGGAACACTAGTCACAGTCTCCTCA SEQ ID NO. 53: Heavy chain
humanised construct H26
MGWSCIILFLVATATGVHSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWIGNINPSN-
GGT
NYNEKFKSRATMTRDTSTSTAYMELSSLRSEDTAVYYCELMQGYWGQGTLVTVSSASTKGPSVFPLAPSSKSTS-
GGT
AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDK-
KVE
PKSCDKTHTCPPCPAPELAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK-
PRE
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTC-
LVK
GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS-
PGK SEQ ID NO. 54: Heavy chain humanised construct H27
MGWSCIILFLVATATGVHSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVKQRPGQGLEWIGNINPSN-
GGT
NYNEKFKSKATLTVDKSTSTAYMELSSLRSEDTAVYYCELMQGYWGQGTLVTVSSASTKGPSVFPLAPSSKSTS-
GGT
AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDK-
KVE
PKSCDKTHTCPPCPAPELAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK-
PRE
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTC-
LVK
GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS-
PGK SEQ ID NO. 55: Heavy chain humanised construct H28
MGWSCIILFLVATATGVHSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWIGNINPSN-
GGT
NYNEKFKSKATMTRDTSTSTAYMELSSLRSEDTAVYYCELMQGYWGQGTLVTVSSASTKGPSVFPLAPSSKSTS-
GGT
AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDK-
KVE
PKSCDKTHTCPPCPAPELAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK-
PRE
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTC-
LVK
GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS-
PGK SEQ ID NO. 56: PN encoding Heavy chain humanised construct H26
SEQ ID: 53
ATGGGATGGAGCTGTATCATCCTCTTCTTGGTAGCAACAGCTACAGGTGTCCACTCCCAGGTGCAGCTGGTGCA-
GTC
TGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCATCTGGATACACCTTCACCAGCT-
ACT
GGATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATCGGAAATATTAATCCTAGCAATGGTGGT-
ACT
AACTACAATGAGAAGTTCAAGAGCAGAGCCACCATGACCAGGGACACGTCCACGAGCACAGCCTACATGGAGCT-
GAG
CAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGAACTGATGCAGGGCTACTGGGGCCAGGGAACACTAG-
TCA
CAGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGC-
ACA
GCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGAC-
CAG
CGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCT-
CCA
GCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTT-
GAG
CCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCGCGGGGGCACCGTCAGTCTT-
CCT
CTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGA-
GCC
ACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGG-
GAG
GAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGA-
GTA
CAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCC-
GAG
AACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTC-
AAA
GGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCC-
TCC
CGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGA-
ACG
TCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGT-
AAA TGA SEQ ID NO. 57: PN encoding Heavy chain humanised construct
H27 SEQ ID: 54
ATGGGATGGAGCTGTATCATCCTCTTCTTGGTAGCAACAGCTACAGGTGTCCACTCCCAGGTGCAGCTGGTGCA-
GTC
TGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCATCTGGATACACCTTCACCAGCT-
ACT
GGATGCACTGGGTGAAACAGCGACCTGGACAAGGGCTTGAGTGGATCGGAAATATTAATCCTAGCAATGGTGGT-
ACT
AACTACAATGAGAAGTTCAAGAGCAAAGCCACCCTCACCGTCGACAAATCCACGAGCACAGCCTACATGGAGCT-
GAG
CAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGAACTGATGCAGGGCTACTGGGGCCAGGGAACACTAG-
TCA
CAGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGC-
ACA
GCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGAC-
CAG
CGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCT-
CCA
GCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTT-
GAG
CCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCGCGGGGGCACCGTCAGTCTT-
CCT
CTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGA-
GCC
ACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGG-
GAG
GAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGA-
GTA
CAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCC-
GAG
AACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTC-
AAA
GGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCC-
TCC
CGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGA-
ACG
TCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGT-
AAA TGA SEQ ID NO. 58: PN encoding Heavy chain humanised construct
H28 SEQ ID: 55
ATGGGATGGAGCTGTATCATCCTCTTCTTGGTAGCAACAGCTACAGGTGTCCACTCCCAGGTGCAGCTGGTGCA-
GTC
TGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCATCTGGATACACCTTCACCAGCT-
ACT
GGATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATCGGAAATATTAATCCTAGCAATGGTGGT-
ACT
AACTACAATGAGAAGTTCAAGAGCAAGGCCACCATGACCAGGGACACGTCCACGAGCACAGCCTACATGGAGCT-
GAG
CAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGAACTGATGCAGGGCTACTGGGGCCAGGGAACACTAG-
TCA
CAGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGC-
ACA
GCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGAC-
CAG
CGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCT-
CCA
GCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTT-
GAG
CCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCGCGGGGGCACCGTCAGTCTT-
CCT
CTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGA-
GCC
ACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGG-
GAG
GAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGA-
GTA
CAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCC-
GAG
AACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTC-
AAA
GGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCC-
TCC
CGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGA-
ACG
TCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGT-
AAA TGA SEQ ID NO. 59: Heavy chain Hc (G95M)
MGWSCIILFLVAAATGVHSQVQLQQPGTELVKPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGNINPSN-
GGT
NYNEKFKSKATLTVDKSSSTAYMQLSSLTSEDSAVYYCELMQGYWGQGTLVTVSSASTKGPSVFPLAPSSKSTS-
GGT
AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDK-
KVE
PKSCDKTHTCPPCPAPELAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK-
PRE
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTC-
LVK
GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS-
PGK SEQ ID 60: Epitope VLPDIVMEAPLN SEQ ID 61: 2A10 VH humanised
construct H99
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWMGNINPSNGGTNYNEKFKSRVTMTRDT-
STS TVYMELSSLRSEDTAVYYCELGQSYWGQGTLVTVSS SEQ ID NO. 62: CDR H3 GQSY
SEQ ID NO. 63: VH humanised construct H100
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWIGNINPSNGGTNYNEKFKSRATMTRDT-
STS TAYMELSSLRSEDTAVYYCELGQSYWGQGTLVTVSS SEQ ID NO. 64: VH
humanised construct H101
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVKQRPGQGLEWIGNINPSNGGTNYNEKFKSKATLTVDK-
STS TAYMELSSLRSEDTAVYYCELGQSYWGQGTLVTVSS SEQ ID NO. 65: VH
humanised construct H102
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWIGNINPSNGGTNYNEKFKSKATMTRDT-
STS TAYMELSSLRSEDTAVYYCELGQSYWGQGTLVTVSS SEQ ID NO. 66 2A10 VH
humanised construct H98
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWMGNINPSNGGTNYNEKFKSRVTMTRDT-
STS TVYMELSSLRSEDTAVYYCELMQGYWGQGTLVTVSS SEQ ID NO. 67
DIVMTQSPLSLPVTLGQPASISCRSSKSLLYKDGKTYLNWFRQRPGQSPQLLIYLMSTRASGVPDRFSGGGSGT-
DFT LKISRVEAEDVGVYYCQQLVEYPLTFGQGTKLEIK SEQ ID NO. 68
DIVMTQSPLSLPVTLGQPASISCRSSKSLLYKDGKTYLNWFQQRPGQSPRLLIYLMSTRASGVPDRFSGGGSGT-
DFT LKISRVEAEDVGVYYCQQLVEYPLTFGQGTKLEIK SEQ ID NO. 69
DIVMTQSPLSLPVTLGQPASISCRSSKSLLYKDGKTYLNWFRQRPGQSPRLLIYLMSTRASGVPDRFSGGGSGT-
DFT LKISRVEAEDVGVYYCQQLVEYPLTFGQGTKLEIK SEQ ID NO. 70
DIVMTQSPLSNPVTLGQPVSISCRSSKSLLYKDGKTYLNWFRQRPGQSPQLLIYLMSTRASGVPDRFSGGGSGT-
DFT LKISRVEAEDVGVYYCQQLVEYPLTFGQGTKLEIK SEQ ID NO. 71
DIVMTQSPLSNPVTLGQPVSISCRSSKSLLYKDGKTYLNWFLQRPGQSPPLLIYLMSTRASGVPDRFSGGGSGT-
DFT LKISRVEAEDVGVYYCQQLVEYPLTFGQGTKLEIK SEQ ID NO. 72
DIVMTQSPLSNPVTLGQPVSISCRSSKSLLYKDGKTYLNWFRQRPGQSPRLLIYLMSTRASGVPDRFSGGGSGT-
DFT LKISRVEAEDVGVYYCQQLVEYPLTFGQGTKLEIK SEQ ID NO. 73
TPSPVLPDIVMEAPLN SEQ ID NO. 74 VLPDIVMEAPLNSAVP SEQ ID NO. 75 RQGY
SEQ ID NO. 76 IQGY SEQ ID NO. 77
GDGY SEQ ID NO. 78 GIGY SEQ ID NO. 79 GSGY SEQ ID NO. 80 GQNY SEQ
ID NO. 81 GQYY SEQ ID NO. 82 GQLY SEQ ID NO. 83 GQFY SEQ ID NO. 84
GQGW SEQ ID NO. 85 YESIKHEPENPPPYEE SEQ ID NO. 86 WQGY SEQ ID NO.
87 GAGY SEQ ID NO. 88 GLGY SEQ ID NO. 89 GVGY SEQ ID NO. 90 GQWY
SEQ ID NO. 91
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSMAIIRY-
IAD
KHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHP-
DFM
LYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLEVLFQGP-
LGS
MQESLYPVAQLCPSFEESEATPSPVLPDIVMEAPLNSAVPSAVASAVQPSLSPLEASSVNYESVKHEPENPPPY-
EEA
MNVSLKKVSGIKEEIKEPESIKAAVQETEAPYISIACDLIKETKLSAEPTPDFSNYSEMAKVEQPLPDHSEIVE-
DSS PDSEPVDLFSDDSIPDVPQKQDEAVILVKENLTETSFESMIEHENKLERPHRD SEQ ID
NO. 92
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSMAIIRY-
IAD
KHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHP-
DFM
LYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLEVLFQGP-
LGS
KMDLVQTSEVMQESLYPAAQLCPSFEESEATPSPVLPDIVMEAPLNSAVPSAGASAVQPSSSPLEASSVNYESI-
IHE
PENPPPYEEAMSVSLKKVSGIKEEIKEPESINAAVQETEAPYISIACDLIKETKLSAEPTPDFSDYSEMAKVEQ-
PVP
DHSELVEDSSPDSEPVDLFSDDSIPDVPQKQDEAVMLVKENLPETSFESMIEHENKEKLSALPPEGGSSGRIVT-
D SEQ ID NO. 93
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSMAIIRY-
IAD
KHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHP-
DFM
LYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLEVLFQGP-
LGS
VQDSLCPVAQLCPSFEESEATPSPVLPDIVMEAPLNSAVPSAGASAVQPSSSPLEASSVNFESVKHEPENPPPY-
EEA
MNVSRKKVSGIKEEIKEPESINAAVQETEAPYISIACDLIKETKLSAEPTPDFSSYSEMAKVEQPLPDHSELVE-
DSS PDSEPVDLFSDDSIPDVPQKQDEAVILVKETLTETSFESMIEHENKLERPHRD SEQ ID
NO. 94
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSMAIIRY-
IAD
KHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHP-
DFM
LYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLEVLFQGP-
LGS
IQESLYPTAQLCPSFEEAEATPSPVLPDIVMEAPLNSLLPSAGASVVQPSVSPLEAPPPVSYDSIKLEPENPPP-
YEE
AMNVALKALGTKEGIKEPESFNAAVQETEAPYISIACDLIKETKLSTEPSPDFSNYSEIAKFEKSVPEHAELVE-
DSS PESEPVDLFSDDSIPEVPQTQEEAVMLMKESLTEVSETVAQHKEERL SEQ ID NO. 95
DETFAL SEQ ID NO. 96 ELSKTS
Sequence CWU 1
1
9615PRTMus musculus 1Ser Tyr Trp Met His1 5 217PRTMus musculus 2Asn
Ile Asn Pro Ser Asn Gly Gly Thr Asn Tyr Asn Glu Lys Phe Lys1 5 10
15 Ser34PRTMus musculus 3Gly Gln Gly Tyr1 416PRTMus musculus 4Arg
Ser Ser Lys Ser Leu Leu Tyr Lys Asp Gly Lys Thr Tyr Leu Asn1 5 10
15 57PRTMus musculus 5Leu Met Ser Thr Arg Ala Ser1 5 69PRTMus
musculus 6Gln Gln Leu Val Glu Tyr Pro Leu Thr1 5 7113PRTMus
musculus 7Gln Val Gln Leu Gln Gln Pro Gly Thr Glu Leu Val Lys Pro
Gly Ala1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr
Phe Thr Ser Tyr 20 25 30 Trp Met His Trp Val Lys Gln Arg Pro Gly
Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asn Ile Asn Pro Ser Asn Gly
Gly Thr Asn Tyr Asn Glu Lys Phe 50 55 60 Lys Ser Lys Ala Thr Leu
Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr65 70 75 80 Met Gln Leu Ser
Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Glu Leu
Gly Gln Gly Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser 100 105 110
Ser8112PRTMus musculus 8Asp Ile Val Ile Thr Gln Asp Glu Leu Ser Asn
Pro Val Thr Ser Gly1 5 10 15 Glu Ser Val Ser Ile Ser Cys Arg Ser
Ser Lys Ser Leu Leu Tyr Lys 20 25 30 Asp Gly Lys Thr Tyr Leu Asn
Trp Phe Leu Gln Arg Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile
Tyr Leu Met Ser Thr Arg Ala Ser Gly Val Ser 50 55 60 Asp Arg Phe
Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Glu Ile65 70 75 80 Ser
Arg Val Lys Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Leu 85 90
95 Val Glu Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
100 105 110 9462PRTArtificial SequenceChimeric Ab comprising
sequences from mus musculus and homo sapiens 9Met Gly Trp Ser Cys
Ile Ile Leu Phe Leu Val Ala Ala Ala Thr Gly1 5 10 15 Val His Ser
Gln Val Gln Leu Gln Gln Pro Gly Thr Glu Leu Val Lys 20 25 30 Pro
Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe 35 40
45 Thr Ser Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu
50 55 60 Glu Trp Ile Gly Asn Ile Asn Pro Ser Asn Gly Gly Thr Asn
Tyr Asn65 70 75 80 Glu Lys Phe Lys Ser Lys Ala Thr Leu Thr Val Asp
Lys Ser Ser Ser 85 90 95 Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr
Ser Glu Asp Ser Ala Val 100 105 110 Tyr Tyr Cys Glu Leu Gly Gln Gly
Tyr Trp Gly Gln Gly Thr Leu Val 115 120 125 Thr Val Ser Ser Ala Ser
Thr Lys Gly Pro Ser Val Phe Pro Leu Ala 130 135 140 Pro Ser Ser Lys
Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu145 150 155 160 Val
Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly 165 170
175 Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser
180 185 190 Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser
Ser Leu 195 200 205 Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys
Pro Ser Asn Thr 210 215 220 Lys Val Asp Lys Lys Val Glu Pro Lys Ser
Cys Asp Lys Thr His Thr225 230 235 240 Cys Pro Pro Cys Pro Ala Pro
Glu Leu Ala Gly Ala Pro Ser Val Phe 245 250 255 Leu Phe Pro Pro Lys
Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro 260 265 270 Glu Val Thr
Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val 275 280 285 Lys
Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr 290 295
300 Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
Val305 310 315 320 Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
Glu Tyr Lys Cys 325 330 335 Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
Ile Glu Lys Thr Ile Ser 340 345 350 Lys Ala Lys Gly Gln Pro Arg Glu
Pro Gln Val Tyr Thr Leu Pro Pro 355 360 365 Ser Arg Asp Glu Leu Thr
Lys Asn Gln Val Ser Leu Thr Cys Leu Val 370 375 380 Lys Gly Phe Tyr
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly385 390 395 400 Gln
Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp 405 410
415 Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
420 425 430 Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
Leu His 435 440 445 Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
Gly Lys 450 455 460 10239PRTArtificial SequenceChimeric Ab
comprising sequences from mus musculus and homo sapiens 10Met Arg
Cys Ser Leu Gln Phe Leu Gly Val Leu Met Phe Trp Ile Ser1 5 10 15
Gly Val Ser Gly Asp Ile Val Ile Thr Gln Asp Glu Leu Ser Asn Pro 20
25 30 Val Thr Ser Gly Glu Ser Val Ser Ile Ser Cys Arg Ser Ser Lys
Ser 35 40 45 Leu Leu Tyr Lys Asp Gly Lys Thr Tyr Leu Asn Trp Phe
Leu Gln Arg 50 55 60 Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu
Met Ser Thr Arg Ala65 70 75 80 Ser Gly Val Ser Asp Arg Phe Ser Gly
Ser Gly Ser Gly Thr Asp Phe 85 90 95 Thr Leu Glu Ile Ser Arg Val
Lys Ala Glu Asp Val Gly Val Tyr Tyr 100 105 110 Cys Gln Gln Leu Val
Glu Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys 115 120 125 Leu Glu Leu
Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro 130 135 140 Pro
Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu145 150
155 160 Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val
Asp 165 170 175 Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr
Glu Gln Asp 180 185 190 Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr
Leu Thr Leu Ser Lys 195 200 205 Ala Asp Tyr Glu Lys His Lys Val Tyr
Ala Cys Glu Val Thr His Gln 210 215 220 Gly Leu Ser Ser Pro Val Thr
Lys Ser Phe Asn Arg Gly Glu Cys225 230 235 11113PRTArtificial
SequenceHumanized antibody construct comprising sequences from mus
musculus and homo sapiens 11Gln Val Gln Leu Val Gln Ser Gly Ala Glu
Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala
Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met His Trp Val Arg
Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asn Ile Asn
Pro Ser Asn Gly Gly Thr Asn Tyr Asn Glu Lys Phe 50 55 60 Lys Ser
Arg Ala Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85
90 95 Glu Leu Gly Gln Gly Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
Ser 100 105 110 Ser12113PRTArtificial SequenceHumanized Ab
construct comprising sequences from mus musculus and homo sapiens
12Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1
5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser
Tyr 20 25 30 Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu
Glu Trp Ile 35 40 45 Gly Asn Ile Asn Pro Ser Asn Gly Gly Thr Asn
Tyr Asn Glu Lys Phe 50 55 60 Lys Ser Lys Ala Thr Leu Thr Val Asp
Lys Ser Thr Ser Thr Ala Tyr65 70 75 80 Met Glu Leu Ser Ser Leu Arg
Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Glu Leu Gly Gln Gly
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110
Ser13112PRTArtificial SequenceHumanized Ab construct comprising
sequences from mus musculus and homo sapiens 13Asp Ile Val Met Thr
Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly1 5 10 15 Gln Pro Ala
Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu Tyr Lys 20 25 30 Asp
Gly Lys Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser 35 40
45 Pro Gln Leu Leu Ile Tyr Leu Met Ser Thr Arg Ala Ser Gly Val Pro
50 55 60 Asp Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu
Lys Ile65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr
Cys Gln Gln Leu 85 90 95 Val Glu Tyr Pro Leu Thr Phe Gly Gln Gly
Thr Lys Leu Glu Ile Lys 100 105 110 14112PRTArtificial
SequenceHumanized Ab construct comprising sequences from mus
musculus and homo sapiens 14Asp Ile Val Met Thr Gln Ser Pro Leu Ser
Asn Pro Val Thr Leu Gly1 5 10 15 Gln Pro Val Ser Ile Ser Cys Arg
Ser Ser Lys Ser Leu Leu Tyr Lys 20 25 30 Asp Gly Lys Thr Tyr Leu
Asn Trp Phe Leu Gln Arg Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu
Ile Tyr Leu Met Ser Thr Arg Ala Ser Gly Val Pro 50 55 60 Asp Arg
Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Leu 85
90 95 Val Glu Tyr Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
Lys 100 105 110 15462PRTArtificial SequenceHumanized antibody
construct comprising sequences from mus musculus and homo sapiens
15Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly1
5 10 15 Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys
Lys 20 25 30 Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly
Tyr Thr Phe 35 40 45 Thr Ser Tyr Trp Met His Trp Val Arg Gln Ala
Pro Gly Gln Gly Leu 50 55 60 Glu Trp Ile Gly Asn Ile Asn Pro Ser
Asn Gly Gly Thr Asn Tyr Asn65 70 75 80 Glu Lys Phe Lys Ser Arg Ala
Thr Met Thr Arg Asp Thr Ser Thr Ser 85 90 95 Thr Ala Tyr Met Glu
Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val 100 105 110 Tyr Tyr Cys
Glu Leu Gly Gln Gly Tyr Trp Gly Gln Gly Thr Leu Val 115 120 125 Thr
Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala 130 135
140 Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys
Leu145 150 155 160 Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
Trp Asn Ser Gly 165 170 175 Ala Leu Thr Ser Gly Val His Thr Phe Pro
Ala Val Leu Gln Ser Ser 180 185 190 Gly Leu Tyr Ser Leu Ser Ser Val
Val Thr Val Pro Ser Ser Ser Leu 195 200 205 Gly Thr Gln Thr Tyr Ile
Cys Asn Val Asn His Lys Pro Ser Asn Thr 210 215 220 Lys Val Asp Lys
Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr225 230 235 240 Cys
Pro Pro Cys Pro Ala Pro Glu Leu Ala Gly Ala Pro Ser Val Phe 245 250
255 Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
260 265 270 Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
Glu Val 275 280 285 Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
Asn Ala Lys Thr 290 295 300 Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
Tyr Arg Val Val Ser Val305 310 315 320 Leu Thr Val Leu His Gln Asp
Trp Leu Asn Gly Lys Glu Tyr Lys Cys 325 330 335 Lys Val Ser Asn Lys
Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser 340 345 350 Lys Ala Lys
Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro 355 360 365 Ser
Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val 370 375
380 Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
Gly385 390 395 400 Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
Leu Asp Ser Asp 405 410 415 Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
Val Asp Lys Ser Arg Trp 420 425 430 Gln Gln Gly Asn Val Phe Ser Cys
Ser Val Met His Glu Ala Leu His 435 440 445 Asn His Tyr Thr Gln Lys
Ser Leu Ser Leu Ser Pro Gly Lys 450 455 460 16462PRTArtificial
SequenceHumanized antibody construct comprising sequences from mus
musculus and homo sapiens 16Met Gly Trp Ser Cys Ile Ile Leu Phe Leu
Val Ala Thr Ala Thr Gly1 5 10 15 Val His Ser Gln Val Gln Leu Val
Gln Ser Gly Ala Glu Val Lys Lys 20 25 30 Pro Gly Ala Ser Val Lys
Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe 35 40 45 Thr Ser Tyr Trp
Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu 50 55 60 Glu Trp
Ile Gly Asn Ile Asn Pro Ser Asn Gly Gly Thr Asn Tyr Asn65 70 75 80
Glu Lys Phe Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Thr Ser 85
90 95 Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala
Val 100 105 110 Tyr Tyr Cys Glu Leu Gly Gln Gly Tyr Trp Gly Gln Gly
Thr Leu Val 115 120 125 Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
Val Phe Pro Leu Ala 130 135 140 Pro Ser Ser Lys Ser Thr Ser Gly Gly
Thr Ala Ala Leu Gly Cys Leu145 150 155 160 Val Lys Asp Tyr Phe Pro
Glu Pro Val Thr Val Ser Trp Asn Ser Gly 165 170 175 Ala Leu Thr Ser
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser 180 185 190 Gly Leu
Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu 195 200 205
Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr 210
215 220 Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His
Thr225 230 235 240 Cys Pro Pro Cys Pro Ala Pro Glu Leu Ala Gly Ala
Pro Ser Val Phe 245 250 255 Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
Met Ile Ser Arg Thr Pro 260 265 270 Glu Val Thr
Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val 275 280 285 Lys
Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr 290 295
300 Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
Val305 310 315 320 Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
Glu Tyr Lys Cys 325 330 335 Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
Ile Glu Lys Thr Ile Ser 340 345 350 Lys Ala Lys Gly Gln Pro Arg Glu
Pro Gln Val Tyr Thr Leu Pro Pro 355 360 365 Ser Arg Asp Glu Leu Thr
Lys Asn Gln Val Ser Leu Thr Cys Leu Val 370 375 380 Lys Gly Phe Tyr
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly385 390 395 400 Gln
Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp 405 410
415 Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
420 425 430 Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
Leu His 435 440 445 Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
Gly Lys 450 455 460 17238PRTArtificial SequenceHumanized antibody
construct comprising sequences from mus musculus and homo sapiens
17Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly1
5 10 15 Val His Ser Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro
Val 20 25 30 Thr Leu Gly Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser
Lys Ser Leu 35 40 45 Leu Tyr Lys Asp Gly Lys Thr Tyr Leu Asn Trp
Phe Gln Gln Arg Pro 50 55 60 Gly Gln Ser Pro Gln Leu Leu Ile Tyr
Leu Met Ser Thr Arg Ala Ser65 70 75 80 Gly Val Pro Asp Arg Phe Ser
Gly Gly Gly Ser Gly Thr Asp Phe Thr 85 90 95 Leu Lys Ile Ser Arg
Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys 100 105 110 Gln Gln Leu
Val Glu Tyr Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu 115 120 125 Glu
Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro 130 135
140 Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu
Leu145 150 155 160 Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp
Lys Val Asp Asn 165 170 175 Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser
Val Thr Glu Gln Asp Ser 180 185 190 Lys Asp Ser Thr Tyr Ser Leu Ser
Ser Thr Leu Thr Leu Ser Lys Ala 195 200 205 Asp Tyr Glu Lys His Lys
Val Tyr Ala Cys Glu Val Thr His Gln Gly 210 215 220 Leu Ser Ser Pro
Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 230 235
18238PRTArtificial SequenceHumanized antibody construct comprising
sequences from mus musculus and homo sapiens 18Met Gly Trp Ser Cys
Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly1 5 10 15 Val His Ser
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Asn Pro Val 20 25 30 Thr
Leu Gly Gln Pro Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu 35 40
45 Leu Tyr Lys Asp Gly Lys Thr Tyr Leu Asn Trp Phe Leu Gln Arg Pro
50 55 60 Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Met Ser Thr Arg
Ala Ser65 70 75 80 Gly Val Pro Asp Arg Phe Ser Gly Gly Gly Ser Gly
Thr Asp Phe Thr 85 90 95 Leu Lys Ile Ser Arg Val Glu Ala Glu Asp
Val Gly Val Tyr Tyr Cys 100 105 110 Gln Gln Leu Val Glu Tyr Pro Leu
Thr Phe Gly Gln Gly Thr Lys Leu 115 120 125 Glu Ile Lys Arg Thr Val
Ala Ala Pro Ser Val Phe Ile Phe Pro Pro 130 135 140 Ser Asp Glu Gln
Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu145 150 155 160 Asn
Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn 165 170
175 Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser
180 185 190 Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser
Lys Ala 195 200 205 Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val
Thr His Gln Gly 210 215 220 Leu Ser Ser Pro Val Thr Lys Ser Phe Asn
Arg Gly Glu Cys225 230 235 19339DNAMus musculus 19caggtccaac
tgcagcagcc tgggactgaa ctggtgaagc ctggggcttc agtgaagctg 60tcctgcaagg
cttctggcta caccttcacc agctactgga tgcactgggt gaagcagagg
120cctggacaag gccttgagtg gattggaaat attaatccta gcaatggtgg
tactaactac 180aatgagaagt tcaagagcaa ggccacactg actgtagaca
aatcctccag cacagcctac 240atgcagctca gcagcctgac atctgaggac
tctgcggtct attattgtga actgggacag 300ggctactggg gccaaggcac
cactctcaca gtctcctca 33920336DNAMus musculus 20gatattgtga
taacccagga tgaactctcc aatcctgtca cttctggaga atcagtttcc 60atctcctgca
ggtctagtaa gagtctccta tataaggatg ggaagacata cttgaattgg
120tttctgcaga gaccaggaca atctcctcag ctcctgatct atttgatgtc
cacccgtgca 180tcaggagtct cagaccggtt tagtggcagt gggtcaggaa
cagatttcac cctggaaatc 240agtagagtga aggctgagga tgtgggtgtg
tattactgtc aacaacttgt agagtatccg 300ctcacgttcg gtgctgggac
caagctggag ctgaaa 336211389DNAArtificial SequenceChimaeric antibody
construct comprising sequences from mus musculus and homo sapiens
21atgggatgga gctgtatcat cctctttttg gtagcagcag ctacaggtgt ccactcccag
60gtccaactgc agcagcctgg gactgaactg gtgaagcctg gggcttcagt gaagctgtcc
120tgcaaggctt ctggctacac cttcaccagc tactggatgc actgggtgaa
gcagaggcct 180ggacaaggcc ttgagtggat tggaaatatt aatcctagca
atggtggtac taactacaat 240gagaagttca agagcaaggc cacactgact
gtagacaaat cctccagcac agcctacatg 300cagctcagca gcctgacatc
tgaggactct gcggtctatt attgtgaact gggacagggc 360tactggggcc
aaggcacact agtcacagtc tcctcagcct ccaccaaggg cccatcggtc
420ttccccctgg caccctcctc caagagcacc tctgggggca cagcggccct
gggctgcctg 480gtcaaggact acttccccga accggtgacg gtgtcgtgga
actcaggcgc cctgaccagc 540ggcgtgcaca ccttcccggc tgtcctacag
tcctcaggac tctactccct cagcagcgtg 600gtgaccgtgc cctccagcag
cttgggcacc cagacctaca tctgcaacgt gaatcacaag 660cccagcaaca
ccaaggtgga caagaaagtt gagcccaaat cttgtgacaa aactcacaca
720tgcccaccgt gcccagcacc tgaactcgcg ggggcaccgt cagtcttcct
cttcccccca 780aaacccaagg acaccctcat gatctcccgg acccctgagg
tcacatgcgt ggtggtggac 840gtgagccacg aagaccctga ggtcaagttc
aactggtacg tggacggcgt ggaggtgcat 900aatgccaaga caaagccgcg
ggaggagcag tacaacagca cgtaccgtgt ggtcagcgtc 960ctcaccgtcc
tgcaccagga ctggctgaat ggcaaggagt acaagtgcaa ggtctccaac
1020aaagccctcc cagcccccat cgagaaaacc atctccaaag ccaaagggca
gccccgagaa 1080ccacaggtgt acaccctgcc cccatcccgg gatgagctga
ccaagaacca ggtcagcctg 1140acctgcctgg tcaaaggctt ctatcccagc
gacatcgccg tggagtggga gagcaatggg 1200cagccggaga acaactacaa
gaccacgcct cccgtgctgg actccgacgg ctccttcttc 1260ctctacagca
agctcaccgt ggacaagagc aggtggcagc aggggaacgt cttctcatgc
1320tccgtgatgc atgaggctct gcacaaccac tacacgcaga agagcctctc
cctgtctccg 1380ggtaaatga 138922720DNAArtificial SequenceChimaeric
antibody construct comprising sequences from mus musculus and homo
sapiens 22atgaggtgct ctcttcagtt tctgggggtg cttatgttct ggatctctgg
agtcagtggg 60gatattgtga taacccagga tgaactctcc aatcctgtca cttctggaga
atcagtttcc 120atctcctgca ggtctagtaa gagtctccta tataaggatg
ggaagacata cttgaattgg 180tttctgcaga gaccaggaca atctcctcag
ctcctgatct atttgatgtc cacccgtgca 240tcaggagtct cagaccggtt
tagtggcagt gggtcaggaa cagatttcac cctggaaatc 300agtagagtga
aggctgagga tgtgggtgtg tattactgtc aacaacttgt agagtatccg
360ctcacgttcg gtgctgggac caagctggag ctgaaacgta cggtggctgc
accatctgtc 420ttcatcttcc cgccatctga tgagcagttg aaatctggaa
ctgcctctgt tgtgtgcctg 480ctgaataact tctatcccag agaggccaaa
gtacagtgga aggtggacaa cgccctccaa 540tcgggtaact cccaggagag
tgtcacagag caggacagca aggacagcac ctacagcctc 600agcagcaccc
tgacgctgag caaagcagac tacgagaaac acaaagtcta cgcctgcgaa
660gtcacccatc agggcctgag ctcgcccgtc acaaagagct tcaacagggg
agagtgttag 72023339DNAArtificial SequenceHumanized antibody
construct comprising sequences from mus musculus and homo sapiens
23caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtt
60tcctgcaagg catctggata caccttcacc agctactgga tgcactgggt gcgacaggcc
120cctggacaag ggcttgagtg gatcggaaat attaatccta gcaatggtgg
tactaactac 180aatgagaagt tcaagagcag agccaccatg accagggaca
cgtccacgag cacagcctac 240atggagctga gcagcctgag atctgaggac
acggccgtgt attactgtga actgggacag 300ggctactggg gccagggaac
actagtcaca gtctcctca 33924339DNAArtificial SequenceHumanized
antibody construct comprising sequences from mus musculus and homo
sapiens 24caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctggggcctc
agtgaaggtt 60tcctgcaagg catctggata caccttcacc agctactgga tgcactgggt
gaaacagcga 120cctggacaag ggcttgagtg gatcggaaat attaatccta
gcaatggtgg tactaactac 180aatgagaagt tcaagagcaa agccaccctc
accgtcgaca aatccacgag cacagcctac 240atggagctga gcagcctgag
atctgaggac acggccgtgt attactgtga actgggacag 300ggctactggg
gccagggaac actagtcaca gtctcctca 33925336DNAArtificial
SequenceHumanized antibody construct comprising sequences from mus
musculus and homo sapiens 25gatattgtga tgacccagtc tccactctcc
ctgcccgtca cccttggaca gccggcctcc 60atctcctgca ggtctagtaa gagtctccta
tataaggatg ggaagacata cttgaattgg 120tttcagcaga ggccaggcca
atctccacag ctcctaattt atttgatgtc cacccgtgca 180tctggggtcc
cagacagatt cagcggcggt gggtcaggca ctgatttcac actgaaaatc
240agcagggtgg aggctgagga tgttggggtt tattactgcc aacaacttgt
agagtatccg 300ctcacgtttg gccaggggac caagctggag atcaaa
33626336DNAArtificial SequenceHumanized antibody construct
comprising sequences from mus musculus and homo sapiens
26gatattgtga tgacccagtc tccactctcc aaccccgtca cccttggaca gccggtctcc
60atctcctgca ggtctagtaa gagtctccta tataaggatg ggaagacata cttgaattgg
120tttctccaga ggccaggcca atctccacag ctcctaattt atttgatgtc
cacccgtgca 180tctggggtcc cagacagatt cagcggcggt gggtcaggca
ctgatttcac actgaaaatc 240agcagggtgg aggctgagga tgttggggtt
tattactgcc aacaacttgt agagtatccg 300ctcacgtttg gccaggggac
caagctggag atcaaa 336271389DNAArtificial SequenceHumanized antibody
construct comprising sequences from mus musculus and homo sapiens
27atgggatgga gctgtatcat cctcttcttg gtagcaacag ctacaggtgt ccactcccag
60gtgcagctgg tgcagtctgg ggctgaggtg aagaagcctg gggcctcagt gaaggtttcc
120tgcaaggcat ctggatacac cttcaccagc tactggatgc actgggtgcg
acaggcccct 180ggacaagggc ttgagtggat cggaaatatt aatcctagca
atggtggtac taactacaat 240gagaagttca agagcagagc caccatgacc
agggacacgt ccacgagcac agcctacatg 300gagctgagca gcctgagatc
tgaggacacg gccgtgtatt actgtgaact gggacagggc 360tactggggcc
agggaacact agtcacagtc tcctcagcct ccaccaaggg cccatcggtc
420ttccccctgg caccctcctc caagagcacc tctgggggca cagcggccct
gggctgcctg 480gtcaaggact acttccccga accggtgacg gtgtcgtgga
actcaggcgc cctgaccagc 540ggcgtgcaca ccttcccggc tgtcctacag
tcctcaggac tctactccct cagcagcgtg 600gtgaccgtgc cctccagcag
cttgggcacc cagacctaca tctgcaacgt gaatcacaag 660cccagcaaca
ccaaggtgga caagaaagtt gagcccaaat cttgtgacaa aactcacaca
720tgcccaccgt gcccagcacc tgaactcgcg ggggcaccgt cagtcttcct
cttcccccca 780aaacccaagg acaccctcat gatctcccgg acccctgagg
tcacatgcgt ggtggtggac 840gtgagccacg aagaccctga ggtcaagttc
aactggtacg tggacggcgt ggaggtgcat 900aatgccaaga caaagccgcg
ggaggagcag tacaacagca cgtaccgtgt ggtcagcgtc 960ctcaccgtcc
tgcaccagga ctggctgaat ggcaaggagt acaagtgcaa ggtctccaac
1020aaagccctcc cagcccccat cgagaaaacc atctccaaag ccaaagggca
gccccgagaa 1080ccacaggtgt acaccctgcc cccatcccgg gatgagctga
ccaagaacca ggtcagcctg 1140acctgcctgg tcaaaggctt ctatcccagc
gacatcgccg tggagtggga gagcaatggg 1200cagccggaga acaactacaa
gaccacgcct cccgtgctgg actccgacgg ctccttcttc 1260ctctacagca
agctcaccgt ggacaagagc aggtggcagc aggggaacgt cttctcatgc
1320tccgtgatgc atgaggctct gcacaaccac tacacgcaga agagcctctc
cctgtctccg 1380ggtaaatga 1389281389DNAArtificial SequenceHumanized
antibody construct comprising sequences from mus musculus and homo
sapiens 28atgggatgga gctgtatcat cctcttcttg gtagcaacag ctacaggtgt
ccactcccag 60gtgcagctgg tgcagtctgg ggctgaggtg aagaagcctg gggcctcagt
gaaggtttcc 120tgcaaggcat ctggatacac cttcaccagc tactggatgc
actgggtgaa acagcgacct 180ggacaagggc ttgagtggat cggaaatatt
aatcctagca atggtggtac taactacaat 240gagaagttca agagcaaagc
caccctcacc gtcgacaaat ccacgagcac agcctacatg 300gagctgagca
gcctgagatc tgaggacacg gccgtgtatt actgtgaact gggacagggc
360tactggggcc agggaacact agtcacagtc tcctcagcct ccaccaaggg
cccatcggtc 420ttccccctgg caccctcctc caagagcacc tctgggggca
cagcggccct gggctgcctg 480gtcaaggact acttccccga accggtgacg
gtgtcgtgga actcaggcgc cctgaccagc 540ggcgtgcaca ccttcccggc
tgtcctacag tcctcaggac tctactccct cagcagcgtg 600gtgaccgtgc
cctccagcag cttgggcacc cagacctaca tctgcaacgt gaatcacaag
660cccagcaaca ccaaggtgga caagaaagtt gagcccaaat cttgtgacaa
aactcacaca 720tgcccaccgt gcccagcacc tgaactcgcg ggggcaccgt
cagtcttcct cttcccccca 780aaacccaagg acaccctcat gatctcccgg
acccctgagg tcacatgcgt ggtggtggac 840gtgagccacg aagaccctga
ggtcaagttc aactggtacg tggacggcgt ggaggtgcat 900aatgccaaga
caaagccgcg ggaggagcag tacaacagca cgtaccgtgt ggtcagcgtc
960ctcaccgtcc tgcaccagga ctggctgaat ggcaaggagt acaagtgcaa
ggtctccaac 1020aaagccctcc cagcccccat cgagaaaacc atctccaaag
ccaaagggca gccccgagaa 1080ccacaggtgt acaccctgcc cccatcccgg
gatgagctga ccaagaacca ggtcagcctg 1140acctgcctgg tcaaaggctt
ctatcccagc gacatcgccg tggagtggga gagcaatggg 1200cagccggaga
acaactacaa gaccacgcct cccgtgctgg actccgacgg ctccttcttc
1260ctctacagca agctcaccgt ggacaagagc aggtggcagc aggggaacgt
cttctcatgc 1320tccgtgatgc atgaggctct gcacaaccac tacacgcaga
agagcctctc cctgtctccg 1380ggtaaatga 138929717DNAArtificial
SequenceHumanized antibody construct comprising sequences from mus
musculus and homo sapiens 29atgggatgga gctgtatcat cctcttcttg
gtagcaacag ctacaggtgt ccactccgat 60attgtgatga cccagtctcc actctccctg
cccgtcaccc ttggacagcc ggcctccatc 120tcctgcaggt ctagtaagag
tctcctatat aaggatggga agacatactt gaattggttt 180cagcagaggc
caggccaatc tccacagctc ctaatttatt tgatgtccac ccgtgcatct
240ggggtcccag acagattcag cggcggtggg tcaggcactg atttcacact
gaaaatcagc 300agggtggagg ctgaggatgt tggggtttat tactgccaac
aacttgtaga gtatccgctc 360acgtttggcc aggggaccaa gctggagatc
aaacgtacgg tggctgcacc atctgtcttc 420atcttcccgc catctgatga
gcagttgaaa tctggaactg cctctgttgt gtgcctgctg 480aataacttct
atcccagaga ggccaaagta cagtggaagg tggacaacgc cctccaatcg
540ggtaactccc aggagagtgt cacagagcag gacagcaagg acagcaccta
cagcctcagc 600agcaccctga cgctgagcaa agcagactac gagaaacaca
aagtctacgc ctgcgaagtc 660acccatcagg gcctgagctc gcccgtcaca
aagagcttca acaggggaga gtgttag 71730717DNAArtificial
SequenceHumanized antibody construct comprising sequences from mus
musculus and homo sapiens 30atgggatgga gctgtatcat cctcttcttg
gtagcaacag ctacaggtgt ccactccgat 60attgtgatga cccagtctcc actctccaac
cccgtcaccc ttggacagcc ggtctccatc 120tcctgcaggt ctagtaagag
tctcctatat aaggatggga agacatactt gaattggttt 180ctccagaggc
caggccaatc tccacagctc ctaatttatt tgatgtccac ccgtgcatct
240ggggtcccag acagattcag cggcggtggg tcaggcactg atttcacact
gaaaatcagc 300agggtggagg ctgaggatgt tggggtttat tactgccaac
aacttgtaga gtatccgctc 360acgtttggcc aggggaccaa gctggagatc
aaacgtacgg tggctgcacc atctgtcttc 420atcttcccgc catctgatga
gcagttgaaa tctggaactg cctctgttgt gtgcctgctg 480aataacttct
atcccagaga ggccaaagta cagtggaagg tggacaacgc cctccaatcg
540ggtaactccc aggagagtgt cacagagcag gacagcaagg acagcaccta
cagcctcagc 600agcaccctga cgctgagcaa agcagactac gagaaacaca
aagtctacgc ctgcgaagtc 660acccatcagg gcctgagctc gcccgtcaca
aagagcttca acaggggaga gtgttag 7173119PRTArtificial
SequenceHumanized antibody construct comprising sequences from mus
musculus and homo sapiens 31Met Gly Trp Ser Cys Ile Ile Leu Phe Leu
Val Ala Thr Ala Thr Gly1 5 10 15 Val His Ser32439PRTHomo Sapiens
32Met Ser Pro Ile Leu Gly Tyr Trp Lys Ile Lys Gly Leu Val Gln Pro1
5 10 15 Thr Arg Leu Leu Leu Glu Tyr Leu Glu Glu Lys Tyr Glu Glu His
Leu 20 25 30 Tyr Glu Arg Asp Glu Gly Asp Lys Trp Arg Asn Lys Lys
Phe Glu Leu 35 40 45 Gly Leu Glu Phe Pro Asn Leu Pro Tyr Tyr Ile
Asp Gly Asp Val Lys 50 55 60 Leu Thr Gln Ser Met Ala Ile Ile Arg
Tyr Ile Ala Asp Lys His Asn65 70 75 80 Met Leu Gly Gly Cys Pro Lys
Glu Arg Ala Glu Ile Ser Met Leu Glu
85 90 95 Gly Ala Val Leu Asp Ile Arg Tyr Gly Val Ser Arg Ile Ala
Tyr Ser 100 105 110 Lys Asp Phe Glu Thr Leu Lys Val Asp Phe Leu Ser
Lys Leu Pro Glu 115 120 125 Met Leu Lys Met Phe Glu Asp Arg Leu Cys
His Lys Thr Tyr Leu Asn 130 135 140 Gly Asp His Val Thr His Pro Asp
Phe Met Leu Tyr Asp Ala Leu Asp145 150 155 160 Val Val Leu Tyr Met
Asp Pro Met Cys Leu Asp Ala Phe Pro Lys Leu 165 170 175 Val Cys Phe
Lys Lys Arg Ile Glu Ala Ile Pro Gln Ile Asp Lys Tyr 180 185 190 Leu
Lys Ser Ser Lys Tyr Ile Ala Trp Pro Leu Gln Gly Trp Gln Ala 195 200
205 Thr Phe Gly Gly Gly Asp His Pro Pro Lys Ser Asp Leu Glu Val Leu
210 215 220 Phe Gln Gly Pro Leu Gly Ser Met Gln Glu Ser Leu Tyr Pro
Ala Ala225 230 235 240 Gln Leu Cys Pro Ser Phe Glu Glu Ser Glu Ala
Thr Pro Ser Pro Val 245 250 255 Leu Pro Asp Ile Val Met Glu Ala Pro
Leu Asn Ser Ala Val Pro Ser 260 265 270 Ala Gly Ala Ser Val Ile Gln
Pro Ser Ser Ser Pro Leu Glu Ala Ser 275 280 285 Ser Val Asn Tyr Glu
Ser Ile Lys His Glu Pro Glu Asn Pro Pro Pro 290 295 300 Tyr Glu Glu
Ala Met Ser Val Ser Leu Lys Lys Val Ser Gly Ile Lys305 310 315 320
Glu Glu Ile Lys Glu Pro Glu Asn Ile Asn Ala Ala Leu Gln Glu Thr 325
330 335 Glu Ala Pro Tyr Ile Ser Ile Ala Cys Asp Leu Ile Lys Glu Thr
Lys 340 345 350 Leu Ser Ala Glu Pro Ala Pro Asp Phe Ser Asp Tyr Ser
Glu Met Ala 355 360 365 Lys Val Glu Gln Pro Val Pro Asp His Ser Glu
Leu Val Glu Asp Ser 370 375 380 Ser Pro Asp Ser Glu Pro Val Asp Leu
Phe Ser Asp Asp Ser Ile Pro385 390 395 400 Asp Val Pro Gln Lys Gln
Asp Glu Thr Val Met Leu Val Lys Glu Ser 405 410 415 Leu Thr Glu Thr
Ser Phe Glu Ser Met Ile Glu Tyr Glu Asn Lys Glu 420 425 430 Leu Glu
Arg Pro His Arg Asp 435 33113PRTArtificial SequenceHumanized
antibody construct comprising sequences from mus musculus and homo
sapiens 33Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro
Gly Ala1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr
Phe Thr Ser Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly
Gln Gly Leu Glu Trp Met 35 40 45 Gly Asn Ile Asn Pro Ser Asn Gly
Gly Thr Asn Tyr Asn Glu Lys Phe 50 55 60 Lys Ser Arg Val Thr Met
Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr65 70 75 80 Met Glu Leu Ser
Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Glu Leu
Gly Gln Gly Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110
Ser34112PRTArtificial SequenceHumanized antibody construct
comprising sequences from mus musculus and homo sapiens 34Asp Ile
Val Ile Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly1 5 10 15
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu Tyr Lys 20
25 30 Asp Gly Lys Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln
Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Leu Met Ser Thr Arg Ala Ser
Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp
Phe Thr Leu Lys Ile65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly
Val Tyr Tyr Cys Gln Gln Leu 85 90 95 Val Glu Tyr Pro Leu Thr Phe
Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 110 35462PRTArtificial
SequenceHumanized antibody construct comprising sequences from mus
musculus and homo sapiens 35Met Gly Trp Ser Cys Ile Ile Leu Phe Leu
Val Ala Thr Ala Thr Gly1 5 10 15 Val His Ser Gln Val Gln Leu Val
Gln Ser Gly Ala Glu Val Lys Lys 20 25 30 Pro Gly Ala Ser Val Lys
Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe 35 40 45 Thr Ser Tyr Trp
Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu 50 55 60 Glu Trp
Met Gly Asn Ile Asn Pro Ser Asn Gly Gly Thr Asn Tyr Asn65 70 75 80
Glu Lys Phe Lys Ser Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser 85
90 95 Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala
Val 100 105 110 Tyr Tyr Cys Glu Leu Gly Gln Gly Tyr Trp Gly Gln Gly
Thr Leu Val 115 120 125 Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
Val Phe Pro Leu Ala 130 135 140 Pro Ser Ser Lys Ser Thr Ser Gly Gly
Thr Ala Ala Leu Gly Cys Leu145 150 155 160 Val Lys Asp Tyr Phe Pro
Glu Pro Val Thr Val Ser Trp Asn Ser Gly 165 170 175 Ala Leu Thr Ser
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser 180 185 190 Gly Leu
Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu 195 200 205
Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr 210
215 220 Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His
Thr225 230 235 240 Cys Pro Pro Cys Pro Ala Pro Glu Leu Ala Gly Ala
Pro Ser Val Phe 245 250 255 Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
Met Ile Ser Arg Thr Pro 260 265 270 Glu Val Thr Cys Val Val Val Asp
Val Ser His Glu Asp Pro Glu Val 275 280 285 Lys Phe Asn Trp Tyr Val
Asp Gly Val Glu Val His Asn Ala Lys Thr 290 295 300 Lys Pro Arg Glu
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val305 310 315 320 Leu
Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys 325 330
335 Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
340 345 350 Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
Pro Pro 355 360 365 Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu
Thr Cys Leu Val 370 375 380 Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
Glu Trp Glu Ser Asn Gly385 390 395 400 Gln Pro Glu Asn Asn Tyr Lys
Thr Thr Pro Pro Val Leu Asp Ser Asp 405 410 415 Gly Ser Phe Phe Leu
Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp 420 425 430 Gln Gln Gly
Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His 435 440 445 Asn
His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 450 455 460
36238PRTArtificial SequenceHumanized antibody construct comprising
sequences from mus musculus and homo sapiens 36Met Gly Trp Ser Cys
Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly1 5 10 15 Val His Ser
Asp Ile Val Ile Thr Gln Ser Pro Leu Ser Leu Pro Val 20 25 30 Thr
Leu Gly Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu 35 40
45 Leu Tyr Lys Asp Gly Lys Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro
50 55 60 Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Met Ser Thr Arg
Ala Ser65 70 75 80 Gly Val Pro Asp Arg Phe Ser Gly Gly Gly Ser Gly
Thr Asp Phe Thr 85 90 95 Leu Lys Ile Ser Arg Val Glu Ala Glu Asp
Val Gly Val Tyr Tyr Cys 100 105 110 Gln Gln Leu Val Glu Tyr Pro Leu
Thr Phe Gly Gln Gly Thr Lys Leu 115 120 125 Glu Ile Lys Arg Thr Val
Ala Ala Pro Ser Val Phe Ile Phe Pro Pro 130 135 140 Ser Asp Glu Gln
Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu145 150 155 160 Asn
Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn 165 170
175 Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser
180 185 190 Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser
Lys Ala 195 200 205 Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val
Thr His Gln Gly 210 215 220 Leu Ser Ser Pro Val Thr Lys Ser Phe Asn
Arg Gly Glu Cys225 230 235 37339DNAArtificial SequenceHumanized
antibody construct comprising sequences from mus musculus and homo
sapiens 37caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctggggcctc
agtgaaggtt 60tcctgcaagg catctggata caccttcacc agctactgga tgcactgggt
gcgacaggcc 120cctggacaag ggcttgagtg gatgggaaat attaatccta
gcaatggtgg tactaactac 180aatgagaagt tcaagagcag agtcaccatg
accagggaca cgtccacgag cacagtctac 240atggagctga gcagcctgag
atctgaggac acggccgtgt attactgtga actgggacag 300ggctactggg
gccagggaac actagtcaca gtctcctca 33938336DNAArtificial
SequenceHumanized antibody construct comprising sequences from mus
musculus and homo sapiens 38gatattgtga taacccagtc tccactctcc
ctgcccgtca cccttggaca gccggcctcc 60atctcctgca ggtctagtaa gagtctccta
tataaggatg ggaagacata cttgaattgg 120tttcagcaga ggccaggcca
atctccacag ctcctaattt atttgatgtc cacccgtgca 180tctggggtcc
cagacagatt cagcggcggt gggtcaggca ctgatttcac actgaaaatc
240agcagggtgg aggctgagga tgttggggtt tattactgcc aacaacttgt
agagtatccg 300ctcacgtttg gccaggggac caagctggag atcaaa
336391389DNAArtificial SequenceHumanized antibody construct
comprising sequences from mus musculus and homo sapiens
39atgggatgga gctgtatcat cctcttcttg gtagcaacag ctacaggtgt ccactcccag
60gtgcagctgg tgcagtctgg ggctgaggtg aagaagcctg gggcctcagt gaaggtttcc
120tgcaaggcat ctggatacac cttcaccagc tactggatgc actgggtgcg
acaggcccct 180ggacaagggc ttgagtggat gggaaatatt aatcctagca
atggtggtac taactacaat 240gagaagttca agagcagagt caccatgacc
agggacacgt ccacgagcac agtctacatg 300gagctgagca gcctgagatc
tgaggacacg gccgtgtatt actgtgaact gggacagggc 360tactggggcc
agggaacact agtcacagtc tcctcagcct ccaccaaggg cccatcggtc
420ttccccctgg caccctcctc caagagcacc tctgggggca cagcggccct
gggctgcctg 480gtcaaggact acttccccga accggtgacg gtgtcgtgga
actcaggcgc cctgaccagc 540ggcgtgcaca ccttcccggc tgtcctacag
tcctcaggac tctactccct cagcagcgtg 600gtgaccgtgc cctccagcag
cttgggcacc cagacctaca tctgcaacgt gaatcacaag 660cccagcaaca
ccaaggtgga caagaaagtt gagcccaaat cttgtgacaa aactcacaca
720tgcccaccgt gcccagcacc tgaactcgcg ggggcaccgt cagtcttcct
cttcccccca 780aaacccaagg acaccctcat gatctcccgg acccctgagg
tcacatgcgt ggtggtggac 840gtgagccacg aagaccctga ggtcaagttc
aactggtacg tggacggcgt ggaggtgcat 900aatgccaaga caaagccgcg
ggaggagcag tacaacagca cgtaccgtgt ggtcagcgtc 960ctcaccgtcc
tgcaccagga ctggctgaat ggcaaggagt acaagtgcaa ggtctccaac
1020aaagccctcc cagcccccat cgagaaaacc atctccaaag ccaaagggca
gccccgagaa 1080ccacaggtgt acaccctgcc cccatcccgg gatgagctga
ccaagaacca ggtcagcctg 1140acctgcctgg tcaaaggctt ctatcccagc
gacatcgccg tggagtggga gagcaatggg 1200cagccggaga acaactacaa
gaccacgcct cccgtgctgg actccgacgg ctccttcttc 1260ctctacagca
agctcaccgt ggacaagagc aggtggcagc aggggaacgt cttctcatgc
1320tccgtgatgc atgaggctct gcacaaccac tacacgcaga agagcctctc
cctgtctccg 1380ggtaaatga 138940717DNAArtificial SequenceHumanized
antibody construct comprising sequences from mus musculus and homo
sapiens 40atgggatgga gctgtatcat cctcttcttg gtagcaacag ctacaggtgt
ccactccgat 60attgtgataa cccagtctcc actctccctg cccgtcaccc ttggacagcc
ggcctccatc 120tcctgcaggt ctagtaagag tctcctatat aaggatggga
agacatactt gaattggttt 180cagcagaggc caggccaatc tccacagctc
ctaatttatt tgatgtccac ccgtgcatct 240ggggtcccag acagattcag
cggcggtggg tcaggcactg atttcacact gaaaatcagc 300agggtggagg
ctgaggatgt tggggtttat tactgccaac aacttgtaga gtatccgctc
360acgtttggcc aggggaccaa gctggagatc aaacgtacgg tggctgcacc
atctgtcttc 420atcttcccgc catctgatga gcagttgaaa tctggaactg
cctctgttgt gtgcctgctg 480aataacttct atcccagaga ggccaaagta
cagtggaagg tggacaacgc cctccaatcg 540ggtaactccc aggagagtgt
cacagagcag gacagcaagg acagcaccta cagcctcagc 600agcaccctga
cgctgagcaa agcagactac gagaaacaca aagtctacgc ctgcgaagtc
660acccatcagg gcctgagctc gcccgtcaca aagagcttca acaggggaga gtgttag
71741113PRTArtificial SequenceHumanized antibody construct
comprising sequences from mus musculus and homo sapiens 41Gln Val
Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20
25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp
Ile 35 40 45 Gly Asn Ile Asn Pro Ser Asn Gly Gly Thr Asn Tyr Asn
Glu Lys Phe 50 55 60 Lys Ser Lys Ala Thr Met Thr Arg Asp Thr Ser
Thr Ser Thr Ala Tyr65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu
Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Glu Leu Gly Gln Gly Tyr Trp
Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110
Ser42462PRTArtificial SequenceHumanized antibody construct
comprising sequences from mus musculus and homo sapiens 42Met Gly
Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly1 5 10 15
Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys 20
25 30 Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr
Phe 35 40 45 Thr Ser Tyr Trp Met His Trp Val Arg Gln Ala Pro Gly
Gln Gly Leu 50 55 60 Glu Trp Ile Gly Asn Ile Asn Pro Ser Asn Gly
Gly Thr Asn Tyr Asn65 70 75 80 Glu Lys Phe Lys Ser Lys Ala Thr Met
Thr Arg Asp Thr Ser Thr Ser 85 90 95 Thr Ala Tyr Met Glu Leu Ser
Ser Leu Arg Ser Glu Asp Thr Ala Val 100 105 110 Tyr Tyr Cys Glu Leu
Gly Gln Gly Tyr Trp Gly Gln Gly Thr Leu Val 115 120 125 Thr Val Ser
Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala 130 135 140 Pro
Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu145 150
155 160 Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
Gly 165 170 175 Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
Gln Ser Ser 180 185 190 Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
Pro Ser Ser Ser Leu 195 200 205 Gly Thr Gln Thr Tyr Ile Cys Asn Val
Asn His Lys Pro Ser Asn Thr 210 215 220 Lys Val Asp Lys Lys Val Glu
Pro Lys Ser Cys Asp Lys Thr His Thr225 230 235 240 Cys Pro Pro Cys
Pro Ala Pro Glu Leu Ala Gly Ala Pro Ser Val Phe 245 250 255 Leu Phe
Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro 260 265 270
Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val 275
280 285 Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
Thr 290 295 300 Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
Val Ser Val305 310 315 320 Leu Thr Val Leu His Gln Asp Trp Leu Asn
Gly
Lys Glu Tyr Lys Cys 325 330 335 Lys Val Ser Asn Lys Ala Leu Pro Ala
Pro Ile Glu Lys Thr Ile Ser 340 345 350 Lys Ala Lys Gly Gln Pro Arg
Glu Pro Gln Val Tyr Thr Leu Pro Pro 355 360 365 Ser Arg Asp Glu Leu
Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val 370 375 380 Lys Gly Phe
Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly385 390 395 400
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp 405
410 415 Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
Trp 420 425 430 Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
Ala Leu His 435 440 445 Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
Pro Gly Lys 450 455 460 43339DNAArtificial SequenceHumanized
antibody construct comprising sequences from mus musculus and homo
sapiens 43caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctggggcctc
agtgaaggtt 60tcctgcaagg catctggata caccttcacc agctactgga tgcactgggt
gcgacaggcc 120cctggacaag ggcttgagtg gatcggaaat attaatccta
gcaatggtgg tactaactac 180aatgagaagt tcaagagcaa ggccaccatg
accagggaca cgtccacgag cacagcctac 240atggagctga gcagcctgag
atctgaggac acggccgtgt attactgtga actgggacag 300ggctactggg
gccagggaac actagtcaca gtctcctca 339441389DNAArtificial
SequenceHumanized antibody construct comprising sequences from mus
musculus and homo sapiens 44atgggatgga gctgtatcat cctcttcttg
gtagcaacag ctacaggtgt ccactcccag 60gtgcagctgg tgcagtctgg ggctgaggtg
aagaagcctg gggcctcagt gaaggtttcc 120tgcaaggcat ctggatacac
cttcaccagc tactggatgc actgggtgcg acaggcccct 180ggacaagggc
ttgagtggat cggaaatatt aatcctagca atggtggtac taactacaat
240gagaagttca agagcaaggc caccatgacc agggacacgt ccacgagcac
agcctacatg 300gagctgagca gcctgagatc tgaggacacg gccgtgtatt
actgtgaact gggacagggc 360tactggggcc agggaacact agtcacagtc
tcctcagcct ccaccaaggg cccatcggtc 420ttccccctgg caccctcctc
caagagcacc tctgggggca cagcggccct gggctgcctg 480gtcaaggact
acttccccga accggtgacg gtgtcgtgga actcaggcgc cctgaccagc
540ggcgtgcaca ccttcccggc tgtcctacag tcctcaggac tctactccct
cagcagcgtg 600gtgaccgtgc cctccagcag cttgggcacc cagacctaca
tctgcaacgt gaatcacaag 660cccagcaaca ccaaggtgga caagaaagtt
gagcccaaat cttgtgacaa aactcacaca 720tgcccaccgt gcccagcacc
tgaactcgcg ggggcaccgt cagtcttcct cttcccccca 780aaacccaagg
acaccctcat gatctcccgg acccctgagg tcacatgcgt ggtggtggac
840gtgagccacg aagaccctga ggtcaagttc aactggtacg tggacggcgt
ggaggtgcat 900aatgccaaga caaagccgcg ggaggagcag tacaacagca
cgtaccgtgt ggtcagcgtc 960ctcaccgtcc tgcaccagga ctggctgaat
ggcaaggagt acaagtgcaa ggtctccaac 1020aaagccctcc cagcccccat
cgagaaaacc atctccaaag ccaaagggca gccccgagaa 1080ccacaggtgt
acaccctgcc cccatcccgg gatgagctga ccaagaacca ggtcagcctg
1140acctgcctgg tcaaaggctt ctatcccagc gacatcgccg tggagtggga
gagcaatggg 1200cagccggaga acaactacaa gaccacgcct cccgtgctgg
actccgacgg ctccttcttc 1260ctctacagca agctcaccgt ggacaagagc
aggtggcagc aggggaacgt cttctcatgc 1320tccgtgatgc atgaggctct
gcacaaccac tacacgcaga agagcctctc cctgtctccg 1380ggtaaatga
1389454PRTArtificial SequenceHumanized antibody construct
comprising sequences from mus musculus and homo sapiens 45Met Gln
Gly Tyr1 46200PRTCallithrix jacchus 46Val Gln Asp Ser Leu Cys Pro
Val Ala Gln Leu Cys Pro Ser Phe Glu1 5 10 15 Glu Ser Glu Ala Thr
Pro Ser Pro Val Leu Pro Asp Ile Val Met Glu 20 25 30 Ala Pro Leu
Asn Ser Ala Val Pro Ser Ala Gly Ala Ser Ala Val Gln 35 40 45 Pro
Ser Ser Ser Pro Leu Glu Ala Ser Ser Val Asn Phe Glu Ser Val 50 55
60 Lys His Glu Pro Glu Asn Pro Pro Pro Tyr Glu Glu Ala Met Asn
Val65 70 75 80 Ser Arg Lys Lys Val Ser Gly Ile Lys Glu Glu Ile Lys
Glu Pro Glu 85 90 95 Ser Ile Asn Ala Ala Val Gln Glu Thr Glu Ala
Pro Tyr Ile Ser Ile 100 105 110 Ala Cys Asp Leu Ile Lys Glu Thr Lys
Leu Ser Ala Glu Pro Thr Pro 115 120 125 Asp Phe Ser Ser Tyr Ser Glu
Met Ala Lys Val Glu Gln Pro Leu Pro 130 135 140 Asp His Ser Glu Leu
Val Glu Asp Ser Ser Pro Asp Ser Glu Pro Val145 150 155 160 Asp Leu
Phe Ser Asp Asp Ser Ile Pro Asp Val Pro Gln Lys Gln Asp 165 170 175
Glu Ala Val Ile Leu Val Lys Glu Thr Leu Thr Glu Thr Ser Phe Glu 180
185 190 Ser Met Ile Glu His Glu Asn Lys 195 200 47113PRTArtificial
SequenceHumanized antibody construct comprising sequences from mus
musculus and homo sapiens 47Gln Val Gln Leu Val Gln Ser Gly Ala Glu
Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala
Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met His Trp Val Arg
Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asn Ile Asn
Pro Ser Asn Gly Gly Thr Asn Tyr Asn Glu Lys Phe 50 55 60 Lys Ser
Arg Ala Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85
90 95 Glu Leu Met Gln Gly Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
Ser 100 105 110 Ser48113PRTArtificial SequenceHumanized antibody
construct comprising sequences from mus musculus and homo sapiens
48Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1
5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser
Tyr 20 25 30 Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu
Glu Trp Ile 35 40 45 Gly Asn Ile Asn Pro Ser Asn Gly Gly Thr Asn
Tyr Asn Glu Lys Phe 50 55 60 Lys Ser Lys Ala Thr Leu Thr Val Asp
Lys Ser Thr Ser Thr Ala Tyr65 70 75 80 Met Glu Leu Ser Ser Leu Arg
Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Glu Leu Met Gln Gly
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110
Ser49113PRTArtificial SequenceHumanized antibody construct
comprising sequences from mus musculus and homo sapiens 49Gln Val
Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20
25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp
Ile 35 40 45 Gly Asn Ile Asn Pro Ser Asn Gly Gly Thr Asn Tyr Asn
Glu Lys Phe 50 55 60 Lys Ser Lys Ala Thr Met Thr Arg Asp Thr Ser
Thr Ser Thr Ala Tyr65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu
Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Glu Leu Met Gln Gly Tyr Trp
Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110
Ser50339DNAArtificial SequenceHumanized antibody construct
comprising sequences from mus musculus and homo sapiens
50caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtt
60tcctgcaagg catctggata caccttcacc agctactgga tgcactgggt gcgacaggcc
120cctggacaag ggcttgagtg gatcggaaat attaatccta gcaatggtgg
tactaactac 180aatgagaagt tcaagagcag agccaccatg accagggaca
cgtccacgag cacagcctac 240atggagctga gcagcctgag atctgaggac
acggccgtgt attactgtga actgatgcag 300ggctactggg gccagggaac
actagtcaca gtctcctca 33951339DNAArtificial SequenceHumanized
antibody construct comprising sequences from mus musculus and homo
sapiens 51caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctggggcctc
agtgaaggtt 60tcctgcaagg catctggata caccttcacc agctactgga tgcactgggt
gaaacagcga 120cctggacaag ggcttgagtg gatcggaaat attaatccta
gcaatggtgg tactaactac 180aatgagaagt tcaagagcaa agccaccctc
accgtcgaca aatccacgag cacagcctac 240atggagctga gcagcctgag
atctgaggac acggccgtgt attactgtga actgatgcag 300ggctactggg
gccagggaac actagtcaca gtctcctca 33952339DNAArtificial
SequenceHumanized antibody construct comprising sequences from mus
musculus and homo sapiens 52caggtgcagc tggtgcagtc tggggctgag
gtgaagaagc ctggggcctc agtgaaggtt 60tcctgcaagg catctggata caccttcacc
agctactgga tgcactgggt gcgacaggcc 120cctggacaag ggcttgagtg
gatcggaaat attaatccta gcaatggtgg tactaactac 180aatgagaagt
tcaagagcaa ggccaccatg accagggaca cgtccacgag cacagcctac
240atggagctga gcagcctgag atctgaggac acggccgtgt attactgtga
actgatgcag 300ggctactggg gccagggaac actagtcaca gtctcctca
33953462PRTArtificial SequenceHumanized antibody construct
comprising sequences from mus musculus and homo sapiens 53Met Gly
Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly1 5 10 15
Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys 20
25 30 Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr
Phe 35 40 45 Thr Ser Tyr Trp Met His Trp Val Arg Gln Ala Pro Gly
Gln Gly Leu 50 55 60 Glu Trp Ile Gly Asn Ile Asn Pro Ser Asn Gly
Gly Thr Asn Tyr Asn65 70 75 80 Glu Lys Phe Lys Ser Arg Ala Thr Met
Thr Arg Asp Thr Ser Thr Ser 85 90 95 Thr Ala Tyr Met Glu Leu Ser
Ser Leu Arg Ser Glu Asp Thr Ala Val 100 105 110 Tyr Tyr Cys Glu Leu
Met Gln Gly Tyr Trp Gly Gln Gly Thr Leu Val 115 120 125 Thr Val Ser
Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala 130 135 140 Pro
Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu145 150
155 160 Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
Gly 165 170 175 Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
Gln Ser Ser 180 185 190 Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
Pro Ser Ser Ser Leu 195 200 205 Gly Thr Gln Thr Tyr Ile Cys Asn Val
Asn His Lys Pro Ser Asn Thr 210 215 220 Lys Val Asp Lys Lys Val Glu
Pro Lys Ser Cys Asp Lys Thr His Thr225 230 235 240 Cys Pro Pro Cys
Pro Ala Pro Glu Leu Ala Gly Ala Pro Ser Val Phe 245 250 255 Leu Phe
Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro 260 265 270
Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val 275
280 285 Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
Thr 290 295 300 Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
Val Ser Val305 310 315 320 Leu Thr Val Leu His Gln Asp Trp Leu Asn
Gly Lys Glu Tyr Lys Cys 325 330 335 Lys Val Ser Asn Lys Ala Leu Pro
Ala Pro Ile Glu Lys Thr Ile Ser 340 345 350 Lys Ala Lys Gly Gln Pro
Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro 355 360 365 Ser Arg Asp Glu
Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val 370 375 380 Lys Gly
Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly385 390 395
400 Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
405 410 415 Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
Arg Trp 420 425 430 Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
Glu Ala Leu His 435 440 445 Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
Ser Pro Gly Lys 450 455 460 54462PRTArtificial SequenceHumanized
antibody construct comprising sequences from mus musculus and homo
sapiens 54Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala
Thr Gly1 5 10 15 Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala
Glu Val Lys Lys 20 25 30 Pro Gly Ala Ser Val Lys Val Ser Cys Lys
Ala Ser Gly Tyr Thr Phe 35 40 45 Thr Ser Tyr Trp Met His Trp Val
Lys Gln Arg Pro Gly Gln Gly Leu 50 55 60 Glu Trp Ile Gly Asn Ile
Asn Pro Ser Asn Gly Gly Thr Asn Tyr Asn65 70 75 80 Glu Lys Phe Lys
Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Thr Ser 85 90 95 Thr Ala
Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val 100 105 110
Tyr Tyr Cys Glu Leu Met Gln Gly Tyr Trp Gly Gln Gly Thr Leu Val 115
120 125 Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
Ala 130 135 140 Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
Gly Cys Leu145 150 155 160 Val Lys Asp Tyr Phe Pro Glu Pro Val Thr
Val Ser Trp Asn Ser Gly 165 170 175 Ala Leu Thr Ser Gly Val His Thr
Phe Pro Ala Val Leu Gln Ser Ser 180 185 190 Gly Leu Tyr Ser Leu Ser
Ser Val Val Thr Val Pro Ser Ser Ser Leu 195 200 205 Gly Thr Gln Thr
Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr 210 215 220 Lys Val
Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr225 230 235
240 Cys Pro Pro Cys Pro Ala Pro Glu Leu Ala Gly Ala Pro Ser Val Phe
245 250 255 Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
Thr Pro 260 265 270 Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
Asp Pro Glu Val 275 280 285 Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
Val His Asn Ala Lys Thr 290 295 300 Lys Pro Arg Glu Glu Gln Tyr Asn
Ser Thr Tyr Arg Val Val Ser Val305 310 315 320 Leu Thr Val Leu His
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys 325 330 335 Lys Val Ser
Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser 340 345 350 Lys
Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro 355 360
365 Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
370 375 380 Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
Asn Gly385 390 395 400 Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
Val Leu Asp Ser Asp 405 410 415 Gly Ser Phe Phe Leu Tyr Ser Lys Leu
Thr Val Asp Lys Ser Arg Trp 420 425 430 Gln Gln Gly Asn Val Phe Ser
Cys Ser Val Met His Glu Ala Leu His 435 440 445 Asn His Tyr Thr Gln
Lys Ser Leu Ser Leu Ser Pro Gly Lys 450 455 460 55462PRTArtificial
SequenceHumanized antibody construct comprising sequences from mus
musculus and homo sapiens 55Met Gly Trp Ser Cys Ile Ile Leu Phe Leu
Val Ala Thr Ala Thr Gly1 5 10 15 Val His Ser Gln Val Gln Leu Val
Gln Ser Gly Ala Glu Val Lys Lys 20 25 30 Pro Gly Ala Ser Val Lys
Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe 35 40 45 Thr Ser Tyr Trp
Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu 50 55 60 Glu Trp
Ile Gly Asn Ile Asn Pro Ser Asn Gly Gly Thr Asn Tyr Asn65 70 75 80
Glu
Lys Phe Lys Ser Lys Ala Thr Met Thr Arg Asp Thr Ser Thr Ser 85 90
95 Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val
100 105 110 Tyr Tyr Cys Glu Leu Met Gln Gly Tyr Trp Gly Gln Gly Thr
Leu Val 115 120 125 Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
Phe Pro Leu Ala 130 135 140 Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr
Ala Ala Leu Gly Cys Leu145 150 155 160 Val Lys Asp Tyr Phe Pro Glu
Pro Val Thr Val Ser Trp Asn Ser Gly 165 170 175 Ala Leu Thr Ser Gly
Val His Thr Phe Pro Ala Val Leu Gln Ser Ser 180 185 190 Gly Leu Tyr
Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu 195 200 205 Gly
Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr 210 215
220 Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His
Thr225 230 235 240 Cys Pro Pro Cys Pro Ala Pro Glu Leu Ala Gly Ala
Pro Ser Val Phe 245 250 255 Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
Met Ile Ser Arg Thr Pro 260 265 270 Glu Val Thr Cys Val Val Val Asp
Val Ser His Glu Asp Pro Glu Val 275 280 285 Lys Phe Asn Trp Tyr Val
Asp Gly Val Glu Val His Asn Ala Lys Thr 290 295 300 Lys Pro Arg Glu
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val305 310 315 320 Leu
Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys 325 330
335 Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
340 345 350 Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
Pro Pro 355 360 365 Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu
Thr Cys Leu Val 370 375 380 Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
Glu Trp Glu Ser Asn Gly385 390 395 400 Gln Pro Glu Asn Asn Tyr Lys
Thr Thr Pro Pro Val Leu Asp Ser Asp 405 410 415 Gly Ser Phe Phe Leu
Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp 420 425 430 Gln Gln Gly
Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His 435 440 445 Asn
His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 450 455 460
561389DNAArtificial SequenceHumanized antibody construct comprising
sequences from mus musculus and homo sapiens 56atgggatgga
gctgtatcat cctcttcttg gtagcaacag ctacaggtgt ccactcccag 60gtgcagctgg
tgcagtctgg ggctgaggtg aagaagcctg gggcctcagt gaaggtttcc
120tgcaaggcat ctggatacac cttcaccagc tactggatgc actgggtgcg
acaggcccct 180ggacaagggc ttgagtggat cggaaatatt aatcctagca
atggtggtac taactacaat 240gagaagttca agagcagagc caccatgacc
agggacacgt ccacgagcac agcctacatg 300gagctgagca gcctgagatc
tgaggacacg gccgtgtatt actgtgaact gatgcagggc 360tactggggcc
agggaacact agtcacagtc tcctcagcct ccaccaaggg cccatcggtc
420ttccccctgg caccctcctc caagagcacc tctgggggca cagcggccct
gggctgcctg 480gtcaaggact acttccccga accggtgacg gtgtcgtgga
actcaggcgc cctgaccagc 540ggcgtgcaca ccttcccggc tgtcctacag
tcctcaggac tctactccct cagcagcgtg 600gtgaccgtgc cctccagcag
cttgggcacc cagacctaca tctgcaacgt gaatcacaag 660cccagcaaca
ccaaggtgga caagaaagtt gagcccaaat cttgtgacaa aactcacaca
720tgcccaccgt gcccagcacc tgaactcgcg ggggcaccgt cagtcttcct
cttcccccca 780aaacccaagg acaccctcat gatctcccgg acccctgagg
tcacatgcgt ggtggtggac 840gtgagccacg aagaccctga ggtcaagttc
aactggtacg tggacggcgt ggaggtgcat 900aatgccaaga caaagccgcg
ggaggagcag tacaacagca cgtaccgtgt ggtcagcgtc 960ctcaccgtcc
tgcaccagga ctggctgaat ggcaaggagt acaagtgcaa ggtctccaac
1020aaagccctcc cagcccccat cgagaaaacc atctccaaag ccaaagggca
gccccgagaa 1080ccacaggtgt acaccctgcc cccatcccgg gatgagctga
ccaagaacca ggtcagcctg 1140acctgcctgg tcaaaggctt ctatcccagc
gacatcgccg tggagtggga gagcaatggg 1200cagccggaga acaactacaa
gaccacgcct cccgtgctgg actccgacgg ctccttcttc 1260ctctacagca
agctcaccgt ggacaagagc aggtggcagc aggggaacgt cttctcatgc
1320tccgtgatgc atgaggctct gcacaaccac tacacgcaga agagcctctc
cctgtctccg 1380ggtaaatga 1389571389DNAArtificial SequenceHumanized
antibody construct comprising sequences from mus musculus and homo
sapiens 57atgggatgga gctgtatcat cctcttcttg gtagcaacag ctacaggtgt
ccactcccag 60gtgcagctgg tgcagtctgg ggctgaggtg aagaagcctg gggcctcagt
gaaggtttcc 120tgcaaggcat ctggatacac cttcaccagc tactggatgc
actgggtgaa acagcgacct 180ggacaagggc ttgagtggat cggaaatatt
aatcctagca atggtggtac taactacaat 240gagaagttca agagcaaagc
caccctcacc gtcgacaaat ccacgagcac agcctacatg 300gagctgagca
gcctgagatc tgaggacacg gccgtgtatt actgtgaact gatgcagggc
360tactggggcc agggaacact agtcacagtc tcctcagcct ccaccaaggg
cccatcggtc 420ttccccctgg caccctcctc caagagcacc tctgggggca
cagcggccct gggctgcctg 480gtcaaggact acttccccga accggtgacg
gtgtcgtgga actcaggcgc cctgaccagc 540ggcgtgcaca ccttcccggc
tgtcctacag tcctcaggac tctactccct cagcagcgtg 600gtgaccgtgc
cctccagcag cttgggcacc cagacctaca tctgcaacgt gaatcacaag
660cccagcaaca ccaaggtgga caagaaagtt gagcccaaat cttgtgacaa
aactcacaca 720tgcccaccgt gcccagcacc tgaactcgcg ggggcaccgt
cagtcttcct cttcccccca 780aaacccaagg acaccctcat gatctcccgg
acccctgagg tcacatgcgt ggtggtggac 840gtgagccacg aagaccctga
ggtcaagttc aactggtacg tggacggcgt ggaggtgcat 900aatgccaaga
caaagccgcg ggaggagcag tacaacagca cgtaccgtgt ggtcagcgtc
960ctcaccgtcc tgcaccagga ctggctgaat ggcaaggagt acaagtgcaa
ggtctccaac 1020aaagccctcc cagcccccat cgagaaaacc atctccaaag
ccaaagggca gccccgagaa 1080ccacaggtgt acaccctgcc cccatcccgg
gatgagctga ccaagaacca ggtcagcctg 1140acctgcctgg tcaaaggctt
ctatcccagc gacatcgccg tggagtggga gagcaatggg 1200cagccggaga
acaactacaa gaccacgcct cccgtgctgg actccgacgg ctccttcttc
1260ctctacagca agctcaccgt ggacaagagc aggtggcagc aggggaacgt
cttctcatgc 1320tccgtgatgc atgaggctct gcacaaccac tacacgcaga
agagcctctc cctgtctccg 1380ggtaaatga 1389581389DNAArtificial
SequenceHumanized antibody construct comprising sequences from mus
musculus and homo sapiens 58atgggatgga gctgtatcat cctcttcttg
gtagcaacag ctacaggtgt ccactcccag 60gtgcagctgg tgcagtctgg ggctgaggtg
aagaagcctg gggcctcagt gaaggtttcc 120tgcaaggcat ctggatacac
cttcaccagc tactggatgc actgggtgcg acaggcccct 180ggacaagggc
ttgagtggat cggaaatatt aatcctagca atggtggtac taactacaat
240gagaagttca agagcaaggc caccatgacc agggacacgt ccacgagcac
agcctacatg 300gagctgagca gcctgagatc tgaggacacg gccgtgtatt
actgtgaact gatgcagggc 360tactggggcc agggaacact agtcacagtc
tcctcagcct ccaccaaggg cccatcggtc 420ttccccctgg caccctcctc
caagagcacc tctgggggca cagcggccct gggctgcctg 480gtcaaggact
acttccccga accggtgacg gtgtcgtgga actcaggcgc cctgaccagc
540ggcgtgcaca ccttcccggc tgtcctacag tcctcaggac tctactccct
cagcagcgtg 600gtgaccgtgc cctccagcag cttgggcacc cagacctaca
tctgcaacgt gaatcacaag 660cccagcaaca ccaaggtgga caagaaagtt
gagcccaaat cttgtgacaa aactcacaca 720tgcccaccgt gcccagcacc
tgaactcgcg ggggcaccgt cagtcttcct cttcccccca 780aaacccaagg
acaccctcat gatctcccgg acccctgagg tcacatgcgt ggtggtggac
840gtgagccacg aagaccctga ggtcaagttc aactggtacg tggacggcgt
ggaggtgcat 900aatgccaaga caaagccgcg ggaggagcag tacaacagca
cgtaccgtgt ggtcagcgtc 960ctcaccgtcc tgcaccagga ctggctgaat
ggcaaggagt acaagtgcaa ggtctccaac 1020aaagccctcc cagcccccat
cgagaaaacc atctccaaag ccaaagggca gccccgagaa 1080ccacaggtgt
acaccctgcc cccatcccgg gatgagctga ccaagaacca ggtcagcctg
1140acctgcctgg tcaaaggctt ctatcccagc gacatcgccg tggagtggga
gagcaatggg 1200cagccggaga acaactacaa gaccacgcct cccgtgctgg
actccgacgg ctccttcttc 1260ctctacagca agctcaccgt ggacaagagc
aggtggcagc aggggaacgt cttctcatgc 1320tccgtgatgc atgaggctct
gcacaaccac tacacgcaga agagcctctc cctgtctccg 1380ggtaaatga
138959462PRTArtificial SequenceChimaeric antibody construct
comprising sequences from mus musculus and homo sapiens 59Met Gly
Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Ala Ala Thr Gly1 5 10 15
Val His Ser Gln Val Gln Leu Gln Gln Pro Gly Thr Glu Leu Val Lys 20
25 30 Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr
Phe 35 40 45 Thr Ser Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly
Gln Gly Leu 50 55 60 Glu Trp Ile Gly Asn Ile Asn Pro Ser Asn Gly
Gly Thr Asn Tyr Asn65 70 75 80 Glu Lys Phe Lys Ser Lys Ala Thr Leu
Thr Val Asp Lys Ser Ser Ser 85 90 95 Thr Ala Tyr Met Gln Leu Ser
Ser Leu Thr Ser Glu Asp Ser Ala Val 100 105 110 Tyr Tyr Cys Glu Leu
Met Gln Gly Tyr Trp Gly Gln Gly Thr Leu Val 115 120 125 Thr Val Ser
Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala 130 135 140 Pro
Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu145 150
155 160 Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
Gly 165 170 175 Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
Gln Ser Ser 180 185 190 Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
Pro Ser Ser Ser Leu 195 200 205 Gly Thr Gln Thr Tyr Ile Cys Asn Val
Asn His Lys Pro Ser Asn Thr 210 215 220 Lys Val Asp Lys Lys Val Glu
Pro Lys Ser Cys Asp Lys Thr His Thr225 230 235 240 Cys Pro Pro Cys
Pro Ala Pro Glu Leu Ala Gly Ala Pro Ser Val Phe 245 250 255 Leu Phe
Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro 260 265 270
Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val 275
280 285 Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
Thr 290 295 300 Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
Val Ser Val305 310 315 320 Leu Thr Val Leu His Gln Asp Trp Leu Asn
Gly Lys Glu Tyr Lys Cys 325 330 335 Lys Val Ser Asn Lys Ala Leu Pro
Ala Pro Ile Glu Lys Thr Ile Ser 340 345 350 Lys Ala Lys Gly Gln Pro
Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro 355 360 365 Ser Arg Asp Glu
Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val 370 375 380 Lys Gly
Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly385 390 395
400 Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
405 410 415 Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
Arg Trp 420 425 430 Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
Glu Ala Leu His 435 440 445 Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
Ser Pro Gly Lys 450 455 460 6012PRTHomo Sapiens 60Val Leu Pro Asp
Ile Val Met Glu Ala Pro Leu Asn1 5 10 61113PRTArtificial
SequenceHumanized antibody construct comprising sequences from mus
musculus and homo sapiens 61Gln Val Gln Leu Val Gln Ser Gly Ala Glu
Val Lys Lys Pro Gly Ala1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala
Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Met His Trp Val Arg
Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Asn Ile Asn
Pro Ser Asn Gly Gly Thr Asn Tyr Asn Glu Lys Phe 50 55 60 Lys Ser
Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85
90 95 Glu Leu Gly Gln Ser Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
Ser 100 105 110 Ser624PRTArtificial SequenceHumanized antibody
construct comprising sequences from mus musculus and homo sapiens
62Gly Gln Ser Tyr1 63113PRTArtificial SequenceHumanized antibody
construct comprising sequences from mus musculus and homo sapiens
63Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1
5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser
Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
Glu Trp Ile 35 40 45 Gly Asn Ile Asn Pro Ser Asn Gly Gly Thr Asn
Tyr Asn Glu Lys Phe 50 55 60 Lys Ser Arg Ala Thr Met Thr Arg Asp
Thr Ser Thr Ser Thr Ala Tyr65 70 75 80 Met Glu Leu Ser Ser Leu Arg
Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Glu Leu Gly Gln Ser
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110
Ser64113PRTArtificial SequenceHumanized antibody construct
comprising sequences from mus musculus and homo sapiens 64Gln Val
Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20
25 30 Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp
Ile 35 40 45 Gly Asn Ile Asn Pro Ser Asn Gly Gly Thr Asn Tyr Asn
Glu Lys Phe 50 55 60 Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser
Thr Ser Thr Ala Tyr65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu
Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Glu Leu Gly Gln Ser Tyr Trp
Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110
Ser65113PRTArtificial SequenceHumanized antibody construct
comprising sequences from mus musculus and homo sapiens 65Gln Val
Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20
25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp
Ile 35 40 45 Gly Asn Ile Asn Pro Ser Asn Gly Gly Thr Asn Tyr Asn
Glu Lys Phe 50 55 60 Lys Ser Lys Ala Thr Met Thr Arg Asp Thr Ser
Thr Ser Thr Ala Tyr65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu
Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Glu Leu Gly Gln Ser Tyr Trp
Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110
Ser66113PRTArtificial SequenceHumanized antibody construct
comprising sequences from mus musculus and homo sapiens 66Gln Val
Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20
25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp
Met 35 40 45 Gly Asn Ile Asn Pro Ser Asn Gly Gly Thr Asn Tyr Asn
Glu Lys Phe 50 55 60 Lys Ser Arg Val Thr Met Thr Arg Asp Thr Ser
Thr Ser Thr Val Tyr65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu
Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Glu Leu Met Gln Gly Tyr Trp
Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110
Ser67112PRTArtificial SequenceHumanized antibody construct
comprising sequences from mus musculus and homo sapiens 67Asp Ile
Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly1 5 10 15
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu Tyr Lys 20
25 30 Asp Gly Lys Thr Tyr Leu Asn Trp Phe Arg Gln Arg Pro Gly Gln
Ser 35 40 45 Pro Gln Leu
Leu Ile Tyr Leu Met Ser Thr Arg Ala Ser Gly Val Pro 50 55 60 Asp
Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile65 70 75
80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Leu
85 90 95 Val Glu Tyr Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu
Ile Lys 100 105 110 68112PRTArtificial SequenceHumanized antibody
construct comprising sequences from mus musculus and homo sapiens
68Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly1
5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu Tyr
Lys 20 25 30 Asp Gly Lys Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro
Gly Gln Ser 35 40 45 Pro Arg Leu Leu Ile Tyr Leu Met Ser Thr Arg
Ala Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Gly Gly Ser Gly
Thr Asp Phe Thr Leu Lys Ile65 70 75 80 Ser Arg Val Glu Ala Glu Asp
Val Gly Val Tyr Tyr Cys Gln Gln Leu 85 90 95 Val Glu Tyr Pro Leu
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 110
69112PRTArtificial SequenceHumanized antibody construct comprising
sequences from mus musculus and homo sapiens 69Asp Ile Val Met Thr
Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly1 5 10 15 Gln Pro Ala
Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu Tyr Lys 20 25 30 Asp
Gly Lys Thr Tyr Leu Asn Trp Phe Arg Gln Arg Pro Gly Gln Ser 35 40
45 Pro Arg Leu Leu Ile Tyr Leu Met Ser Thr Arg Ala Ser Gly Val Pro
50 55 60 Asp Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu
Lys Ile65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr
Cys Gln Gln Leu 85 90 95 Val Glu Tyr Pro Leu Thr Phe Gly Gln Gly
Thr Lys Leu Glu Ile Lys 100 105 110 70112PRTArtificial
SequenceHumanized antibody construct comprising sequences from mus
musculus and homo sapiens 70Asp Ile Val Met Thr Gln Ser Pro Leu Ser
Asn Pro Val Thr Leu Gly1 5 10 15 Gln Pro Val Ser Ile Ser Cys Arg
Ser Ser Lys Ser Leu Leu Tyr Lys 20 25 30 Asp Gly Lys Thr Tyr Leu
Asn Trp Phe Arg Gln Arg Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu
Ile Tyr Leu Met Ser Thr Arg Ala Ser Gly Val Pro 50 55 60 Asp Arg
Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Leu 85
90 95 Val Glu Tyr Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
Lys 100 105 110 71112PRTArtificial SequenceHumanized antibody
construct comprising sequences from mus musculus and homo sapiens
71Asp Ile Val Met Thr Gln Ser Pro Leu Ser Asn Pro Val Thr Leu Gly1
5 10 15 Gln Pro Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu Tyr
Lys 20 25 30 Asp Gly Lys Thr Tyr Leu Asn Trp Phe Leu Gln Arg Pro
Gly Gln Ser 35 40 45 Pro Arg Leu Leu Ile Tyr Leu Met Ser Thr Arg
Ala Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Gly Gly Ser Gly
Thr Asp Phe Thr Leu Lys Ile65 70 75 80 Ser Arg Val Glu Ala Glu Asp
Val Gly Val Tyr Tyr Cys Gln Gln Leu 85 90 95 Val Glu Tyr Pro Leu
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 110
72112PRTArtificial SequenceHumanized antibody construct comprising
sequences from mus musculus and homo sapiens 72Asp Ile Val Met Thr
Gln Ser Pro Leu Ser Asn Pro Val Thr Leu Gly1 5 10 15 Gln Pro Val
Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu Tyr Lys 20 25 30 Asp
Gly Lys Thr Tyr Leu Asn Trp Phe Arg Gln Arg Pro Gly Gln Ser 35 40
45 Pro Arg Leu Leu Ile Tyr Leu Met Ser Thr Arg Ala Ser Gly Val Pro
50 55 60 Asp Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu
Lys Ile65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr
Cys Gln Gln Leu 85 90 95 Val Glu Tyr Pro Leu Thr Phe Gly Gln Gly
Thr Lys Leu Glu Ile Lys 100 105 110 7316PRTHomo Sapiens 73Thr Pro
Ser Pro Val Leu Pro Asp Ile Val Met Glu Ala Pro Leu Asn1 5 10 15
7416PRTHomo sapiens 74Val Leu Pro Asp Ile Val Met Glu Ala Pro Leu
Asn Ser Ala Val Pro1 5 10 15 754PRTArtificial SequenceHumanized
antibody construct comprising sequences from mus musculus and homo
sapiens 75Arg Gln Gly Tyr1 764PRTArtificial SequenceHumanized
antibody construct comprising sequences from mus musculus and homo
sapiens 76Ile Gln Gly Tyr1 774PRTArtificial SequenceHumanized
antibody construct comprising sequences from mus musculus and homo
sapiens 77Gly Asp Gly Tyr1 784PRTArtificial SequenceHumanized
antibody construct comprising sequences from mus musculus and homo
sapiens 78Gly Ile Gly Tyr1 794PRTArtificial SequenceHumanized
antibody construct comprising sequences from mus musculus and homo
sapiens 79Gly Ser Gly Tyr1 804PRTArtificial SequenceHumanized
antibody construct comprising sequences from mus musculus and homo
sapiens 80Gly Gln Asn Tyr1 814PRTArtificial SequenceHumanized
antibody construct comprising sequences from mus musculus and homo
sapiens 81Gly Gln Tyr Tyr1 824PRTArtificial SequenceHumanized
antibody construct comprising sequences from mus musculus and homo
sapiens 82Gly Gln Leu Tyr1 834PRTArtificial SequenceHumanized
antibody construct comprising sequences from mus musculus and homo
sapiens 83Gly Gln Phe Tyr1 844PRTArtificial SequenceHumanized
antibody construct comprising sequences from mus musculus and homo
sapiens 84Gly Gln Gly Trp1 8516PRTArtificial SequenceHumanized
antibody construct comprising sequences from mus musculus and homo
sapiens 85Tyr Glu Ser Ile Lys His Glu Pro Glu Asn Pro Pro Pro Tyr
Glu Glu1 5 10 15 864PRTArtificial SequenceHumanized antibody
construct comprising sequences from mus musculus and homo sapiens
86Trp Gln Gly Tyr1 874PRTArtificial SequenceHumanized antibody
construct comprising sequences from mus musculus and homo sapiens
87Gly Ala Gly Tyr1 884PRTArtificial SequenceHumanized antibody
construct comprising sequences from mus musculus and homo sapiens
88Gly Leu Gly Tyr1 894PRTArtificial SequenceHumanized antibody
construct comprising sequences from mus musculus and homo sapiens
89Gly Val Gly Tyr1 904PRTArtificial SequenceHumanized antibody
construct comprising sequences from mus musculus and homo sapiens
90Gly Gln Trp Tyr1 91438PRTSaimiri boliviensis 91Met Ser Pro Ile
Leu Gly Tyr Trp Lys Ile Lys Gly Leu Val Gln Pro1 5 10 15 Thr Arg
Leu Leu Leu Glu Tyr Leu Glu Glu Lys Tyr Glu Glu His Leu 20 25 30
Tyr Glu Arg Asp Glu Gly Asp Lys Trp Arg Asn Lys Lys Phe Glu Leu 35
40 45 Gly Leu Glu Phe Pro Asn Leu Pro Tyr Tyr Ile Asp Gly Asp Val
Lys 50 55 60 Leu Thr Gln Ser Met Ala Ile Ile Arg Tyr Ile Ala Asp
Lys His Asn65 70 75 80 Met Leu Gly Gly Cys Pro Lys Glu Arg Ala Glu
Ile Ser Met Leu Glu 85 90 95 Gly Ala Val Leu Asp Ile Arg Tyr Gly
Val Ser Arg Ile Ala Tyr Ser 100 105 110 Lys Asp Phe Glu Thr Leu Lys
Val Asp Phe Leu Ser Lys Leu Pro Glu 115 120 125 Met Leu Lys Met Phe
Glu Asp Arg Leu Cys His Lys Thr Tyr Leu Asn 130 135 140 Gly Asp His
Val Thr His Pro Asp Phe Met Leu Tyr Asp Ala Leu Asp145 150 155 160
Val Val Leu Tyr Met Asp Pro Met Cys Leu Asp Ala Phe Pro Lys Leu 165
170 175 Val Cys Phe Lys Lys Arg Ile Glu Ala Ile Pro Gln Ile Asp Lys
Tyr 180 185 190 Leu Lys Ser Ser Lys Tyr Ile Ala Trp Pro Leu Gln Gly
Trp Gln Ala 195 200 205 Thr Phe Gly Gly Gly Asp His Pro Pro Lys Ser
Asp Leu Glu Val Leu 210 215 220 Phe Gln Gly Pro Leu Gly Ser Met Gln
Glu Ser Leu Tyr Pro Val Ala225 230 235 240 Gln Leu Cys Pro Ser Phe
Glu Glu Ser Glu Ala Thr Pro Ser Pro Val 245 250 255 Leu Pro Asp Ile
Val Met Glu Ala Pro Leu Asn Ser Ala Val Pro Ser 260 265 270 Ala Val
Ala Ser Ala Val Gln Pro Ser Leu Ser Pro Leu Glu Ala Ser 275 280 285
Ser Val Asn Tyr Glu Ser Val Lys His Glu Pro Glu Asn Pro Pro Pro 290
295 300 Tyr Glu Glu Ala Met Asn Val Ser Leu Lys Lys Val Ser Gly Ile
Lys305 310 315 320 Glu Glu Ile Lys Glu Pro Glu Ser Ile Lys Ala Ala
Val Gln Glu Thr 325 330 335 Glu Ala Pro Tyr Ile Ser Ile Ala Cys Asp
Leu Ile Lys Glu Thr Lys 340 345 350 Leu Ser Ala Glu Pro Thr Pro Asp
Phe Ser Asn Tyr Ser Glu Met Ala 355 360 365 Lys Val Glu Gln Pro Leu
Pro Asp His Ser Glu Ile Val Glu Asp Ser 370 375 380 Ser Pro Asp Ser
Glu Pro Val Asp Leu Phe Ser Asp Asp Ser Ile Pro385 390 395 400 Asp
Val Pro Gln Lys Gln Asp Glu Ala Val Ile Leu Val Lys Glu Asn 405 410
415 Leu Thr Glu Thr Ser Phe Glu Ser Met Ile Glu His Glu Asn Lys Leu
420 425 430 Glu Arg Pro His Arg Asp 435 92460PRTMacaca fascicularis
92Met Ser Pro Ile Leu Gly Tyr Trp Lys Ile Lys Gly Leu Val Gln Pro1
5 10 15 Thr Arg Leu Leu Leu Glu Tyr Leu Glu Glu Lys Tyr Glu Glu His
Leu 20 25 30 Tyr Glu Arg Asp Glu Gly Asp Lys Trp Arg Asn Lys Lys
Phe Glu Leu 35 40 45 Gly Leu Glu Phe Pro Asn Leu Pro Tyr Tyr Ile
Asp Gly Asp Val Lys 50 55 60 Leu Thr Gln Ser Met Ala Ile Ile Arg
Tyr Ile Ala Asp Lys His Asn65 70 75 80 Met Leu Gly Gly Cys Pro Lys
Glu Arg Ala Glu Ile Ser Met Leu Glu 85 90 95 Gly Ala Val Leu Asp
Ile Arg Tyr Gly Val Ser Arg Ile Ala Tyr Ser 100 105 110 Lys Asp Phe
Glu Thr Leu Lys Val Asp Phe Leu Ser Lys Leu Pro Glu 115 120 125 Met
Leu Lys Met Phe Glu Asp Arg Leu Cys His Lys Thr Tyr Leu Asn 130 135
140 Gly Asp His Val Thr His Pro Asp Phe Met Leu Tyr Asp Ala Leu
Asp145 150 155 160 Val Val Leu Tyr Met Asp Pro Met Cys Leu Asp Ala
Phe Pro Lys Leu 165 170 175 Val Cys Phe Lys Lys Arg Ile Glu Ala Ile
Pro Gln Ile Asp Lys Tyr 180 185 190 Leu Lys Ser Ser Lys Tyr Ile Ala
Trp Pro Leu Gln Gly Trp Gln Ala 195 200 205 Thr Phe Gly Gly Gly Asp
His Pro Pro Lys Ser Asp Leu Glu Val Leu 210 215 220 Phe Gln Gly Pro
Leu Gly Ser Lys Met Asp Leu Val Gln Thr Ser Glu225 230 235 240 Val
Met Gln Glu Ser Leu Tyr Pro Ala Ala Gln Leu Cys Pro Ser Phe 245 250
255 Glu Glu Ser Glu Ala Thr Pro Ser Pro Val Leu Pro Asp Ile Val Met
260 265 270 Glu Ala Pro Leu Asn Ser Ala Val Pro Ser Ala Gly Ala Ser
Ala Val 275 280 285 Gln Pro Ser Ser Ser Pro Leu Glu Ala Ser Ser Val
Asn Tyr Glu Ser 290 295 300 Ile Ile His Glu Pro Glu Asn Pro Pro Pro
Tyr Glu Glu Ala Met Ser305 310 315 320 Val Ser Leu Lys Lys Val Ser
Gly Ile Lys Glu Glu Ile Lys Glu Pro 325 330 335 Glu Ser Ile Asn Ala
Ala Val Gln Glu Thr Glu Ala Pro Tyr Ile Ser 340 345 350 Ile Ala Cys
Asp Leu Ile Lys Glu Thr Lys Leu Ser Ala Glu Pro Thr 355 360 365 Pro
Asp Phe Ser Asp Tyr Ser Glu Met Ala Lys Val Glu Gln Pro Val 370 375
380 Pro Asp His Ser Glu Leu Val Glu Asp Ser Ser Pro Asp Ser Glu
Pro385 390 395 400 Val Asp Leu Phe Ser Asp Asp Ser Ile Pro Asp Val
Pro Gln Lys Gln 405 410 415 Asp Glu Ala Val Met Leu Val Lys Glu Asn
Leu Pro Glu Thr Ser Phe 420 425 430 Glu Ser Met Ile Glu His Glu Asn
Lys Glu Lys Leu Ser Ala Leu Pro 435 440 445 Pro Glu Gly Gly Ser Ser
Gly Arg Ile Val Thr Asp 450 455 460 93438PRTCallithrix jacchus
93Met Ser Pro Ile Leu Gly Tyr Trp Lys Ile Lys Gly Leu Val Gln Pro1
5 10 15 Thr Arg Leu Leu Leu Glu Tyr Leu Glu Glu Lys Tyr Glu Glu His
Leu 20 25 30 Tyr Glu Arg Asp Glu Gly Asp Lys Trp Arg Asn Lys Lys
Phe Glu Leu 35 40 45 Gly Leu Glu Phe Pro Asn Leu Pro Tyr Tyr Ile
Asp Gly Asp Val Lys 50 55 60 Leu Thr Gln Ser Met Ala Ile Ile Arg
Tyr Ile Ala Asp Lys His Asn65 70 75 80 Met Leu Gly Gly Cys Pro Lys
Glu Arg Ala Glu Ile Ser Met Leu Glu 85 90 95 Gly Ala Val Leu Asp
Ile Arg Tyr Gly Val Ser Arg Ile Ala Tyr Ser 100 105 110 Lys Asp Phe
Glu Thr Leu Lys Val Asp Phe Leu Ser Lys Leu Pro Glu 115 120 125 Met
Leu Lys Met Phe Glu Asp Arg Leu Cys His Lys Thr Tyr Leu Asn 130 135
140 Gly Asp His Val Thr His Pro Asp Phe Met Leu Tyr Asp Ala Leu
Asp145 150 155 160 Val Val Leu Tyr Met Asp Pro Met Cys Leu Asp Ala
Phe Pro Lys Leu 165 170 175 Val Cys Phe Lys Lys Arg Ile Glu Ala Ile
Pro Gln Ile Asp Lys Tyr 180 185 190 Leu Lys Ser Ser Lys Tyr Ile Ala
Trp Pro Leu Gln Gly Trp Gln Ala 195 200 205 Thr Phe Gly Gly Gly Asp
His Pro Pro Lys Ser Asp Leu Glu Val Leu 210 215 220 Phe Gln Gly Pro
Leu Gly Ser Val Gln Asp Ser Leu Cys Pro Val Ala225 230 235 240 Gln
Leu Cys Pro Ser Phe Glu Glu Ser Glu Ala Thr Pro Ser Pro Val 245 250
255 Leu Pro Asp Ile Val Met Glu Ala Pro Leu Asn Ser Ala Val Pro Ser
260 265 270 Ala Gly Ala Ser Ala Val Gln Pro Ser Ser Ser Pro Leu Glu
Ala Ser 275 280 285 Ser Val Asn Phe Glu Ser Val Lys His Glu Pro Glu
Asn Pro Pro Pro 290 295 300 Tyr Glu Glu Ala Met Asn Val Ser Arg Lys
Lys Val Ser Gly Ile Lys305 310 315 320 Glu Glu Ile Lys Glu Pro Glu
Ser Ile Asn Ala Ala Val Gln Glu Thr 325 330 335 Glu Ala Pro Tyr Ile
Ser Ile Ala Cys Asp Leu Ile Lys Glu Thr Lys
340 345 350 Leu Ser Ala Glu Pro Thr Pro Asp Phe Ser Ser Tyr Ser Glu
Met Ala 355 360 365 Lys Val Glu Gln Pro Leu Pro Asp His Ser Glu Leu
Val Glu Asp Ser 370 375 380 Ser Pro Asp Ser Glu Pro Val Asp Leu Phe
Ser Asp Asp Ser Ile Pro385 390 395 400 Asp Val Pro Gln Lys Gln Asp
Glu Ala Val Ile Leu Val Lys Glu Thr 405 410 415 Leu Thr Glu Thr Ser
Phe Glu Ser Met Ile Glu His Glu Asn Lys Leu 420 425 430 Glu Arg Pro
His Arg Asp 435 94432PRTRattus rattus 94Met Ser Pro Ile Leu Gly Tyr
Trp Lys Ile Lys Gly Leu Val Gln Pro1 5 10 15 Thr Arg Leu Leu Leu
Glu Tyr Leu Glu Glu Lys Tyr Glu Glu His Leu 20 25 30 Tyr Glu Arg
Asp Glu Gly Asp Lys Trp Arg Asn Lys Lys Phe Glu Leu 35 40 45 Gly
Leu Glu Phe Pro Asn Leu Pro Tyr Tyr Ile Asp Gly Asp Val Lys 50 55
60 Leu Thr Gln Ser Met Ala Ile Ile Arg Tyr Ile Ala Asp Lys His
Asn65 70 75 80 Met Leu Gly Gly Cys Pro Lys Glu Arg Ala Glu Ile Ser
Met Leu Glu 85 90 95 Gly Ala Val Leu Asp Ile Arg Tyr Gly Val Ser
Arg Ile Ala Tyr Ser 100 105 110 Lys Asp Phe Glu Thr Leu Lys Val Asp
Phe Leu Ser Lys Leu Pro Glu 115 120 125 Met Leu Lys Met Phe Glu Asp
Arg Leu Cys His Lys Thr Tyr Leu Asn 130 135 140 Gly Asp His Val Thr
His Pro Asp Phe Met Leu Tyr Asp Ala Leu Asp145 150 155 160 Val Val
Leu Tyr Met Asp Pro Met Cys Leu Asp Ala Phe Pro Lys Leu 165 170 175
Val Cys Phe Lys Lys Arg Ile Glu Ala Ile Pro Gln Ile Asp Lys Tyr 180
185 190 Leu Lys Ser Ser Lys Tyr Ile Ala Trp Pro Leu Gln Gly Trp Gln
Ala 195 200 205 Thr Phe Gly Gly Gly Asp His Pro Pro Lys Ser Asp Leu
Glu Val Leu 210 215 220 Phe Gln Gly Pro Leu Gly Ser Ile Gln Glu Ser
Leu Tyr Pro Thr Ala225 230 235 240 Gln Leu Cys Pro Ser Phe Glu Glu
Ala Glu Ala Thr Pro Ser Pro Val 245 250 255 Leu Pro Asp Ile Val Met
Glu Ala Pro Leu Asn Ser Leu Leu Pro Ser 260 265 270 Ala Gly Ala Ser
Val Val Gln Pro Ser Val Ser Pro Leu Glu Ala Pro 275 280 285 Pro Pro
Val Ser Tyr Asp Ser Ile Lys Leu Glu Pro Glu Asn Pro Pro 290 295 300
Pro Tyr Glu Glu Ala Met Asn Val Ala Leu Lys Ala Leu Gly Thr Lys305
310 315 320 Glu Gly Ile Lys Glu Pro Glu Ser Phe Asn Ala Ala Val Gln
Glu Thr 325 330 335 Glu Ala Pro Tyr Ile Ser Ile Ala Cys Asp Leu Ile
Lys Glu Thr Lys 340 345 350 Leu Ser Thr Glu Pro Ser Pro Asp Phe Ser
Asn Tyr Ser Glu Ile Ala 355 360 365 Lys Phe Glu Lys Ser Val Pro Glu
His Ala Glu Leu Val Glu Asp Ser 370 375 380 Ser Pro Glu Ser Glu Pro
Val Asp Leu Phe Ser Asp Asp Ser Ile Pro385 390 395 400 Glu Val Pro
Gln Thr Gln Glu Glu Ala Val Met Leu Met Lys Glu Ser 405 410 415 Leu
Thr Glu Val Ser Glu Thr Val Ala Gln His Lys Glu Glu Arg Leu 420 425
430 956PRTHomo Sapiens 95Asp Glu Thr Phe Ala Leu1 5 966PRTHomo
Sapiens 96Glu Leu Ser Lys Thr Ser1 5
* * * * *